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ABSTRACT
Schizophrenia is a serious psychiatric disorder causing a wide range of devastating
impairments. A combination of several genetic and environmental factors is considered to result in a range of neurobiological changes underlying the symptom spectrum of schizophrenia. Differences in the γ-aminobutyric acid (GABA)ergic, glutamatergic and dopaminergic neurotransmitter systems have been most consistently
observed in patients with schizophrenia. Current pharmacological treatment options
for patients with schizophrenia are, however, still limited in their ability to address
the range of symptoms and identified neurobiological differences.
Substantial evidence from human studies has linked the neurotrophic factor neuregulin 1 (NRG1) to the pathophysiology of schizophrenia, with further support from animal studies. Acute NRG1 signalling has been shown to affect GABAergic and glutamatergic neurotransmission in vitro in the prefrontal cortex (PFC) and hippocampus, two regions strongly linked to the symptomatology of schizophrenia. Due to the
acute signalling properties of NRG1 in attenuating schizophrenia-relevant neurotransmission, a therapeutic potential of the NRG1 signalling system for the treatment
of schizophrenia has been hypothesized, but never explored.
In the present PhD thesis I assessed the possible antipsychotic-like characteristics of
NRG1 treatment on schizophrenia-relevant behavioural and molecular impairments
focusing on GABAergic and glutamatergic signalling. I modelled schizophrenia-like
impairments in adult male mice by acute phencyclidine (PCP). Acute PCP treatment
in mice has been shown to induce a wide spectrum of schizophrenia-relevant symptoms, including hyperlocomotion, impaired sensorimotor gating and neurotransmission impairments. This treatment paradigm is therefore widely used as a first step in
antipsychotic drug development studies.
In my first study, I examined the effects of concurrent NRG1 and PCP treatment on
locomotor activity and sensorimotor gating. Central and peripheral NRG1 administration dose-dependently prevented PCP-induced hyperlocomotion and prepulse
inhibition impairment. Advancing on these findings, I then studied the effects of
NRG1 application on acute neurotransmission in the presence of PCP by microdialysis in the PFC and hippocampus of freely moving mice. In the PFC, NRG1 reduced
glutamate and glycine levels, while combined NRG1 and PCP treatment triggered an
increase in extracellular glycine. In the hippocampus, PCP treatment triggered a sigIII

nificant increase in GABA levels without affecting glutamate or glycine. The GABA
increase was not observed following combined NRG1 and PCP treatment, suggesting
that NRG1 prevented the PCP effect. An increase in glycine was again observed following combined treatment, here accompanied by a reduction in glutamate levels.
In my final study, I treated cells from primary frontal cortex cultures with NRG1 in
the presence of PCP, measuring components of the GABAergic system relevant to
the pathophysiology of schizophrenia. PCP changed the mRNA expression of GABA
producing enzymes and the calcium binding protein parvalbumin. Combined treatment with NRG1 dose-dependently prevented these PCP-induced expression changes
in the frontal cortex cells.
Prevention of PCP-induced hyperlocomotion and PPI impairments demonstrates a
clear involvement of the NRG1 signalling pathway in neuronal circuits relevant for
spontaneous behaviour. The region specific influence of NRG1 on glutamate and
glycine levels confirms the involvement of NRG1-ERBB signalling in adult excitatory neurotransmission. Furthermore, preventing the PCP-induced GABA increase in
the hippocampus provides support for a functional role in inhibitory neurotransmitter
signalling. An involvement of NRG1 in the regulation of inhibitory neurotransmission was further supported by in vitro frontal cortex experiments where NRG1 treatment prevented changes to GABA producing enzymes.
The combined outcomes of my experiments provide initial support for potential antipsychotic-like characteristics of NRG1 treatment in a mouse model with induced
schizophrenia-relevant behavioural and molecular impairments. The observed efficacy of peripherally administered NRG1 to prevent PCP-induced behavioural deficits
indicates its potential as a new therapy for schizophrenia patients. Exploring the consequences of long-term NRG1 treatment on a broader spectrum of behavioural performance and molecular changes, particularly of the dopaminergic system, will be
required to advance on the present findings and take the next step towards a potential
suitability of NRG1 treatment in a clinical setting.
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1 INTRODUCTION
1.1

Schizophrenia

Schizophrenia is a severe psychiatric disorder leading to life-long burden for the affected patients and their social environment. The risk of developing schizophrenia is
0.4 to 0.7% for the general population independent of world region or economic development (Bhugra 2005; Saha et al. 2005). This risk increases by having a family
member with schizophrenia, depending on the degree of consanguinity, with a lifetime risk of close to 50% for a monozygotic twin of an affected patient (Cardno &
Gottesman 2000; Kendler & Gardner 1997). Despite the strong heritability (about
80%), no consistent genetic differences have been identified across schizophrenia
patient populations (Fromer et al. 2014; Purcell et al. 2014). In fact, a recent report
identified over 1500 single nucleotide differences which contribute to the risk of developing schizophrenia (Ripke et al. 2013). In addition to the genetic susceptibility, a
variety of environmental factors have been identified which contribute to the actual
incidence rate of schizophrenia; these include (but are not limited to) prenatal infection (Meyer et al. 2009; Patterson 2009), cannabis consumption (Barkus & Murray
2010; Casadio et al. 2011),vitamin D deficiency during early development (McGrath
et al. 2010), urbanicity and migration (Tandon et al. 2008; Réthelyi et al. 2013; Linscott & van Os 2013).

1.1.1 The symptoms of schizophrenia
The combination of genetic and environmental factors that contribute to the development of schizophrenia result in a broad range of clinical symptoms. The types of
symptoms and their severity vary between individual patients as well as throughout
the progress of the disorder. Prior to the onset of schizophrenia, retrospective studies
report delayed motor coordination and impaired neuromotor function in individuals
who later developed schizophrenia (Schenkel & Silverstein 2004). These early signs
are followed by minor cognitive impairments, such as language based deficits, deficits in attention and problem solving abilities, all of which are present prior the first
psychotic episode (Schenkel & Silverstein 2004; Tandon et al. 2009).
1

The onset of schizophrenia is marked by an initial psychotic episode often in late adolescence or early adulthood, during which patients experience a range of symptoms
including hallucinations, anxiety, impaired social abilities, disordered thoughts, depression and cognitive impairments (Tandon et al. 2009).
Lacking any cure, patients suffer mostly for the rest of their life, a period which is
marked by recurring psychotic episodes with varying frequencies and intensities
(Tandon et al. 2009; Tandon et al. 2008). The period between psychotic episodes is
dominated by an initial worsening of cognitive symptoms in combination with anxiety, depression and social impairments, which later on plateau with a only small
chance of recovery (Tandon et al. 2009). Furthermore, patients with schizophrenia
suffer from an increased risk of suicide (12 times the general average) (Saha et al.
2007) and 50% of patients suffer from substance abuse (compared to 15% in the
general population) (Tyrer et al. 2011). However, the cognitive symptoms, such as
impaired working and procedural memory and reduced language and executive function abilities, have a long-lasting dire impact on the social interactions and vocational
opportunities of affected individuals (Millan et al. 2012; Tandon et al. 2010).

1.1.2 The neurobiology of schizophrenia
Several neurobiological factors have been implicated in the pathophysiology underlying the broad spectrum of clinical schizophrenia symptoms. However, identifying
consistent biological differences in patients with schizophrenia has proven very challenging. Firstly, the range of genetic and environmental factors which contribute to
the risk of developing schizophrenia varies between patients. Secondly, the first psychotic episode occurs predominantly during late adolescence and early adulthood, a
period of increased cortical plasticity (Uhlhaas & Singer 2011), making it difficult to
identify pre-existing neurobiological differences. Finally, differences in antipsychotic
treatment regimens between patients limit the ability of post-mortem studies to shed
light on the symptom-causing pathophysiology (Smieskova et al. 2009).
Nonetheless, variations in specific neurotransmitter signalling systems have been reported from a growing number of patient cohorts, allowing the identification of
chemical differences in relation to the observed symptomatology. Among the investigated neurotransmitter systems, differences in the dopaminergic, glutamatergic and
γ-aminobutyric acid (GABA) signalling pathways have been the most consistently
2

observed in patients with schizophrenia. Studying the neurotransmitter systems has
been made possible by post-mortem protein and messenger ribonucleic acid (mRNA)
analysis of regional expression profiles for synthesizing enzymes, membrane-bound
receptors, membrane transporters and associated intracellular signalling elements.
Furthermore, recent in vivo imaging methods such as positron emission tomography
(PET), magnetic resonance spectroscopy and single photon emission computed tomography enabled longitudinal evaluation of neurochemical changes in patients
(Mcguire et al. 2008).

1.1.2.1 Dopaminergic system and schizophrenia
The dopaminergic system was the first neurotransmitter system implicated in the
pathophysiology of schizophrenia (Carlsson & Carlsson 2006). Dopamine is a monoamine neurotransmitter that modulates the fast neurotransmission of glutamate and
GABA. Dopamine exerts its effect through G-protein coupled receptors which are
found on neurons in areas critical for voluntary movement, reward, attention, working memory and learning (Beaulieu & Gainetdinov 2011).
In vivo and post-mortem studies in patients with schizophrenia have reported slightly
increased levels of dopamine receptors in the striatum and prefrontal cortex (PFC)
(Chana et al. 2013; Gurevich et al. 1997; Howes & Kapur 2009; Toda & AbiDargham 2007) (Figure 1). Furthermore, increased dopamine synthesis, release and
extracellular levels have been detected in the striatum of patients, while reduced dopamine levels have been identified in the PFC of patients (Howes & Kapur 2009;
Howes et al. 2013) (Figure 1). These findings indicate that pre-synaptic dopaminergic mechanisms are consistently altered in patients with schizophrenia (Howes &
Kapur 2009). Differences in the modulatory action of long-range dopaminergic midbrain projections on to local glutamatergic and GABAergic neurons have therefore
been proposed as a fundamental element underlying a range of schizophrenia symptoms (Howes & Kapur 2009).

3

Figure 1: Neurotransmitter system changes in the prefrontal cortex and hippocampus of schizophrenia
Schematic summary diagram of the predominant cell types in the frontal cortex and
hippocampus and variations in neurotransmitter signalling systems identified in patients with schizophrenia in these cells. Cell types: pyramidal neurons (P, blue), GABAergic interneurons (i, orange), astrocytes (A, green) and oligodendrocytes (O, navy). Protein expression and neurotransmitter level differences have been identified in
the dopaminergic (green insert; D2: dopamine D2 receptor), glutamatergic (blue insert; NR1: NMDA receptor subunit NR1), GABAergic (orange insert; GAD67: glutamate decarboxylase, PV: parvalbumin, GAT: GABA transporter, GABAA-R:
GABA receptor subtype A), serotonergic (5HT-R: serotonin receptor) and cholinergic (α7 nACh-R: acetylcholine receptor subtype α7) system. Arrows indicate predominantly ↓reduced or ↑increased levels, or ↑↓inconsistent findings in schizophrenia patients compared to healthy controls. For expression details and references see
1.1.2. Diagram modified from (Meyer-Lindenberg 2010).

4

1.1.2.2 Glutamatergic system and schizophrenia
After observing psychotic-like symptoms following the recreational use of substances with strong N-Methyl-D-aspartic acid receptor (NMDAR) antagonism, the involvement of the glutamatergic system in the pathophysiology of schizophrenia has
received increasing attention (Moghaddam & Javitt 2012). Glutamate is an excitatory
neurotransmitter throughout the nervous system with binding affinity for pre-, postand extrasynaptic receptors, which include fast- and slow acting ion channels and Gprotein coupled receptors (Traynelis et al. 2010).
Several post-mortem studies provide support for a NMDAR hypofunction hypothesis
in patients with schizophrenia. Protein and mRNA expression of the essential
NMDAR NR1 subunit has been reported to be reduced in the hippocampus of patients, with growing evidence for reduced NMDAR levels also in the dorsolateral
PFC (Geddes et al. 2011; Weickert et al. 2013) (Figure 1). Investigating the levels of
available NMDA receptors in vivo supports the notion of reduced glutamate signalling in schizophrenia, after discovering reduced NMDAR levels in the hippocampus
of unmedicated patients and reduced levels in the frontal cortex of clozapine-treated
patients (Pilowsky et al. 2005) (Figure 1).
Glutamate levels in different brain regions of patients with schizophrenia have been
studied in vivo in recent years. In the PFC of patients with schizophrenia, glutamate
levels reportedly differ compared to controls depending on subregions and antipsychotic medication. Glutamate in the dorsolateral PFC appeared unchanged in unmedicated patients but reduced in patients taking antipsychotics (Poels, Kegeles,
Kantrowitz, Javitt, et al. 2014). Medial PFC and anterior cingulate cortex glutamate
levels however, appear to be elevated in unmedicated patients, while unchanged in
medicated patients (Kegeles et al. 2012; Poels, Kegeles, Kantrowitz, Javitt, et al.
2014). Glutamate levels in other cortical areas appeared not to be altered in patients
with schizophrenia (Poels, Kegeles, Kantrowitz, Slifstein, et al. 2014). In sub-cortical
areas, glutamate levels have been measured in the hippocampus, thalamus and basal
ganglia (Poels, Kegeles, Kantrowitz, Slifstein, et al. 2014). The results of these studies have been inconsistent, but appear to trend towards reduced glutamate levels
(Poels, Kegeles, Kantrowitz, Slifstein, et al. 2014). While the NMDAR hypofunction
hypothesis receives strong support from observed reductions in NMDAR levels, the
lack of significant glutamate level differences suggests an involvement of additional
5

neurotransmitter systems. Glutamatergic pyramidal neurons are under the tonic influence of dopamine as described above. Phasic control over the activity of these
neurons is exerted by rapid GABA release from GABAergic interneurons (Roth &
Draguhn 2012).
GABAergic signalling directly influences the response of pyramidal neurons to both
glutamate and dopamine, particularly in the hippocampus and PFC (Moghaddam &
Javitt 2012; Paz et al. 2008). The observed differences of the glutamatergic and dopaminergic system are therefore possibly related to differences in the GABAergic
system.

1.1.2.3 GABAergic system and schizophrenia
Investigations into the role of the GABAergic system in the pathophysiology of
schizophrenia have recently gained momentum. A small number of in vivo neuroimaging studies have assessed differences in GABA levels in cortical and subcortical
regions. Increased as well as unchanged GABA levels have been found in the PFC of
patients (Goto et al. 2009; Kegeles et al. 2012; Kegeles et al. 2012). Decreased as
well as unchanged GABA levels have also been observed in the basal ganglia of patients (Goto et al. 2009; Tayoshi et al. 2010). These observations are in line with an
older study measuring GABA levels in the cerebrospinal fluid (CSF) of unmedicated,
recently diseased patients, which identified reduced levels during the early stages of
the disorder (van Kammen et al. 1982). The in vivo knowledge on GABA-A receptor
levels is limited, with a recent PET study identifying reduced GABA-A receptor levels in the striatum, but unchanged levels in the hippocampus of subjects with high
risk of developing schizophrenia (Kang et al. 2013). These small numbers of studies
indicate a role of GABA signalling in the critical stage of the disease progression.
Post-mortem investigations have identified expression differences of proteins critical
to the normal functioning of the GABAergic signalling in the PFC and subregions of
the hippocampus. In particular, reduced expression of the GABA synthesizing enzyme glutamate decarboxylase (GAD) and the calcium binding protein parvalbumin
(PV) have repeatedly been identified in frontal cortex regions of patients with schizophrenia (Akbarian et al. 1995; Beasley & Reynolds 1997; Dracheva et al. 2004;
Duncan et al. 2010; Guidotti et al. 2000; Hashimoto, Arion, et al. 2008; Hashimoto,
Bazmi, et al. 2008; Hashimoto et al. 2003; Mellios et al. 2009; Sakai et al. 2008;
6

Straub et al. 2007; Volk et al. 2012; Volk et al. 2000; Woo et al. 2008) (Figure 1). In
the hippocampus, GAD and PV have also been found to be decreased in some patients (Heckers et al. 2002; Zhang & Reynolds 2002; Wang et al. 2011; Thompson
Ray et al. 2011; Knable et al. 2004; Torrey et al. 2005) (Figure 1). While expression
differences appear to differ between patient cohorts, antipsychotic treatment differences are likely the cause for this discrepancy (Heckers et al. 2002; Schreiber et al.
2011). Furthermore, GABA-A receptors have found to be increased while GABA
transporters (GAT) appear decreased in the PFC and hippocampus of patients
(Benes, Khan, et al. 1996; Benes, Vincent, et al. 1996; Duncan et al. 2010; Volk et
al. 2001; Hashimoto, Arion, et al. 2008; Hashimoto, Bazmi, et al. 2008; Schleimer et
al. 2004) (Figure 1). The differences in GABA-A receptors and GAT are likely a
compensatory consequence to the reduced GABA production indicated by reduced
GAD expression. Noteworthy, GABA-A receptors are expressed on pyramidal neurons, interneurons and astrocytes (Lee, Schwab, et al. 2011; Lewis et al. 2005; Pettit
& Augustine 2000), GAD and GAT are expressed in GABAergic interneurons and
GABA-producing astrocytes (Fish et al. 2011; Lee, McGeer, et al. 2011), with PV
exclusively expressed in a subset of GABAergic interneurons (Lewis et al. 2005;
Markram et al. 2004). This expression profile indicates a cell type specific contribution to the schizophrenia pathophysiology. While the cause for reduced GAD and PV
expression remains unknown, it likely indicates a reduction in GABAergic interneuron activity, leading to reduced GABA production and a lower demand for intracellular calcium management. Local populations of GABAergic interneurons are critical
for coordinated signalling inside- as well as across brain regions, in particular for areas strongly associated with symptoms of schizophrenia such as the PFC and the
hippocampus (Godsil et al. 2013; Gonzalez-Burgos et al. 2011; Inan et al. 2013). Differences in the activity level of these interneurons in patients with schizophrenia
would consequentially contribute to a range of the observed symptoms.

1.1.2.4 Other neurotransmitters
While focusing on the three most widely studied neurotransmitter systems in schizophrenia, changes to many other neurotransmitters have been reported, including serotonin, acetylcholine and glycine, which in turn can influence dopamine, glutamate
and GABA signalling.
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Serotonin receptor activity can influence dopamine and glutamate release in several
brain areas (de Bartolomeis et al. 2013). Serotonin receptors have consequentially
been implicated in the pathophysiology of schizophrenia and proposed as possible
treatment targets (de Bartolomeis et al. 2013; Meltzer et al. 2003). Patients with
schizophrenia appear to have reduced expression levels of serotonin receptors in the
frontal cortex and hippocampus (López-Figueroa et al. 2004; Ngan et al. 2000).
However, the knowledge about differences in the serotonergic system in schizophrenia is limited by the lack of specificity of serotonin receptor ligands, as well as the
effect of antipsychotic treatment on the serotonergic system (Chana et al. 2013).
The involvement of acetylcholine neurotransmission in the symptomatology of
schizophrenia has been suggested as a possible explanation for the high incidence of
smoking seen in patients with schizophrenia (de Leon & Diaz 2005). Post-mortem
studies of acetylcholine receptor expression, especially of the α7 nicotinic acetylcholine receptor (nAChR), have identified reductions in several frontal cortex and hippocampus regions in patients with schizophrenia (Thomsen et al. 2010). Since α7
nAChR is highly expressed on GABAergic interneurons in healthy brains (Thomsen
et al. 2010), altered acetylcholine signalling via this receptor might contribute to the
reported activity difference in these interneurons described earlier.
Glycine acts as an allosteric modulator on NMDAR, providing tonic modulation to
the receptor channel opening capacity (Labrie & Roder 2010). Patients with schizophrenia reportedly have lower blood serum glycine levels, which appear to be negatively correlated with symptom severity (Hons et al. 2010; Kantrowitz & Javitt
2010). The observed reduction in glycine levels has been suggested to contribute to
the NMDAR hypofunction hypothesis described above (Labrie & Roder 2010).

1.1.2.5 Brain connectivity and schizophrenia
Activation of NMDAR on GABAergic interneurons in the PFC enables precise feedback control over local pyramidal neuron excitability (recently reviewed by (Bartos
et al. 2007; Chamberland & Topolnik 2012; Isaacson & Scanziani 2011)). PV expressing interneurons synapse with over 1000 pyramidal neurons, synchronizing the
action potential generation across populations of pyramidal neurons (Bartos et al.
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2007). The synchronized excitatory-inhibitory balance of the PFC is considered to be
the corner stone of several functions impaired in schizophrenia such as working
memory, attention and sensory gating (Gonzalez-Burgos et al. 2011; Uhlhaas &
Singer 2010). Several of these abilities appear to additionally depend on afferent and
efferent connections between the PFC and the hippocampus (Godsil et al. 2013).
Deficits in cortical synchrony in the PFC of patients with schizophrenia have been
identified by electrophysiological and neuroimaging studies (Farzan et al. 2010;
Kirihara et al. 2012; Lee et al. 2003; Uhlhaas & Singer 2010; Woo et al. 2010). Furthermore, neuroimaging studies utilizing diffusion tensor imaging and magnetoencephalography have provided evidence suggesting that the interaction between
the PFC and the hippocampus of patients with schizophrenia differs compared to
control subjects (Ellison-Wright & Bullmore 2009; Kumra et al. 2004; Olbrich et al.
2008; Scheel et al. 2013; White et al. 2007) (recently reviewed by (Del Arco & Mora
2009; Javitt et al. 2008; Meyer-Lindenberg 2010; Schmitt et al. 2011)).
Together with local GABAergic and glutamatergic neurotransmission imbalances,
these connectivity and synchronicity deficits are thought to significantly contribute to
the symptom spectrum of schizophrenia (Gonzalez-Burgos et al. 2011; Schmitt et al.
2011).

1.1.3 Current Pharmacological Treatment Situation of Schizophrenia
Sixty years of pharmacological research has resulted in a range of treatment options,
which, however, still have limited efficacy in treating the symptom spectrum of
schizophrenia. All currently available antipsychotics share a common antagonistic
action for the dopamine D2 receptor, with their D2 affinity predicting their clinical
potential (Tandon et al. 2010).
The initial generation of antipsychotics, including substances like chlorpromazine
and haloperidol, provided the very first pharmacological treatment option for patients
with schizophrenia. Patients were able to reduce the severity of their psychotic episodes, particularly hallucinations and delusions (Miyamoto et al. 2012). However,
serious motor control side effects, such as tremor, tardive dyskinesia and Parkinsonism, were common to the first generation of antipsychotics (Farde et al. 1992).
Research aiming at reducing the adverse reactions of the early antipsychotics while
maintaining the beneficial D2 antagonism resulted in the development of the second
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generation of antipsychotics, such as olanzapine, clozapine and risperidone (Tandon
et al. 2010). These newer substances have broader neurotransmitter receptor profiles
targeting serotonergic, histaminergic and muscarinic receptors with reduced affinity
for D2 receptors, resulting in fewer motor control side effects (Miyamoto et al.
2012). Additionally, these second generation antipsychotics were of benefit for patients with schizophrenia who remained unresponsive to the first generation of D2
antagonistic antipsychotics (Meltzer 1992). However, the newer group of drugs have
been shown to cause a range of metabolic side effects, including weight gain and sedation, to a larger extend than the first generation of antipsychotics (Leucht et al.
2013). The retained beneficial D2 antagonisms led to the formation of the first neurotransmitter hypothesis of schizophrenia, proposing that dysregulation of the dopaminergic system underlies the schizophrenia symptomatology, as described in section 1.1.2.1 (Seeman 1987).
The first and second generation antipsychotics show a strong therapeutic potential
against the so called positive symptom spectrum, which describes reality distorting
perceptions such as auditory and visual hallucinations, thought insertion and delusion
of control (Leucht et al. 2013; Tandon et al. 2010; Tandon et al. 2009). However,
antipsychotics are less efficient in reducing anxiety, depression and social impairments and show very little effect against cognitive symptoms (Millan et al. 2012;
Miyamoto et al. 2012; Tandon et al. 2010). This treatment deficit suggests that not all
neurotransmission differences are addressed by the available antipsychotics.
The effect of antipsychotics on neurotransmitter levels and network activity in the
frontal cortex and hippocampus formation in patients with schizophrenia has been
assessed by several neuroimaging studies. Haloperidol, clozapine and aripiprazole
have been reported to reduce the relative metabolic activity within the PFC of patients with schizophrenia (Cohen et al. 1999; Kim et al. 2013; Lahti et al. 2005).
However, olanzapine and sertindole appear to increase the relative metabolic activity
within the PFC in patients (Buchsbaum et al. 2009; Buchsbaum et al. 2007). The observed difference in PFC activation by the different antipsychotics likely contributes
to the varying effects of these treatments on the symptom spectrum in patients with
schizophrenia (Bilder et al. 2002; Carpenter & Buchanan 2008; Keefe et al. 2004;
Leucht et al. 2009; Ramaekers et al. 1999). Interestingly, while antipsychotic treat10

ment did not appear to effect glutamate concentration in the anterior cingulate cortex
(which is connected to the PFC) (Tayoshi et al. 2009), GABA concentration in the
same region appeared to negatively correlate with the dose of antipsychotics in patients with schizophrenia (Tayoshi et al. 2010). In light of the proposed reduction of
GABA levels in the PFC of patients described earlier, this finding suggests that
symptoms caused by an altered excitatory-inhibitory balance in the PFC might not be
sufficiently addressed by classical antipsychotics. Since this aspect might be of critical importance for antipsychotic treatment development, further research will need to
investigate this observed interaction.
The effect of antipsychotic treatment on hippocampal neurotransmitter levels has not
been well studied, with some indication for increased glutamate levels following
chronic antipsychotic treatment (Poels, Kegeles, Kantrowitz, Slifstein, et al. 2014).
However, as summarized in a recent review by Poels and colleagues, large differences in experimental and subject parameters between studies limit the reliable identification of the neurotransmitter level and receptor changes caused by antipsychotics
(Poels, Kegeles, Kantrowitz, Javitt, et al. 2014).
Yet, animal studies assessing the effects of chronic antipsychotic treatment indicate
lasting differences to neurotransmitter systems. Despite the common antagonism of
D2 receptors, increased and decreased GABA receptors levels, g-protein coupled receptor levels and NMDA receptor phosphorylation, among others have been reported
following chronic antipsychotic treatment (reviewed by Lieberman et al. (2008)).
Despite over 60 available antipsychotics and over 100,000 research publications
about the cause and management of schizophrenia (Scopus, 2014), the current treatments are insufficient in fully addressing the severely debilitating symptom spectrum. The strong focus of the current antipsychotics on the dopaminergic and serotonergic system leaves differences in the GABAergic and glutamatergic system undertreated. It has been discussed that this likely contributes to the limited ability of
current antipsychotics to sufficiently improve the cognitive impairments, which are a
strong predictor of the poor social outcomes of schizophrenia (Tandon et al. 2009).
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1.1.4 Current attempts in targeting GABA for treating schizophrenia
The proposed role of GABAergic neurotransmission in the cognitive symptoms of
schizophrenia has promoted the ionotropic GABA receptor subtype A to a prime target for antipsychotic treatments. The post-synaptical expression of GABA-A receptors facilitates the synchronization between interneurons and pyramidal neurons in
frontal cortex and hippocampal regions (Benardo 1997; Cobb et al. 1995). Targeting
the synaptic GABA-A receptors with benzodiazepines, however, causes several adverse reactions such as sedation, ataxia and cognitive impairments (Möhler et al.
2002).
As reported earlier, reduced expression of α-subtype containing GABA-A receptors
has been found in some cohorts of patients with schizophrenia (Duncan et al. 2010;
Hashimoto, Arion, et al. 2008; Volk et al. 2002). A small number of GABA-A αspecific clinical trials, however, failed to show consistent improvements to the symptoms of patients with schizophrenia (Rudolph & Knoflach 2011; Vinkers et al. 2010).
While targeting the GABA-A receptor to address GABAergic interneuron differences in schizophrenia has so far been unsuccessful, different strategies for the
GABA aspect of the schizophrenia pathophysiology will have to be considered
(Vinkers et al. 2010). In particular, modifying GABAergic neurotransmission by targeting the activity of GABAergic interneurons instead of directly affecting GABA-A
receptors might form a fruitful strategy.
The epidermal growth factor receptor tyrosine kinase ERBB4 has been detected on
GABAergic interneurons in the PFC and hippocampus, while not being expressed on
pyramidal neurons in the same regions (Neddens & Buonanno 2010; Neddens et al.
2011; Vullhorst et al. 2009; Abe, Namba, et al. 2009; Longart et al. 2007; Nagano et
al. 2007; Yau et al. 2003). The restricted neuronal expression profile of ERBB4 to
GABAergic interneurons with reported deficits in schizophrenia raises the possibility
that its ligand neuregulin 1 (NRG1) might selectively alter GABAergic interneuron
activity as could be relevant for schizophrenia signalling aberrations.
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1.2

Neuregulin 1 and ERBB4 signalling

1.2.1 ERBB4
ERBB4 is part of a family of membrane-spanning tyrosine kinase receptors (ERBB14), homologous to epidermal growth factor (EGF) receptors. ERBB4 homodimers
and ERBB4-ERBB2,3 heterodimers can be activated by NRG1 and other EGF-like
factors of the neuregulin family, (reviewed by (Iwakura & Nawa 2013)). ERBB2 and
ERBB3 build functional receptors by forming heterodimers with other ERBB proteins, which then determine their binding ligands (Guy et al. 1994; Iwakura & Nawa
2013; Tzahar et al. 1996).
ERBB receptors show a subtype specific expression pattern across the body. In the
periphery ERBB receptors are expressed on neuromuscular junctions, including cardiomyocytes, influencing cholinergic neurotransmission between peripheral nerves
and their target muscle (Bersell et al. 2009; Wadugu & Kühn 2012; Zhu et al. 1995).
ERBB receptors have further been detected in endocrine organs (Zhao 2013) and tumour cells (Hegde et al. 2013; Seshacharyulu et al. 2012). Additionally, macrophages also appear to express ERBB receptors, suggesting an involvement of NRG1 signalling in immune system actions (Calvo et al. 2010).
In the central nervous system, ERBB receptors are found on a range of glial cell
types in different cortical and subcortical regions, with ERBB4 expressed on astrocytes, microglia and oligodendrocytes (Calvo et al. 2010; Dimayuga et al. 2003; Gerecke et al. 2001; Raabe et al. 2004; Sharif et al. 2009; Vartanian et al. 1997).
Neuronal expression of ERBB4 has been identified on cortical and hippocampal
GABAergic interneurons (Abe, Nawa, et al. 2009; Longart et al. 2007; Nagano et al.
2007; Yau et al. 2003). The neuronal ERBB4 expression in both regions has been
confirmed to be limited to post-synaptic densities of GABAergic interneurons (Fazzari et al. 2010; Garcia et al. 2000; Neddens et al. 2011; Vullhorst et al. 2009). Interneurons expressing the calcium binding protein PV contain the majority of ERBB4
found in the PFC and hippocampus, with interneurons expressing the calcium binding proteins calretinin or somatostatin containing only a fraction of available ERBB4
receptors (Fazzari et al. 2010). Initial observations of ERBB4 being expressed on
pyramidal neurons or pre-synaptic sites of interneurons have been revised due to unspecific antibody binding (Neddens et al. 2011). Outside of the cortex, ERBB4 has
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also been found on dopaminergic neurons in the striatum (Abe, Namba, et al. 2009;
Depboylu et al. 2012; Gerecke et al. 2001; Steiner et al. 1999), PV-negative neurons
in the amygdala (Shamir et al. 2012), cerebellar granule cells (Fenster et al. 2012),
and on neuroprogenitor cells of the dentate gyrus (Mahar et al. 2011). The ERBB4
expression data of some of these studies, however, relies mainly on the anti-ERBB4
antibody sc-283 from Santa Cruz, which has been shown to exhibit non-specific labelling of other subunits (Neddens et al. 2011) and will therefore need additional
confirmation.

1.2.2 Neuregulin 1
NRG1 is part of a family of growth and differentiation factors which are transcribed
by the NRG1-4 genes. The NRG1 genes encode six types of proteins (I-VI) with predicted 31 isoforms (Mei & Xiong 2008). The commonly known isoforms of NRG1
include Neu differentiation factor (NDF), heregulin, glial growth factor (GGF) and
acetylcholine-receptor-inducing activator (ARIA), with ARIA being the first one
identified (Falls et al. 1990). Each NRG1 isoform consists of an extracellular typespecific sequence and a transmembrane domain followed by an intracellular cytoplasmic tail (Figure 2). Each member of the NRG1 family contains an EGF-like domain between the transmembrane domain and the extracellular tail in either α or β
configuration (Figure 2). The type-specific segment of NRG1 type III contains a second transmembrane domain and intracellular segment, leading to an extracellular
loop exposing the EGF-like domain to extracellular space (Figure 2) (reviewed in
detail by (Buonanno 2010; Mei & Xiong 2008; Talmage 2008).
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Figure 2: Schematic diagram of neuregulin 1 protein family members expressed
in the frontal cortex and hippocampus
Schematic diagram of the predominant cell types in the frontal cortex and hippocampus and neuregulin 1 protein family members expressed by these cells. Cell types:
pyramidal neurons (P, blue), GABAergic interneurons (I, orange), astrocytes (A,
green) and oligodendrocytes (O, navy). Insert: schematic structure of Neuregulin 1
type I to IV proteins expressed on the cell membranes of pyramidal neurons, astrocytes and interneurons. References for signalling, cleavage and expression details see
1.2.2.
All NRG1 subtypes signal via their extracellular EGF-like domain, which can be
cleaved off the transmembrane domain by different metalloproteases including ADAM10, 17, 19/TACE (tumour necrosis factor α-converting enzyme), β-secretase 1
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(BACE1), γ-secretase (Fleck et al. 2013; Fleck et al. 2012; Luo et al. 2011) and neuropsin (Tamura et al. 2012). NRG1 type III is additionally equipped for intracellular
signalling via the second, cysteine-rich intracellular domain, following cleavage by
Aph1B/C γ secretase (Dejaegere et al. 2008) (Figure 2).
NRG1 expression has been detected in cells of the peripheral and central nervous
system (reviewed by (Talmage 2008)), the cardiac system (Wadugu & Kühn 2012)
as well as the endocrine and gastrointestinal system (Zhao 2013). The majority of
NRG1 isoforms in the nervous system contain the β-EGF-like domain configuration
(Meyer & Birchmeier 1994; Shinoda et al. 1997). Localisation of the EGF-like domain of all NRG1 isoforms shows a broad expression pattern in the human brain
across the PFC, cingulate cortex, hippocampus, thalamus, amygdala, cerebellum and
brain stem (Law et al. 2004). The specific expression patterns of the different NRG1
isoforms vary throughout the nervous system development with peak expression for
all forms shortly after birth (X. Liu et al. 2011).
The NRG1 type I-IV isoforms have been detected in varying ratios in the PFC, hippocampus, thalamus, hypothalamus, amygdala and cerebellum (Bare et al. 2011;
Chen et al. 2008; Eilam et al. 1998; Hashimoto et al. 2004; X. Liu et al. 2011; Loeb
et al. 1999; Mei & Xiong 2008; Parlapani et al. 2010; Woo et al. 2007). The expression patterns of NRG1 type V and VI have so far not been published. In the cortical
grey matter, pyramidal cells are the primary producer of NRG1 (Pankonin et al.
2009). NRG1 isoforms have primarily been found in the cell soma and dendrites,
with NRG1 type III also expressed on axons (Bare et al. 2011; Brinkmann et al.
2008; X. Liu et al. 2011; Shamir & Buonanno 2010).
The different patterns of NRG1 isoform and ERBB isoform expression across the
nervous system and inside cells suggest distinct functions for NRG1-ERBB signalling in different cell types and anatomical locations. For the present study, ERBB4
receptors are of particular interest due to their confirmed expression on GABAergic
interneurons in the PFC and hippocampus.

1.2.3 Acute Neuregulin 1-ERBB4 signalling
The NRG1 type I / ARIA isoform was found to strongly affect nervous system functions in the developed brain when signalling through ERBB4. Indeed, the NRG1 type
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I expression is strongly influenced by neuronal activity during development and
adulthood (Eilam et al. 1998; X. Liu et al. 2011), which suggests that this isoform is
a likely candidate for neurotransmission related functions.
Upon binding of NRG1 to the post-synaptically expressed ERBB4 receptor, several
intracellular reactions can be triggered, which are summarized in Figure 3. The range
of actions include phosphorylation of ERBB4 tyrosine kinase (Bennett 2009), translocation of the intracellular domain to the nucleus for gene expression regulation (Allison et al. 2011), interaction with the postsynaptic density protein 95 (PSD95), altering NMDA-R receptor subunit phosphorylation (Bjarnadottir et al. 2007; Pitcher et
al. 2011; Yu et al. 1997) and less studied mechanisms such as protein kinase C interactions (Mitchell et al. 2013) (Figure 3). Acute consequences of these reactions on
neurotransmitter signalling have been identified in different brain regions of rodents,
primarily by stimulation with the recombinant NRG1 type 1 β-EGF extracellular
domain.
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Figure 3: Schematic diagram of ERBB4 intracellular signalling following neuregulin 1 binding on interneuron post-synaptic membrane
Schematic diagram of the predominant cell types in the frontal cortex and hippocampus and the intracellular signalling cascade triggered by neuregulin 1 type 1 (NRG1).
NRG1 binding (1) triggers formation of ERBB3-ERBB4 heterodimers (2) bound to
postsynaptic density protein 95 (PSD95), triggering a range of different intracellular
signalling cascades, including: (3) gene expression regulation by cytoplasmic domain
1 (CYT1) via Jak/Stat pathway; (4) regulation of mTor pathway and intracellular
Ca2+ levels by cytoplasmic domain 2 (CYT2) via PI3K and AKT phosphorylation
and (5) altering NMDA receptor (NMDAR) activity through phosphorylation of family kinases SRC and FYN. References for signalling, binding and expression details
see 1.2.1 and 1.2.3
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1.2.3.1 Effect of NRG1-ERBB4 signalling on GABAergic neurotransmission
In cortical slice preparations, increased depolarization-evoked GABA release was
observed following application of NRG1, while basal GABA release remained unaffected (Woo et al. 2007). Further experiments confirmed that this effect was caused
by activating ERBB4 on PV-expressing interneurons (Wen et al. 2010). The increase
in GABA release by NRG1 treatment also triggered an increase in GABA-A receptor
currents (Chen et al. 2010; Woo et al. 2007), consequentially reducing the action potential rate of the post-synaptic pyramidal neuron (Wen et al. 2010). Additionally, the
stimulation of ERBB4 by NRG1 has been shown to directly result in the internalization of GABA-A receptors on the post-synaptic membrane of hippocampal interneurons (Mitchell et al. 2013). This reduction of GABA-A receptors was visible even
after prolonged in vitro treatment with NRG1 for six days in hippocampal slices
(Okada & Corfas 2004). Also, treatment of hippocampal neurons with NRG1 increased ubiquitin mRNA, an enzyme which can regulate GABA-A receptor synapse
expression (Allison et al. 2011). In contrast, treatment of cerebellar granule cells with
NRG1 has been found to increase GABA-A receptor expression (Rieff et al. 1999;
Xie et al. 2004). These studies show that NRG1-ERBB4 signalling can acutely regulate GABA-A mediated neurotransmission in a region specific manner.

1.2.3.2 Effect of NRG1-ERBB4 signalling on glutamatergic neurotransmission
GABA neurotransmission by GABAergic interneurons in the PFC and hippocampus
directly affects glutamatergic pyramidal neurons (Markram et al. 2004). The effect of
NRG1-ERBB4 signalling on GABAergic neurotransmission therefore suggests a
possible influence on glutamatergic neurotransmission in both the PFC and hippocampus.
While in vitro experiments have shown that NRG1 treatment has no effect on glutamate release (Gu et al. 2005; Pitcher et al. 2011), a recent experiment with transgenic
animals indicated that NRG1 can reduce the fusion of glutamate vesicles with the
pre-synaptic membrane resulting in glutamatergic dysfunction (Yin et al. 2013).
Baseline excitatory post-synaptic potentials in hippocampal pyramidal neurons in
vitro, however, do not appear to be affected by the presence of NRG1 (Shamir et al.
2012).
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NMDA receptor currents in the PFC on the other hand were reduced following prolonged NRG1 application, which has been suggested to result in a reduction of functional NMDAR receptors on the post-synaptic membrane (Gu et al. 2005).
Altered glutamatergic signalling has also been proposed to result directly from
ERBB4 activation. ERBB4 and NMDAR are connected via PSD95 in GABAergic
interneurons (Garcia et al. 2000; Huang et al. 2000). Activation of ERBB4 by NRG1
has been shown to inhibit phosphorylation of the non-receptor protein kinase SRC
and FYN, resulting in dose-dependent changes of NMDAR function (Bennett 2009;
Bjarnadottir et al. 2007; Pitcher et al. 2011). Regarding the second dominant postsynaptic glutamate receptor α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
(AMPAR), acute NRG1 treatment does not appear to effect AMPAR currents, while
preventing NRG1-ERBB4 signalling destabilizes AMPAR surface expression (Fenster et al. 2012; Gu et al. 2005; Li et al. 2007). The potential effect on glutamate release as well as the observed changes in NMDAR function by NRG1-ERBB4 signalling suggests that local NRG1-ERBB4 signalling can influence efferent pyramidal
neuron connections to other cortical and subcortical structures. NRG1-ERBB4 signalling could consequentially influence different behaviour and cognitive abilities
relying on these networks.

1.2.3.3 Effect of NRG1-ERBB4 signalling on other neurotransmitter systems
1.2.3.3.1

Dopamine

The identification of ERBB4 on dopaminergic neurons in the striatum has triggered
investigations in to the effect of NRG1-ERBB4 signalling on dopaminergic neurotransmission. Microdialysis experiments have shown that local infusion of NRG1
into the striatum and hippocampus and peripheral NRG1 injections result in increased extracellular dopamine levels in both regions (Carlsson et al. 2011; Kwon et
al. 2008; Yurek et al. 2004). The co-expression of ERBB4 and D4 on interneurons in
the hippocampus might contribute to this effect, which also appears to influence network signalling underlying cognitive functions (Andersson et al. 2012).
1.2.3.3.2

Acetylcholine

Hippocampal interneurons express both ERBB4 and α7 nAChR and an interaction
between both signalling systems has therefore been studied in vitro. Application of
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NRG1 type I appears to alter the surface expression levels of α7 nAChR and acetylcholine currents in the hippocampus, although the direction of this change is debated
(Chang & Fischbach 2006; Liu et al. 2001). Furthermore, recent work suggests that
endogenous NRG1 type III signalling is required for sustained membrane expression
levels of α7 nAChR and acetylcholine currents (Hancock et al. 2008; Zhong et al.
2008).
In summary, the in vitro and in vivo studies in rodents suggest that acute NRG1ERBB4 signalling influences several neurotransmitter systems that are strongly implicated in the symptomatology of schizophrenia.
The consequences of acute NRG1-ERBB4 signalling have also been studied in transgenic animal models with over and under-expression of NRG1 isoforms and ERBB4
(Deng et al. 2013). However, the critical role of NRG1 signalling in central nervous
system development could have altered the response to acute NRG1-ERBB4 interventions in adulthood. The identified differences in neurotransmitter receptor expression and function in these transgenic animals are therefore of limited value for our
understanding of the acute effect of NRG1-ERBB4 signalling on neurotransmission
in the developed brain.

1.2.4 Schizophrenia and the NRG1-ERBB4 pathway
Additionally to the reported effect of NRG1-ERBB4 signalling on schizophreniarelevant neurotransmitter systems, a genetic association between NRG1-ERBB4 and
schizophrenia has been identified.

1.2.4.1 Genetic association between NRG1, ERBB4 and schizophrenia
The NRG1 gene has been considered as a potential risk factor for developing schizophrenia following a discovery by Stefansson and colleagues (2002). This group identified an association and linkage between a haplotype in the NRG1 gene on chromosome 8 and schizophrenia in an Icelandic population of patients with schizophrenia
(Stefansson et al. 2002). Following this initial finding, the same and other DNA sequences on the NRG1 gene have been associated with schizophrenia (Agim et al.
2013; Alaerts et al. 2009; Bousman et al. 2013; Georgieva et al. 2008; Huertas21

Vazquez et al. 2013; Law et al. 2006; Munafò et al. 2008; Munafò et al. 2006; Nicodemus et al. 2009; Petryshen et al. 2005; Stefansson et al. 2003; Walker et al. 2010;
Walss-Bass et al. 2006; Williams et al. 2003). Additionally, particular polymorphisms in the ERBB4 gene have also been associated with schizophrenia (Law et al.
2007; Nicodemus et al. 2006; Silberberg et al. 2006). However, not all patient populations show a genetic associations between NRG1 and schizophrenia (Gardner et al.
2006; Gong et al. 2009; Kampman et al. 2004; Loh et al. 2013; Moon et al. 2011;
Munafò et al. 2006; Walker et al. 2010) nor ERBB4 and schizophrenia (Chen et al.
2012; Stefanis et al. 2013).

1.2.4.2 Molecular association between NRG1, ERBB4 and schizophrenia
The majority of genetic polymorphisms associating NRG1 with a risk for developing
schizophrenia have been found in the non-coding region of the NRG1 gene, which
suggests a change in expression of NRG1 isoforms, rather than a change in the amino
acid sequence of the proteins themselves (Buonanno 2010). Several studies have
therefore been performed to assess the mRNA and protein expression levels of the
different NRG1 isoforms in the brain and periphery of patient with schizophrenia.
NRG1 type I appears to be increased in both the PFC and hippocampus, while type
II, III and IV remain unaltered in patients with schizophrenia (Hashimoto et al. 2004;
Law et al. 2006). Interestingly, reduced NRG1 type I levels have been observed in
the blood plasma of schizophrenia patients (Shibuya et al. 2010). Increased as well as
unaltered ERBB4 expression levels have been observed in the PFC of patients with
schizophrenia (Chong et al. 2008; Hahn et al. 2006; Joshi et al. 2014), with no data
available on hippocampus levels.
The NRG1 and ERBB4 protein quantification studies are hampered by the unavailability of reliable isoform-specific antibodies. This is highlighted by studies with isoform-unspecific NRG1 antibodies which have identified increased, decreased and
unchanged NRG1 levels in the PFC of patients (Barakat et al. 2010; Bertram et al.
2007; Chong et al. 2008; Hahn et al. 2006).
While the results of these expression studies are challenged by specificity issues, and
are at times inconsistent in their findings, they still support the genetic association
studies in suggesting an involvement of altered NRG1-ERBB4 signalling system in
the schizophrenia pathophysiology.
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1.3

General aim

Impaired dopaminergic, GABAergic and glutamatergic neurotransmission has been
observed in patients with schizophrenia. While currently available antipsychotics
primarily address the dopaminergic (and serotonergic) system, the GABAergic and
glutamatergic systems are not being targeted. Acute signalling of the neurotrophic
factor NRG1 via its ERBB4 receptor has been shown to affect, among others, GABAergic and also glutamatergic neurotransmission in schizophrenia-relevant brain
areas, particularly in the PFC and hippocampus. The aim of my thesis is therefore to
assess potential antipsychotic-like characteristics of NRG1 treatment with a focus on
GABAergic and glutamatergic neurotransmission.

1.4

Pharmacological animal model strategy for antipsychotic drug development

The discovery process of a novel antipsychotic pharmacological treatments includes
several stages from single cell response measurements in vitro to treating modelled
schizophrenia-relevant behavioural impairments in vivo (Sarter & Tricklebank 2012).
For acute NRG1 application, the effect on different neurotransmitter systems has
been assessed in vitro and partially in vivo (see 1.2.3). Furthermore, several studies
have administered the active NRG1β1-EGF domain to healthy mice, showing that
peripheral treatments have the potential to cross the blood-brain barrier and interact
with central ERBB receptors (Carlsson et al. 2011; Cui et al. 2013; Kastin et al.
2004; Kato et al. 2011; Rösler et al. 2011). Based on this, the first step for me to
identify potential antipsychotic properties was to assess the effect of NRG1 treatment
on schizophrenia-relevant behavioural impairments in mice.

1.4.1 Chronic vs acute rodent models
Schizophrenia is characterized by a combination of different symptoms that vary in
their severity throughout the progress of the disorder, as described in 1.1. Animal
modelling attempts have therefore focused either on triggering a psychotic episodelike state (acute models), which causes a range of functional impairments, or on cre23

ating long-lasting behavioural and molecular differences (chronic or sub-chronic
models), which would represent psychotic deficits between episodes (Pratt et al.
2012).
Chronic or non-acute modelling strategies include the introduction of schizophreniarelevant genetic mutations, applying long-term chemical treatments, altering developmental processes or environmental interventions (Arguello & Gogos 2011; Arguello & Gogos 2006; Pratt et al. 2012). However, as schizophrenia is a multifaceted
and unique human disorder, there is ongoing debate of how to achieve construct validity for the complex combination of environmental and genetic risk factors in nonacute animal models (Harrison et al. 2012; Jones et al. 2011).
Modelling the acute psychotic state in animals is primarily achieved by administering
illicit/psychodelic drugs with pharmacological actions relevant to alterations of neurotransmission observed in patients with schizophrenia (Arguello & Gogos 2006).
Phencyclidine (PCP), also known as angel dust, is a commonly used substance for
this purpose, providing an environment for early treatment validation (Adell et al.
2012). Use of PCP has been considered for animal models after observing that acute
and chronic use can trigger schizophrenia-like symptoms, such as disorganization of
thoughts and body-image changes, and prolonged psychosis in healthy adults (Javitt
& Zukin 1991; Luby et al. 1959; Smith & Wesson 1980; Yago et al. 1981). Furthermore, PCP has also been shown to increase symptom severity in patients with schizophrenia (Javitt et al. 2012; Luby et al. 1959; Murray 2002).

1.4.2 The acute PCP schizophrenia rodent model
PCP is a potent non-competitive NMDAR antagonist and an agonist for the dopamine D2 receptors (Kapur & Seeman 2002; Seeman et al. 2009; Seeman et al. 2005),
with additional lower binding affinity for several other targets such as acetylcholine,
kappa opioid and muscarinic receptors (Amir et al. 1985; Hustveit et al. 1995; Maayani & Weinstein 1979; Zukin 1982). PCP treatment in rodents has therefore been
used to model the glutamate hypofunction and dopamine hyperfunction hypotheses
of schizophrenia (Moghaddam & Krystal 2012; Seeman 2009). The combination of
pharmacological actions and observed behavioural consequences in humans provides
face validity to the acute PCP treatment for modelling acute psychotic episodes of
schizophrenia (Adell et al. 2012; Javitt et al. 2012; Pratt et al. 2012).
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1.4.2.1 Behavioural effects of acute PCP treatment in rodents
Acute PCP treatment in rodents has been shown to induce a wide spectrum of schizophrenia-relevant symptoms, including hyperlocomotion and impaired sensorimotor
gating (Geyer et al. 2001; Gleason & Shannon 1997). Increased locomotor activity
after acute PCP treatment has been considered a model for aspects of positive symptoms experienced by patients with schizophrenia during the acute psychotic state of a
psychotic episode (Adell et al. 2012). The relevance of this behavioural change has
recently been highlighted in a human-equivalent for the rodent locomotor activity
test, observing increased activity of patients with psychosis (Perry et al. 2010; Perry
et al. 2009). A range of studies have therefore been performed to assess the ability of
current antipsychotics to reduce or prevent the PCP-induced hyperlocomotion impairments in rodents, summarized in Table 1.
Patients with schizophrenia also show impaired sensorimotor gating (Braff et al.
2001). Sensorimotor gating describes the ability to “gate” trivial or currently irrelevant sensory information from awareness to focus attention on situation-relevant information (Braff & Geyer 1990). Sensorimotor gating experiments utilise the inhibition of startle response which occurs when a startling stimulus is preceded by a weak
pre-stimulus, so called prepulse inhibition (PPI). Impairments in PPI have been observed in patients with schizophrenia (Braff et al. 2001; Swerdlow et al. 2008). PPI
deficits can be induced by acute PCP treatment in rodents (Yee et al. 2004) and prevented or reduced by several current antipsychotics (Table 1). In humans, antipsychotic drugs have shown to improve PPI impairments in some (Wynn et al. 2007),
but not all patients with schizophrenia (Mackeprang et al. 2002; Geyer et al. 2001).
This has made the PCP-induced hyperlocomotion and sensorimotor gating impairment widely used drug screening paradigms.
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Table 1: Effect of current antipsychotics on acute PCP-induced
hyperlocomotion and sensorimotor gating impairments in rodents
Drug
Species Locomotor activity
Prepulse inhibition
PCP (mg/kg)

Mouse

↑ (3, 5, 7.5)f, i, k, w, h

Rat

↑ (1.25, 1.5, 2, 2.5 3, ↓ (1, 1.25, 1.5, 2, 2.5, 3,
7.5)c, e, o, t, u, x, y, z

Aripiprazole
Clozapine
Haloperidol
Ketanserin

↓ (2.5, 3, 4, 5, 8, 10)a, f, n, r, s
5)b, d, g, l, m, o, p, q, t, v, x
˅a

Mouse
Rat

˅x, ~u

~x

Mouse

˅f, h, i, k, w,

˅f, ~a,

Rat

˅y, z , ~c

˅b, d, p, v, ~l, q

Mouse

˅i, k, w

˅n, ~a,

Rat

˅c, t, y, z, ~e

˅p, ~l, m, t

Mouse

˅k
~b

Rat
Mouse

˅k

~a

Rat

~u

˅g, o, p

Mouse

˅h

˅p

Rat

~u

Ritanserin

Mouse

˅k

Ziprasidone

Mouse

˅e

Olanzapine
Risperidone

PCP treatment (mg/kg either intraperitoneal or subcutaneous) effect direction: ↑ increase, ↔ no change, ↓ reduction;
Antipsychotic treatment effect direction: ˅ reduces PCP effect, ~ no change to PCP
effect, ˄ increases PCP effect
References: a(Fejgin et al. 2007), b(Bakshi et al. 1994), c(Abekawa et al. 2006),
d
(Ballmaier et al. 2007), e(Abdul-Monim et al. 2003), f(Adage et al. 2008), g(Bakshi
& Geyer 1995), h(Fell et al. 2008), i(Vanover et al. 2004), k(Gleason & Shannon
1997), l(Johansson et al. 1994), m(Keith et al. 1991), n(Klamer et al. 2004), o(Wiley &
Kennedy 2002), p(Yamada et al. 1999), q(Wiley 1994), r(Burban et al. 2010),
s
(Curzon & Decker 1998), t(Furuya et al. 1998), u(Gyertyán et al. 2011), v(Leng et al.
2003), w(Marquis et al. 2007), x(Nordquist et al. 2008), y(Cartmell et al. 1999),
z
(Chiusaroli et al. 2010)
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1.4.2.2 Neurobiological effects of acute PCP treatment in rodents
The observed behavioural differences following acute PCP treatment in rodents have
been attributed to neurotransmission changes similar to those observed in patients
with schizophrenia (Adell et al. 2012; Javitt et al. 2012). Microdialysis experiments
have shown that acute PCP treatment affects the extracellular levels of several neurotransmitters in a range of brain regions, including the PFC and hippocampus (Table
2). These findings confirm that the diverse pharmacological profile of PCP broadly
disrupts neurotransmission across the central nervous system. The caused differences
in neurotransmitter systems are similarly found altered in patients with schizophrenia
(see 1.1.2). These neurotransmission alterations are of particularl relevance for the
model validity, as they have been identified in symptom-relevant brain areas (Table
2). While the majority of microdialysis studies have assessed neurotransmitter levels
in the PFC and striatum, post-mortem studies add support for the involvement of the
hippocampus in the effect of acute PCP treatment (Zavitsanou et al. 2008).
The acute effect of PCP treatment on neurotransmission therefore supports the face
validity of the acute PCP rodent model for treatment development studies. The ability of current antipsychotic treatments to alter PCP-induced neurotransmitter level
changes has been assessed in a small number of rodent studies. PCP-induced changes
to glutamate and serotonin levels in the PFC were amendable by current antipsychotics (Table 2). However, the effect of these antipsychotics on hippocampal neurotransmitter levels following PCP-treatment is unknown. The lack of available data is
possibly due to the limited effect of current antipsychotics on hippocampusassociated schizophrenia symptoms such as long-term memory impairments (Boyer
et al. 2007; Désaméricq et al. 2014). Furthermore, the ability of these pharmacological substances to influence GABA levels in the presence of PCP has also not been
investigated.
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Table 2: Effect of current antipsychotics on neurotransmitter levels following acute PCP treatment in rodents
Drug
GABA
Glutamate
Dopamine
Serotonin
PCP

↓ PFC (rd) p, u; ↔ (s.c.) s

↑ mPFC (s.c. & i.p.)

↑ NAc (rd) c, (i.p.) f, g, l, v, (s.c.)h; ↔ (i.p.) m

↔ mPFC (rd) a, ↑ (rd) p

↑ Str (rd) n; ↔ (rd) q, (i.p.) n

b, d, e, j, l, t

↑ mPFC (i.p.) f, i, j, k, l, o, v, (rd) p, u, (s.c.) r

↑ mPFC (i.p.)a, e, f, j, v,

↓ Hip (s.c.) s

↔ PFC(rd) p

↑ Str (rd) n, (i.p.) f,

(s.c.) s

n, v

, (s.c.) r; ↔ (i.p.) i, v

↔ NAc l

↔ Str (i.p.) f, u

↔ Str (rd) n, q, (i.p.) n

↑ NAc (i.p.) v

Acetylcholine
↑ NAc (i.p.) m

↑ Hip (s.c.) s
Clozapine

˅ mPFC (i.p.) d, e

˅ mPFC (s.c.) a

Haloperidol

˅ mPFC (i.p.) d, ~ e

~ mPFC (s.c.) a

Olanzapine

˅ mPFC (s.c.) a

Prazosin

˅ mPFC (s.c.) a

Ritanserin

~ mPFC (i.p.) i

˅ mPFC (i.p.) a

Effect direction: ↑ increase, ↔ no change, ↓ reduction; ˅ reduce PCP effect, ~ no change to PCP effect, ˄ increase PCP effect
Brain region: mPFC: medial prefrontal cortex, NAc: nucleus accumbense, Str: striatum
Administration type: rd: retrodialysis, infusion via microdialysis probe; i.p. intraperitoneal, s.c. subcutaneous
References: a(Amargos-Bosch et al. 2006), b(Amitai et al. 2012), c(McCullough & Salamone 1992), d(Abekawa et al. 2006), e(Adams &
Moghaddam 2001), f(Etou et al. 1998), g(Jacobsen et al. 2005), h(Javitt et al. 1999), i(Kuroki et al. 1999), j(Li et al. 2010), k(Jentsch et al. 2008),
l
(Adams & Moghaddam 1998), m(Del Arco et al. 2007), n(Lillrank et al. 1994), o(Maeda et al. 2003), p(Zhu et al. 2004), q(Yamamoto et al. 1999),
r
(Hagino et al. 2010), s(Martin et al. 1998), t(Baker et al. 2008), u(Yonezawa et al. 1998), v(Millan et al. 1999)
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The consequence of prolonged PCP exposure on the expression of receptors and other neurotransmission-related proteins has been studied following several different
treatment regimes. Expression levels of GABA-A receptors (Abe et al. 2000; Yu et
al. 2002), GAD67 (Amitai et al. 2012), PV (Reynolds et al. 2004; Thomsen et al.
2009; Cochran et al. 2003), NMDA-R (Lindahl & Keifer 2004; Wang et al. 1999)
and other GABAergic and glutamatergic system elements have been reported to be
altered by different chronic and sub-chronic PCP treatments (Javitt et al. 2012; Mouri
et al. 2007). The variation in treatment timing and concentration as well as the use of
different species and the inconsistency of the observed differences make the chronic
and sub-chronic PCP treatments a less robust schizophrenia model than the acute
PCP treatment. However, little data is available on the consequence of acute PCP on
neurotransmission-related protein expression levels.

1.5

Summary and aims

Several aspects of the symptomatology and pathophysiology of schizophrenia are not
addressed by current antipsychotic drugs. The strong focus of current pharmacological treatments on the dopaminergic system leaves the prominent differences in the
GABAergic and glutamatergic system untreated. GABAergic and glutamatergic neurotransmission have been reported to be influenced by NRG1, particularly through its
receptor ERBB4.
In regards to these considerations, the specific aims of my thesis are to:
(1) assess the potential of acute NRG1 application to prevent PCP-induced schizophrenia-like behavioural impairments,
(2) study the effect of NRG1 treatment on GABAergic and glutamatergic neurotransmission in the presence of PCP and finally
(3) treat frontal cortex networks with NRG1 in the presence of PCP to identify its
effect on components of the GABAergic and glutamatergic system relevant to the
pathophysiology of schizophrenia.
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2 THE EFFECT OF NRG1 ON PCP-INDUCED BEHAVIOURAL IMPAIRMENTS

2.1

Introduction

Addressing behavioural impairments in schizophrenia-relevant rodent models is fundamental and therefore a common strategy to explore potential antipsychotic abilities
of pharmacological treatments (Jones et al. 2011). While it is important for novel antipsychotics to address identified biological alterations in patients with schizophrenia, pharmacological treatments ultimately have to improve the behaviour of patients. Initial drug screening experiments therefore rely on models with quantifiable
behavioural differences. A range of interventions, each with demonstrable construct
validity from clinical studies, have been developed to model behavioural differences.
The suitability of a pharmacological agent can initially be tested in a broad model,
like acute administration of PCP to rodents, which is widely used for early treatment
identification studies (Adell et al. 2012; Javitt et al. 2012). Successful compounds
can then be assessed in a more specialised environment, modelling single disease
components while the potential of unsuccessful substances can be doubted early in
the drug development process.
Acute PCP treatment in rodents has been shown to induce a wide spectrum of schizophrenia-relevant phenotypes, including hyperlocomotor activity and impairment of
sensorimotor gating (Gleason & Shannon 1997; Yee et al. 2004). Several studies
have therefore assessed the ability of current and novel antipsychotics to reduce or
prevent PCP-induced hyperlocomotion and sensorimotor gating impairment (Table
1). Recent reviews of the acute PCP model have supported the justification of these
preclinical studies by proposing that improving these PCP-induced impairments has
translational validity for the clinical setting (Adell et al. 2012; Javitt et al. 2012; Pratt
et al. 2012).
Transgenic and knockout animal models with mutations in the NRG1 or ERBB4
genes express sensorimotor gating impairments as well as increased locomotor activity (Chen et al. 2008; Deakin et al. 2009; Duffy et al. 2008; Karl et al. 2007; Kato et
al. 2010; Stefansson et al. 2002). While developmental compensatory mechanisms
likely contribute to these impairments, these studies indicate that unbalanced NRG130

ERBB4 signalling can have behavioural consequence. Furthermore, overexpressing
NRG1 in mice appears to have a different effect on adult neurotransmission compared to NRG1 administration during adulthood (Kwon et al. 2008; Kato et al. 2010),
which supports the involvement of acute NRG1-ERBB4 signalling in behaviourrelevant CNS structures.
The aim of this first study was therefore to assess potential antipsychotic characteristics of acute NRG1 treatment on schizophrenia-relevant locomotor activity and PPI
impairments induced by acute PCP treatment. Using these behavioural paradigms in
my study allowed me to set effects of NRG1 treatment in relation to treatment outcomes observed in previous studies for a range of existing antipsychotics (see Table
1).
While receptors for NRG1 are expressed in several brain regions (see 1.2.1), they
have also been found on muscle tissue (Bersell et al. 2009; Wadugu & Kühn 2012;
Zhu et al. 1995). Peripheral NRG1 treatment might therefore directly affect muscle
cells, masking possible central nervous system (CNS) responses. To separately examine the effect of central and peripheral NRG1 administration on PCP-induced impairments, I performed independent experiments with intracerebroventricular (i.c.v.)
and intraperitoneal (i.p.) NRG1 administration.
Several studies have reported that i.p. PCP treatment triggers hyperlocomotion and
impairs sensory motor gating in mice (Table 1). I therefore hypothesized that PCP
treatment would also induce hyperlocomotion and PPI impairments in the present
study. The small number of in vitro and in vivo experiments studying the effect of
NRG1 on neurotransmission indicate that NRG1 treatment could alter acute neurotransmission relevant to these behaviours (see 1.2.3). I therefore hypothesized that
combined treatment of NRG1 and PCP would reduce the PCP effect on locomotor
activity and PPI. Finally, as NRG1 has been reported to readily cross the bloodbrain-barrier, I hypothesized that peripheral and central treatment will have similar
therapeutic effects.
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2.2

Materials and Methods

2.2.1 Subjects
Ten-week old male C57BL/6J mice were purchased from Animal Resource Centre
(Perth, WA, Australia) and Australian BioResources (Moss Vale, NSW, Australia).
Animals were housed two to four per open-lid cage with minimal environmental enrichment (M1 polypropylene cages with sawdust bedding; Able Scientific). Animals
were maintained on a 12 h light/dark cycle (light on at 0600 hours) with food and
water available ad libitum in the animal facilities of the University of Wollongong
(Wollongong, Australia) and Neuroscience Research Australia (Sydney, Australia).
All research and animal care procedures were approved by either the Animal Ethics
Committee of the University of Wollongong (AE 11/18) or University of New South
Wales (11/80B) and were in agreement with the ‘Australian Code of Practice for the
Care and Use of Animals for Scientific Purposes’. All steps were taken to ameliorate
any suffering in all work involving animals in my studies. All animals were acclimatised to the animal facilities for at least one week prior to behavioural experiments
and testing order was pseudo-randomised to account for potential diurnal variations.

2.2.2 Drugs
All compounds were obtained from Sigma (Castle Hill, NSW, Australia) except
where specified otherwise. The principal isoforms of NRG1 expressed within the
nervous system are those containing the β1-EGF domain, which I therefore selected
for my treatment experiments (Meyer & Birchmeier 1994; Shinoda et al. 1997).
Drugs were freshly prepared on each treatment day. Recombinant human NRG1
(#396 NRG1-β1/HRG1-β1 EGF domain carrier free; R&D Systems, USA) and PCP
were dissolved in either artificial cerebrospinal fluid (ACSF, 119mM NaCl; 2.5mM
CaCl2; 2.5mM KCl; 1.3mM MgSO4; 1mM NaH2PO4; 26.2mM NaHCO3; 11mM glucose, 7.4pH, 290mOsm/kg) for i.c.v. injections or in 0.9% NaCl (vehicle) for i.p. injections. Each mouse received no more than three injections with an inter-test interval of at least six days.
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2.2.3

I.C.V. Surgery

Mice destined for i.c.v. treatment underwent surgical implantation of an i.c.v. cannula one week prior to experiments. Animals were anaesthetised with an inhalation
1.5% isoflurane (Delvet, USA)/98.5% oxygen mix. Using a stereotactic frame (Kopf
Instruments, USA), a 21G guide cannula (1cm) was implanted into the brain targeting the right lateral ventricle (Bregma -0.25mm rostral, -1mm medial, -1.5mm from
top of skull (Paxinos & Franklin 2001)). The guide cannula was fixed to the skull
with three anchor screws (2mm, Microbiotech, Sweden) and dental acrylic (Ketac
Cem, Halas Dental Limited, Australia). All animals were injected with 0.1ml of a
depot-antibiotic substance (Medicam®, Boehriner Ingelheim, Germany) and which
was also added to their drinking water (0.1%) for three days following surgery.
Dummy cannulae (28G), were inserted into the guide to keep it clean and prevent
occlusion. Following surgery, mice were individually housed and their recovery was
monitored daily until the behavioural experiments commenced.

2.2.4

Locomotor activity

For locomotor activity assessment during the light phase, each mouse was placed in a
round open field chamber (black PVC, grey floor, 40cm diameter, 9lx for a least
anxiogenic environment, Figure 4A). After 30min habituation, the mice received an
i.c.v and/or i.p. injection according to their treatment scheme and their activity was
monitored over a subsequent 30min period (Figure 4B).

A

B

Treatment (i.p. ± i.c.v.)
Baseline

‐30 min

‐10 min
Habituation

+30 min

0 min
Experiment

Figure 4: Schematic of the open field experiment schedule
(A) For the locomotor activity experiments, all animals were placed in a round open
field arena and distance travelled was video recorded. (B) Animals were habituated
to the arena for 30min, followed by i.p. or i.p. + i.c.v. treatment and further 30min in
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the arena. The distance travelled during the 30min post-treatment response time was
normalised to the 10min baseline before injections.
Distance was analysed from video recordings using the EthoVision tracking system
(Noldus, Netherlands). Activity data were collected in 5min intervals. The average
distance 10min before treatment was set as baseline for each animal, with posttreatment intervals normalised to this baseline (Figure 4).

2.2.5 Sensorimotor gating (prepulse inhibition of startle assessment)
Acoustic startle response (ASR) and PPI were tested during the light phase in special
mouse startle chambers (SR-Lab: San Diego Instruments, San Diego, USA). Animal
enclosures were cleaned with detergent between animals. Startle response was measured as the average amplitude of the startle. The duration of the prepulse was 20ms
and 40ms for the startle. The inter-trial interval was averaged over 10–25s. ASR was
calculated as the startle amplitude in arbitrary units averaged over the test trial. For
ASR habituation, blocks of startle responses were averaged at the beginning, middle
and end of the PPI protocol (3 startle response blocks). Percentage of PPI (%PPI)
was calculated as [(ASR 120dB – prepulse response) × 100/ASR 120dB].

Treatment (i.p.)

30min

1 week

5min

Habituation

30min

Experiment

Figure 5: Schematic of the sensorimotor gating experiment schedule
One week prior to the beginning of each experiment, all animals were habituated to
the startle chambers for 30min at 70dB white noise. On the experiment day, animals
were placed in the startle chamber following i.p. treatment, with experiments commencing after an additional 5min habituation period at 70dB.
Following habituation to the startle chamber (30min one week before testing, Figure
5), and a 5min acclimatisation period (70dB background noise) upon test, the protocol was as following: The session started with five 120dB startle pulses after which
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three startle pulses (70/100/120dB) were presented five times each in a pseudorandomised order. After this, 75 PPI response trials (prepulse intensities of
74/82/86dB followed by a 120dB startle pulse) were presented five times in a quasirandomised order employing five different inter-trail stimulus intervals (ISIs)
(32/64/128/256/512ms) followed by final five 120dB startle pulses.

2.2.6 Drug treatment scheme for open field and PPI
For the i.p. experiments, all animals (n=8/group) received an i.p. injection of either
PCP (3mg/kg), PCP+NRG1 (5, 25 or 50µg/kg), NRG1 (5, 25 or 50µg/kg) or vehicle.
For the i.c.v. experiments, all animals (n=6-8/group) received an i.c.v. injection of
either NRG1 (3, 30 or 300ng/kg) or ACSF and simultaneously an i.p. injection of
PCP (3mg/kg) or vehicle. The PCP concentration of 3mg/kg has been selected based
on previous reports on its suitability for the locomotor activity and PPI paradigms
without causing unwanted adverse reactions (Gleason & Shannon 1997; Kitaichi et
al. 1994; Yee et al. 2004).

2.2.7 Statistical Analysis
Pre-injection habituation locomotor activity and startle response following pulseonly trails were assessed by one-way analysis of variance (ANOVA), and followed
by Bonferroni’s multiple comparison post-hoc analysis if applicable. Differences in
post-treatment locomotion were analysed using a General Linear Model for repeated
measurements, followed by Tukey’s post-hoc analysis when applicable. Differences
in startle habituation and PPI, averaged for all ISIs, were assessed using two-way repeated measure ANOVA (with the factors treatment and prepulse intensity or pulse
timing), and followed by Bonferroni’s multiple comparison post-hoc analysis where
applicable. Outliers were screened as mean ±2 standard deviations and removed.
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2.3

Results

2.3.1 NRG1 prevents PCP-induced hyperlocomotion following peripheral administration
Spontaneous locomotion of i.p. treated animals during habituation (mean=101.4
cm/min) did not differ between treatment groups (F(3, 28)=0.43, P=0.73) (Figure 6).
Post-injection time (F(5, 140)=2.321, P<0.05) and treatment (F(3, 28)=7.86, P<0.01)
affected locomotion and an interaction of time and treatment was observed (F(15,
140)=2.817, P<0.001).
PCP administration led to an increase in distance travelled compared to vehicle
treatment and remained above vehicle levels for the entire recording period (P<0.001
vs vehicle) (Figure 6).
Combining PCP with NRG1 i.p. altered the PCP effect in a concentration-dependant
manner (Figure 6). Locomotor activity following combined treatment of PCP and
25µg/kg NRG1 was significantly less than PCP only treatment (P<0.01) and similar
to vehicle treated animals (P=0.91) (Figure 6A). PCP combined with 5 or 50 μg/kg
NRG1 led to locomotor activity similar to PCP only treated animals (5 μg/kg:
P=0.77, 50 μg/kg: P=0.71) (Figure 6B). Furthermore, animals treated with 50µg/kg
NRG1 and PCP showed significantly increased locomotor activity compared to vehicle treated animals (P<0.001).
Mice treated with different concentrations of NRG1 i.p. showed no difference in locomotor activity compared to vehicle treated animals (P>0.9 for 5, 25 and 50 μg/kg
NRG1 vs vehicle) (Figure 6B).
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Figure 6: Peripheral administered neuregulin 1 (NRG1) prevents PCP-induced
hyperlocomotion
After habituation, mice (adult male, n=8/group) received intraperitoneal (i.p.) treatment and were returned to the open field arena. Locomotion after i.p. treatment was
normalised to individual baseline performance. Mice were administered veh (0.9%
NaCl), PCP (3 mg/kg). NRG1+PCP (5, 25 or 50μg/kg NRG1 + 3mg/kg PCP) or
NRG1 (5, 25 or 50μg/kg). (A) Post-treatment distance moved during 5 min intervals
following NRG1 (25μg/kg), NRG1 (25μg/kg) + PCP, PCP or Veh is presented as
mean percentage difference to baseline locomotion ± SEM. (B) Average distance
moved across the post-treatment period is presented as mean percentage difference to
baseline locomotion + SEM; NRG1 concentration displayed as μg/kg i.p. **P < 0.01
vs PCP; ###P<0.001 vs Veh.
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2.3.2 NRG1 prevents PCP-induced hyperlocomotion following central administration
In the second experiment, spontaneous locomotor activity during habituation
(mean=98.3 cm/min) did not differ between treatment groups (F(6, 44)=1.17,
P=0.34) when tested one week after i.c.v. surgery. Post-injection time (F(5,
140)=3.84, P<0.01) and treatment (F(3, 28)=14.7, P<0.001) affected locomotion, but
no interaction of time and treatment was observed (F(15, 140)=0.771, P=0.71).
Post-hoc analysis revealed a significant increase in locomotor activity following PCP
treatment compared to vehicle treatment (P<0.001) (Figure 7A), with distance remaining above vehicle levels for entire post-treatment period.
Combined treatment of PCP with NRG1 i.c.v. affected the PCP-induced locomotor
activity changes in a dose-dependent manner (Figure 7B). Locomotor activity following combined treatment of PCP i.p. and 30ng/kg NRG1 i.c.v was significantly
less than PCP only treatment (P<0.01) and similar to vehicle treated animals (P=0.1)
(Figure 7A). However, locomotor activity following PCP with either 3ng/kg or
300ng/kg NRG1 i.c.v. was not different to the PCP only treatment group (P=0.74 and
P=0.24 respectively), but significantly increased compared to vehicle treated animals
(P<0.01 and P<0.05 respectively) (Figure 7B).
Spontaneous locomotor activity following NRG1 i.c.v. treatment was indistinguishable to vehicle treated animals (30 ng/kg: P=0.71; 300 ng/kg: P=0.86) (Figure 7B).
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Figure 7: Central administered neuregulin 1 (NRG1) prevents PCP-induced
hyperlocomotion
After habituation, mice (adult male, n=8/group) received intracerebroventricular
(i.c.v.) and intraperitoneal (i.p.) treatment and were returned to the open field arena.
Locomotion after i.c.v. and i.p. treatment was normalised to individual baseline performance. Mice were administered vehicle (artificial cerebrospinal fluid (aCSF) i.c.v.
+ 0.9% NaCl, i.p.), PCP (aCSF, i.c.v. + 3mg/kg, i.p.), NRG1+PCP (3, 30 or
300ng/kg NRG1, i.c.v. + 3mg/kg PCP, i.p.) or NRG1 (30 or 300ng/kg NRG1, i.c.v. +
0.9% NaCl, i.p.). (A) Post-treatment distance moved during 5 min intervals following NRG1 (30ng/kg i.c.v.), NRG1 (30ng/kg i.c.v.) + PCP, PCP or Veh is presented
as mean percentage difference to baseline locomotion ± SEM. (B) Average distance
moved across the post-treatment period is presented as mean percentage difference to
baseline locomotion + SEM; NRG1 concentration displayed as ng/kg i.c.v. **P <
0.01 vs PCP; #P<0.05, ##P<0.01, ###P<0.001 vs Veh.
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2.3.3 NRG1 prevents PCP-induced deficit of prepulse inhibition of startle
Increase in startle pulse intensity resulted in an increased startle reflex response
across all treatments as revealed by one-way ANOVA for repeated measures (startle
pulse intensity: F(2, 116)=188.0, P<0.001; 70dB=9.1±0.6, 100dB=22.5±1.2,
120dB=68.7±5.49) (Figure 8A). Two-way ANOVA for repeated measures revealed a
significant effect of time (F(2, 116)=23.29, P<0.001) but not treatment (F(7,
58)=1.845, P=0.1), nor an interaction for time x treatment (F(14, 116)=0.62, P=0.84)
on startle reflex habituation throughout the experiment session (Figure 8B).
Critically, there was no treatment effect on startle reflex response in pulse-only trials
when averaged across the experiment session (F(7, 58)= 1.502, P=0.2) (Figure 9).
Using a two-way ANOVA for repeated measures, I identified a significant effect of
treatment (F(6, 45)=5.554, P<0.001) and prepulse intensity on PPI (F(2, 90)=371.4,
P<0.001), but no interaction between treatment and prepulse intensity (F(12,
90)=1.128, P=0.35). Post-hoc analysis revealed a significant reduction in PPI following PCP treatment for each tested prepulse intensity compared to vehicle (74dB:
14.2±3.1%, P<0.01; 82dB: 36.1±4%, P<0.001; 86dB: 42±4%, P<0.01) (Figure 9A).
Combined treatment of NRG1 and PCP had a concentration dependent effect on
PCP-induced PPI disruption. PPI following combined PCP and 25µg/kg NRG1
treatment was significantly higher than following PCP only treatment for 12dB and
16dB prepulse intensity (82dB: 51.5±3.4%, P<0.01; 86dB: 54.1±3%, P<0.05 vs
PCP) (Figure 9B). PPI following combined PCP and 50µg/kg NRG1 differed to
PCP-only treatment at 82dB prepulse intensity (51.3±3.8%, P<0.05 vs PCP) (Figure
9B). PPI following combined treatment of PCP with 5µg/kg NRG1 did not differ for
any prepulse intensities to PCP-only treatment (P>0.8 for each prepulse intensity vs
PCP) (Figure 9B).
NRG1 treatment at 25µg/kg and 50µg/kg had no effect on prepulse inhibition compared to vehicle (Figure 9B). 5µg/kg NRG1 treatment impaired prepulse inhibition at
74dB and 82dB prepulse intensity (74dB: 19.2±3.2%, 82dB: 44.8±3.1%, P<0.05 vs
vehicle each) (Figure 9B).
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Veh
PCP (3 mg/kg)
NRG1 (5 µg/kg) + PCP
NRG1 (25 µg/kg) + PCP
NRG1 (50 µg/kg) + PCP
NRG1 (5 µg/kg)
NRG1 (25 µg/kg)
NRG1 (50 µg/kg)

Figure 8: Startle response to pulse intensity and pulse timing
Mice (adult male, n=7-8/group) received intraperitoneal (i.p.) treatment and were
placed in the startle chambers for 30min experiments. Mice were administered Veh
(0.9% NaCl), PCP (3mg/kg), NRG1+PCP (5, 25 or 50µg/kg NRG1 + 3mg/kg PCP)
or NRG1 (5, 25 or 50µg/kg NRG1). (A) Startle development to pulse-only trials at
three different pulse intensities, presented as startle + SEM. (B) Startle habituation to
120dB pulse-only trials at the beginning, middle and end of the experiment session,
presented as startle + SEM.
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Startle (arbituary value)
Prepulse inhibition (%)

Figure 9: Peripheral neuregulin 1 (NRG1) injection prevents PCP-induced
prepulse inhibition (PPI) impairment
Mice (adult male, n=7-8/group) received intraperitoneal (i.p.) treatment with veh
(0.9% NaCl), PCP (3mg/kg), NRG1+PCP (5, 25 or 50μg/kg NRG1 + 3mg/kg PCP)
or NRG1 (5, 25 or 50μg/kg) before being placed into the startle chamber. Acoustic
startle reactivity was tested in 100 trials following a 5 min acclimatisation period to
white noise (70 dB). (A) Treatments had no effect on average startle response to a
120 dB pulse (One-way ANOVA, F(7, 58)=1.502, P=0.18). Values are presented as
mean of startle intensity + SEM. (B) Treatment effect on PPI following different
prepulse intensities. Values are presented as mean percentage of PPI + SEM.
*P<0.05, **P < 0.01 vs PCP; #P<0.05, ##P<0.01, ###P<0.001 vs veh.
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2.4

Discussion

My behaviour experiments showed that PCP-induced hyperlocomotor activity and
PPI impairments were prevented by combined treatment with NRG1 in a dosedependent manner. Animals treated with NRG1-only showed no behavioural differences compared to vehicle treated animals.

2.4.1 NRG1 treatment prevents PCP-induced hyperlocomotion
I observed an increase in locomotor activity following acute PCP treatment (i.p. experiment: 1.54 times, i.c.v. experiment 2.8 times), which is within the reported range
of existing publications for the same 3mg/kg i.p. PCP concentration (1.3 times
(Mouri et al. 2011), 2 times (Allen et al. 2011; Nagai et al. 2003), 3 times (Gleason
& Shannon 1997)). The increase in distance travelled following PCP treatment was
larger for animals which had undergone i.c.v. surgeries prior to testing than those
only receiving i.p. injections (Figure 6 and Figure 7). PCP-induced hyperlocomotion
has been shown to be dose, strain and environment dependent, thus the extent can
differ between studies (Koseki et al. 2012; Mouri et al. 2011). It is therefore possible
that surgery-related handling made the animals more susceptible to the psychotic-like
actions of PCP.
Currently available antipsychotics have shown to be effective in reducing PCPinduced hyperlocomotor activity following 2-7.5 mg/kg PCP i.p. (Table 1). I therefore selected 3mg/kg PCP i.p. as the concentration of choice for reliably inducing
hyperlocomotor activity effect without causing any of the reported adverse effects on
general motor function as seen with higher PCP concentrations (Gleason & Shannon
1997; Kitaichi et al. 1994; Marquis et al. 2007).
Several experiments have assessed the effect of antipsychotics on PCP-induced hyperlocomotion when administered prior to the PCP injection (Abdul-Monim et al.
2003; Abekawa et al. 2002). While this procedure is likely due to the pharmacokinetics of the assessed substance, the translational value of such a treatment regime is
limited. The behavioural consequences of acute PCP treatment are considered to
simulate an acute psychotic episode (Adell et al. 2012; Javitt et al. 2012). I therefore
decided to administer NRG1 and PCP simultaneously to assess the effect of NRG1
from the onset of the PCP interference.
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When testing NRG1 for its efficacy against PCP, I observed that i.p. and i.c.v. NRG1
treatments were successful in preventing PCP-induced impairments in the open field
arena (Figure 6 and Figure 7). NRG1 at 25µg/kg i.p. and 30ng/kg i.c.v. completely
prevented the induction of hyperlocomotion by PCP. The effectiveness of NRG1 at
these concentrations against PCP-induced impairments is similar to findings in publications where existing antipsychotics were used (see Table 1). The NRG1 treatment
effect was concentration dependent as the high (50µg/kg i.p. or 300ng/kg i.c.v.) or
low (0.5 and 5µg/kg i.p. or 3ng/kg i.c.v.) doses of NRG1 did not prevent PCPinduced hyperlocomotion (Figure 6 and Figure 7).
The comparable outcomes of i.p. and i.c.v. NRG1 administration against PCPinduced hyperlocomotion suggest that central rather than peripheral NRG1 receptors
mediated the beneficial treatment effects. Both administration methods completely
prevent i.p. PCP from inducing hyperlocomotion, which suggests a rapid uptake of
i.p. NRG1 across the blood-brain-barrier in treatment-relevant quantities. This finding is in accordance with existing studies, which have shown that peripherally administered human recombinant NRG1 can readily cross the blood-brain-barrier in
mice (Kastin et al. 2004; Rösler et al. 2011; Kato et al. 2011; Cui et al. 2013). My
results provide evidence for the suitability of peripheral NRG1 administration with
behavioural consequence, which is further supported by the observed comparable
timing of i.p. and i.c.v. injected NRG1 in preventing the PCP-induced hyperlocomotion (Figure 6 and Figure 7).

2.4.2 NRG1 treatment prevents PCP-induced PPI impairments
I observed a reduction in PPI following acute PCP treatment for each prepulse intensity, with values similar to existing publications (Adage et al. 2008; Fejgin et al.
2007; Klamer et al. 2004). Several currently available antipsychotics have shown to
be effective in reducing the PCP-induced PPI impairments in rodents following 1-5
mg/kg PCP i.p. (Table 1). However, the effects have not always been reproducible
nor are all current antipsychotics effective against PCP-induced PPI impairments
(Fejgin et al. 2007; Johansson et al. 1994; Keith et al. 1991; Wiley & Kennedy
2002). I selected 3mg/kg PCP i.p. as optimal concentration for reliably inducing a
PPI deficit (Curzon & Decker 1998; Johansson et al. 1994) and to remain compara44

ble to my open field experiments. The startle response during the single pulse trials
was not affected by PCP, confirming the suitability of 3mg/kg PCP for my experiment as general reflex mechanisms were not impaired (Figure 8).
In line with my locomotor activity experiments, I opted for simultaneous treatment of
NRG1 and PCP to identify potential antipsychotic-like actions of NRG1, even
though several sensorimotor gating studies administered the drug of interest prior to
PCP (Bakshi & Geyer 1997; Bakshi & Geyer 1995; Ballmaier et al. 2007; Fejgin et
al. 2007; Johansson et al. 1994; Klamer et al. 2004; Wiley & Kennedy 2002; Yamada
et al. 1999). Startle response was not affected by NRG1 injections, confirming the
suitability of the selected NRG1 concentrations (Figure 8). This confirmation is of
critical importance as several current antipsychotics have shown to dose-dependently
reduce the startle reflex in pulse-only trials (Fejgin et al. 2008).
In my study, simultaneous administration of NRG1 and PCP prevented the PCPinduced PPI impairments (Figure 9). The treatment effect was concentration dependent as PPI following high (50µg/kg i.p.) and low (5µg/kg i.p.) doses of NRG1 in the
presence of PCP was impaired (Figure 9). NRG1 at 25µg/kg i.p. prevented the reduction of PPI by PCP for the 12 and 16dB prepulse intensities. The effectiveness of
NRG1 at this concentration against PCP-induced impairments is similar to published
effects of existing antipsychotics (see Table 1).
In line with my locomotor activity experiments, startle response and PPI were not
affected by 25μg/kg NRG1, the most effective concentration against PCP, throughout the experiment (Figure 8). Furthermore, startle response at the start and end of
the experiment were similar for 25μg/kg NRG1, indicating that NRG1 treatment had
no delayed negative effect on relevant CNS circuits (Figure 8).
Preventing sensorimotor gating impairment in this widely used acute psychosis model suggests a critical potential for NRG1 treatment to beneficially address a common
schizophrenia symptom present in patients (Swerdlow & Geyer 2011). The observed
effect of NRG1 on PCP-induced PPI reduction provides additional support for the
suitability of peripheral NRG1 treatment in targeting CNS structures relevant to the
schizophrenia pathophysiology (Swerdlow et al. 2001).
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2.4.3 Behavioural consequences of increased NRG1-ERBB signalling – treatment
implications
The open field and prepulse inhibition experiments have shown that NRG1 administration can prevent behavioural impairments otherwise induced by PCP. This supports my initial hypothesis suggesting that NRG1 treatment can alter behaviourrelevant neurotransmission. Since I am the first one to assess the behavioural implication of acute NRG1 administration on locomotor activity and sensorimotor gating
relevant to schizophrenia, it is also critical to study the effects of NRG1-only treatment on the examined behaviours. This is of particular interest since several current
antipsychotics can have adverse effects on behavioural performance in healthy animals (Adage et al. 2008; Amitai et al. 2007; Bakshi & Geyer 1995; Fejgin et al.
2007; Geyer et al. 2001; Gleason & Shannon 1997; Johansson et al. 1995; Johansson
et al. 1994; Linn et al. 2003; Mutlu et al. 2011; Nordquist et al. 2008; Okuyama et al.
1999; Swerdlow et al. 1991; Wiley 1994).
The results from the i.c.v. and i.p. experiments show that acute NRG1 administration
at different concentrations has no effect on spontaneous locomotor activity (Figure 6
and Figure 7), which had also been indicated by a previous study (Mahar et al. 2011).
Furthermore, neither startle response nor PPI differed in animals treated with the
most effective NRG1 concentrations (Figure 8 and Figure 9).
The outcome of my experiments suggests that NRG1 has a system-dependent effect
within a specific concentration range. Administration of NRG1 appears capable of
improving specifically impaired conditions at concentrations which show no effect
on the healthy phenotype.
In vitro experiments have so far provided conflicting information regarding the effect
of acute NRG1 on neuronal activity. Some studies suggest that NRG1 has little effect
on baseline activity of neuronal networks (Kwon et al. 2005; Kwon et al. 2008;
Fisahn et al. 2009), while others show alterations to neurotransmitter signalling (such
as GABA and glutamate) even at baseline following NRG1 application (Mitchell et
al. 2013; Yin et al. 2013). The concentration-dependent effect of NRG1 signalling
observed in the present study might contribute to the varying effect of NRG1 on neuronal activity.
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In my experiments I explored the dose-dependent effect of acute NRG1 treatment on
locomotor activity and sensorimotor gating. Existing antipsychotics show clear doseresponse effects in preventing PCP-induced impairments (Fejgin et al. 2007; Gleason
& Shannon 1997; Johansson et al. 1994), and more importantly in reducing symptom
severity in patients with schizophrenia (Kinon et al. 2004; Miyamoto et al. 2012). I
observed that the efficiency of NRG1 treatment in preventing PCP-induced impairments is also dose-dependent, following a u-shaped dose-response curve in the locomotor activity and PPI paradigms (Figure 10), with 25μg/kg i.p. and 30ng/kg i.c.v
being the most effective dose (Figure 6, Figure 7 and Figure 9). To identify the precise NRG1 treatment window, additional treatment concentrations are required to
support the indicated u-shaped dose-response curve.
NRG1 has been proposed to cross the blood-brain barrier via a saturable active
transport mechanism (Kastin et al. 2004). In the peripheral treatment paradigms, the
effect of 25µg/kg NRG1+PCP i.p differs to 50μg/kg NRG1+PCP on locomotor activity and PPI (Figure 6, Figure 9). This observed dose-response to NRG1 indicates that
25µg/kg NRG1 i.p. might not fully exhaust the active transport mechanism which
enables blood-brain-barrier crossing.
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Figure 10: Dose-response effect of neuregulin 1 (NRG1) vs PCP on locomotor
activity
U-shaped dose-response curves: Locomotion depicted as deviation from vehicle
treatment with varying doses of i.p. NRG1 (A, µg/kg) or i.c.v. NRG1 (B, ng/kg) administered for NRG1+PCP co-treatment. Shades indicate vehicle and PCP-group
SEM respectively. For detailed dose-effects see Figure 6 and Figure 7.
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Additionally to the NRG1 treatment concentration relevance from my study, treatment duration also appears to be relevant to behavioural regulation. Knockout mouse
studies have shown that constant increase as well as decrease in NRG1 production
can cause hyperlocomotion and PPI impairments (Luo et al. 2013; Wen et al. 2010;
Yin et al. 2013). Altered NRG1 signalling during development is likely to trigger
compensatory mechanisms, which potentially contribute to the observed behavioural
impairments in knockout animals. However, Rescuing NRG1 overexpression during
adulthood also rescued PPI and locomotion impairments in some transgenic animals
(Luo et al. 2013; Yin et al. 2013), suggesting that acute NRG1 signalling is relevant
for behaviour regulation.
Remarkably, a dose-response effect similar to the present study was recently reported
in a phase II clinical trial of NRG1. Patients with chronic heart failure have been
treated successfully with recombinant NRG1, where the medium dose showed the
highest efficacy and the least side effects, with a lasting therapeutic effect beyond
treatment termination (Gao et al. 2010; Jabbour et al. 2011). The early nature of these
clinical trials with intravenous NRG1 administration requires further exploration of
NRG1-concentration dependent effects.
In summary, my behavioural results provide the first evidence for antipsychotic-like
characteristics of NRG1 treatment by demonstrating that NRG1 has neuromodulatory
properties with schizophrenia-relevant behavioural consequences. By improving
PCP-induced hyperlocomotion and PPI impairments NRG1 shows characteristics of
existing antipsychotics without causing observable adverse reactions. Further behaviour experiments with longer NRG1 treatment durations are required to assess its potential suitability for the clinical setting. However, in my next study I investigated the
effect of NRG1 on GABAergic and glutamatergic neurotransmission, since both
have been implicated in locomotor activity regulation and sensorimotor gating (Asinof & Paine 2013; Geyer et al. 2001; Swerdlow et al. 2001; Tanner 1979; Viggiano
2008; Yeomans et al. 2010).
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3 NEUREGULIN 1 TREATMENT AFFECTS GABA AND GLUTAMATE
RELEASE AFTER PCP CO-TREATMENT IN FREELY MOVING MICE

3.1

Introduction

In my behaviour experiments, I have shown that NRG1 treatment improves schizophrenia-relevant behavioural impairments in mice. These findings indicate for the
first time an antipsychotic-like ability of NRG1 treatment in the PCP rodent model of
schizophrenia.
PCP has a range of binding affinities for neurotransmission-relevant receptors and
channels as described in detail in chapter 1.4.2.2. The effect of PCP treatment on the
GABAergic, glutamatertic and dopaminergic system in schizophrenia-relevant brain
areas has been proposed to model aspects of neurotransmission changes during an
acute psychotic episode experienced by patients with schizophrenia (Adell et al.
2012; Javitt et al. 2012).
Differences in the GABAergic, glutamatergic and dopaminergic system have been
identified in the PFC and hippocampus of patients with schizophrenia by in vivo neuroimaging and post-mortem studies (see 1.1.2 for details). Additionally, the activity
of both regions as well as the interaction between the PFC and the hippocampus in
patients with schizophrenia also appear to differ compared to healthy controls (Ellison-Wright & Bullmore 2009; Kumra et al. 2004; Olbrich et al. 2008; Scheel et al.
2013; White et al. 2007) (recently reviewed by (Del Arco & Mora 2009; Javitt et al.
2008; Meyer-Lindenberg 2010; Schmitt et al. 2011)). Effective pharmacological
treatment options would therefore need to address impairments in neurotransmission
in both regions.
Current antipsychotics, however, primarily address differences in the dopaminergic
system with only indirect effects on GABAergic and glutamatergic system alterations (see 1.1.3 for details). This restricted pharmacological profile has been discussed as a likely reason for their limited treatment benefit on a range of schizophrenia symptoms (Vinkers et al. 2010).
NRG1 treatment has shown to affect GABA release and GABA receptor expression
levels in acute PFC and hippocampus in vitro slice preparations (Allison et al. 2011;
Wen et al. 2010; Woo et al. 2007). Furthermore, NRG1 signalling has also been
shown to alter glutamatergic neurotransmission in vitro (see 1.2.3.2 for details).
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Assessing the effect of NRG1-ERBB4 signalling on acute neurotransmission in vivo
has shown that an increase in NRG1 can lead to increased extracellular dopamine
levels in the hippocampus, with no data available on GABA or glutamate levels (see
1.2.3 for details).
Advancing on my behavioural findings, the aim of this study was to assess the effect
of NRG1 treatment on acute neurotransmitter levels in vivo. Specifically, the effect
of NRG1 treatment on extracellular levels of GABA, glutamate and glycine in the
PFC and hippocampus and critically, the ability of NRG1 to alter extracellular neurotransmitter levels in both brain regions in the presence of PCP.
The existing literature strongly supports the broad effect of acute PCP treatment on
neurotransmission in schizophrenia-related brain regions in rodents (Table 2). I have
therefore selected the acute PCP treatment to model schizophrenia-like neurotransmission alterations in vivo. Furthermore, as outlined above, the excitatory-inhibitory
balance of the GABAergic-glutamatergic systems in the PFC and hippocampus are
important for normal behaviour processes. I therefore administered NRG1 and PCP
directly into these brain areas via the microdialysis probe (retrodialysis) to study the
treatment effect on local extracellular transmitter levels in freely moving mice.
The hippocampus is subdivided into functionally discrete subregions, with distinctly
different afferent and efferent connections to other cortical and subcortical structures
(Fanselow & Dong 2010). The CA1 region of the dorsal hippocampus forms monosynaptic connections with the PFC (Fanselow & Dong 2010; Small et al. 2011).
Critically, activity levels of the CA1 region correlate with symptom severity of patients with schizophrenia, which supports the reported post-mortem protein expression differences in this region (Harrison 2004; Schobel et al. 2009). Consequentially,
I selected the dorsal CA1 region for the neurotransmitter analysis in my microdialysis experiment.
The observed effect of NRG1 on local neurotransmitter levels in vitro is likely mediated by ERBB receptors expressed on GABAergic interneurons and astrocytes in the
PFC and hippocampus (Longart et al. 2007; Neddens et al. 2011; Sharif et al. 2009).
Based on these findings I hypothesised that NRG1 administration into the PFC and
hippocampus would alter the extracellular levels of GABA, glutamate and glycine.
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Peripherally and centrally administered PCP has been shown to affect several neurotransmitter levels in the PFC and hippocampus of rodents (Table 2). While no data
exists on changes to glycine levels and effects on glutamate levels are inconclusive, I
hypothesised that PCP administration would increase GABA, with a potential to effect both glutamate and glycine levels. Neurotransmission changes in both brain regions have been suggested to contribute to hyperlocomotion and PPI impairment
(Bast & Feldon 2003; Howland et al. 2004; Jodo et al. 2005; Viggiano 2008). My
behaviour data has shown that NRG1 treatment at the same time as PCP treatment
can prevent the behavioural changes otherwise induced by PCP. Consequentially, I
hypothesised that NRG1 treatment would reduce the effect of PCP on neurotransmitter level changes.
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3.2

Materials and Method

3.2.1 Subjects
Ten-week old male C57BL/6J mice were purchased from Australian BioResources
(Moss Vale, NSW, Australia). Animals were housed two per cage with minimum
enrichment (M1 polypropylene cages with sawdust bedding; Able Scientific) and
maintained on a 12h light/dark cycle (light on at 0600 hours) with food and water
available ad libitum in the animal facility of the University of Wollongong (Wollongong, Australia). All research and animal care procedures were approved by the Animal Ethics Committee of the University of Wollongong (AE10/07) and were in
agreement with the ‘Australian Code of Practice for the Care and Use of Animals for
Scientific Purposes’. All steps were taken to ameliorate any suffering in all work involving animals in my studies.

3.2.2 Drugs
All compounds were obtained from Sigma (Castle Hill, NSW, Australia) except
where specified otherwise. Drugs were freshly prepared on each treatment day. Recombinant human NRG1 (NRG1-β1/HRG1-β1 EGF domain CF; R&D Systems,
USA) and PCP were dissolved in ACSF (119mM NaCl; 2.5mM CaCl2; 2.5mM KCl;
1.3mM MgSO4; 1mM NaH2PO4; 26.2mM NaHCO3; 11mM glucose, 7.4pH,
290mOsm/kg) for retrodialysis.

3.2.3 Microdialysis and amino acid quantification
3.2.3.1 Surgery and housing
All animals were acclimatised for one day prior surgery to their purpose built microdialysis cages (25x25cm, grey PVC with clear front, 40cm high). Animals were
anaesthetised with an inhalation 1.5% isoflurane (Delvet, USA) /98.5% oxygen mix.
Using a stereotactic frame (Kopf Instruments, USA) a single guide cannula (MAB
6.14.IC Microbiotech/SE, Sweden) was implanted into the brain to accommodate a
microdialysis probe targeted at either the medial PFC or dorsal CA1
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(mPFC/prelimbic & infralimbic cortex: 1.7mm rostral to bregma, 0.5mm medial to
bregma, 1.5mm beneath the surface of the skull; dCA1: 2mm caudal to bregma,
1.5mm medial to bregma, 2mm beneath the surface of the skull (Paxinos & Franklin
2001)) (Figure 11). The guide cannula was fixed to the skull with three anchor
screws (2mm, Microbiotech, Sweden) and dental acrylic cement (Ketac Cem, Halas
Dental Limited, Australia). A dummy (Microbiotech, Sweden) was inserted into the
guide cannula to keep it clean and prevent occlusion. Following surgery, all animals
were injected with 0.1ml of a depot-antibiotic substance (Medicam®, Boehriner
Ingelheim, Germany) and additionally received the antibiotic in their drinking water
(0.1%) for three days following surgery. Mice were individually housed in purposebuilt microdialysis cages for all experimental procedures which allowed free access
to food and water.

Figure 11: Microdialysis probe placements
Microdialysis guide cannulas were placed either in the prefrontal cortex (PFC, prelimbic (PrL) and infralimbic (IL) segments) or into the dorsal hippocampus (cornuammonis 1 (CA1) segment) in anaesthetized mice. One week post-surgery, microdialysis probes were inserted into the respective guide cannulae 2.5h before the first
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treatment (Figure 12) and attached to inflow (blue) and outflow (purple) tubing.
Structural diagrams adapted from (Paxinos & Franklin 2001).
3.2.3.2 Dialysis sampling
After seven days of recovery, the microdialysis probe (1mm membrane length,
15kDa cut off, MAB 6.14.1, Microbiotech, Sweden) was inserted into the guide cannula and lowered into the respective target area of the mPFC/dCA1 2.5h before the
first treatment. It was connected via low volume in- and outflow tubing (FEP-tubing,
4001004, Microbiotech, Sweden, fluid swivel 375/D/22QM, Instechlabs, USA) via a
counter-balanced lever arm to a syringe pump (Harvard Instruments, USA). This allowed the animals to freely move during sample collection. The probes were perfused with ACSF at a flow rate of 1μl/min. Microdialysis samples (10µl, 1µl/min)
were collected 2.5h after probe insertion, with treatment and sampling performed according to Figure 12. Animals received 10min retrodialysis infusion with either
NRG1 (10nM), PCP (10µM) or NRG1+PCP, separated by 2.5h of ACSF each, with
samples being collected for 60min from the start of each treatment (Figure 12).
Treatment order was constant for all animals to allow the comparison of molecular
responses.
Probe Insertion & ACSF Flow
NRG1 (10 nM) infusion

PCP (10 µM) infusion

2.5h

2.5h
B -10 0 10 20 30 40 50

NRG1 + PCP infusion
2.5h

B -10 0 10 20 30 40 50

B -10 0 10 20 30 40 50

Figure 12: Microdialysis treatment and sampling scheme for prefrontal cortex
(PFC) and dorsal hippocampus CA1 (dCA1)
Mice (adult male, n=12/treatment) received microdialysis probes one week postsurgery into the respective target area of the PFC/dCA1 2.5h before the first treatment. The probes were perfused with artificial cerebrospinal fluid (ACSF) at a flow
rate of 1 μl/min. After a 2.5h perfusion period without sampling, samples were collected every 10min, with two baseline samples prior the infusion of each treatment
and six samples after each treatment, with a 2.5h inter-treatment interval. Neuregulin
1 (NRG1, 10nM), Phencyclidine (PCP, 10µM) and NRG1+PCP were infused
through the microdialysis probe for 10min into the respective brain area.
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3.2.3.3 Potassium depolarization and location confirmation
After the final experiment ACSF containing high potassium (50mM KCl (Stanford et
al. 2000)) was infused and sampled to confirm depolarisation evoked neurotransmitter release from the surrounding tissue. Following this, the brains were removed, frozen in liquid nitrogen and stored at -80C until cut in 50µm sections using a cryostat
(Leica, USA). The placement of the microdialysis probe was confirmed by Nissl
staining of the relevant coronal sections. Animals with incorrect probe placements
and unresponsive to potassium treatment were excluded from the analysis.

3.2.3.4 GC-MS/MS sample processing and analysis
Derivatisation followed a previously published method (Eckstein et al. 2008). Samples were defrosted on ice, supplemented with heavy isotopes (20pmole GABA-d6,
200pmole Glycine-C13-2, N15, 2pmole Glutamate-d5), and diluted in acetonitrile/methanol (1:1) before centrifugation. The supernatant was dried off at 37°C under nitrogen before derivatisation with pentafluoropropionic acetic anhydride and
2,2,3,3,3-pentafluoro-1-propanol (PFAA and PFPOH, PM Separations PTY, Capalaba, Australia). Following derivatisation, samples were resuspended in toluene for
analysis.
Derivatised samples were analysed on an Agilent 7001B mass selective detector interfaced with an Agilent 7890A gas chromatograph. The injection port, MS source
and GC-MS/MS interface were kept at 250°C, 150°C and 250°C respectively. Separations were carried out on a fused silica capillary column (20m x 180µm i.d.) coated
with cross-linked 5% phenylmethylsiloxane (film thickness 0.18µm), (Agilent,
HP5MS), with Helium as the carrier gas. Column temperature was initially held at
60°C for 0.5min, increased to 210°C at 15°C/min, further increased to 300°C at
30°C/min, and held for 4min. Specific multiple reaction monitoring (MRM) transitions were monitored using the negative chemical ionization mode at 70eV with argon as the reagent gas (1.25ml/min) and the ion source and quadrapole at 150°C. Selected MRM transitions were performed to monitor the GABA ion transition at m/z
190.0 → 109.0, qualifier transitions at m/z 341.0 → m/z 208.0 and m/z 321.0 → m/z
301.0, and m/z 327 → m/z 306 for the corresponding isotopic d6 labelled internal
standard (Figure 13). Glutamate ion transition was detected at m/z 537.0 → m/z
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217.0, qualifier transitions at m/z 537.0 → m/z 313.0 and m/z 379.0 → m/z 188.0,
and m/z 542 → m/z 221 for the corresponding isotopic d5 labelled internal standard
(Figure 14). Glycine ion transition was detected at m/z 333.0 → m/z 313.0, qualifier
transitions at m/z 333.0 → 200.0 and m/z 365.0 → 232.0, and m/z 336.0 → m/z 316.0
for the corresponding isotopic labelled internal standard (Figure 15). The area under
the curve for peaks of GABA, glutamate and glycine were normalised by their respective internal standard peaks, followed by normalisation to the relevant baseline
samples.

3.2.4 Statistical Analysis
Treatment effect in neurotransmitter levels was assessed using Linear Mixed Model
(LMM) on repeated measurements for each brain area and transmitter. Single time
point differences were assessed by one way ANOVA for repeated measurements,
followed by Tukey’s post-hoc analysis when appropriate. Analyses were performed
using SPSS 19.0. Statistical significance was accepted at P<0.05, data are presented
as means±SEM. Outliers were screened as mean ±2 standard deviations and removed.
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Figure 13: Mass spectrometry analysis of GABA
Representative spectra of one cerebrospinal fluid sample following derivatization and
gas chromatography/mass spectrometry detection in negative chemical ionization.
Multiple-reaction monitoring (MRM) segments were defined for the amino acids of
interest. Segment four spans the acquisition time for GABA at 5min (A), monitoring
the reactions for GABA (B) and GABA-d6 (C). The area under the curve for the
product ion of (D) GABA and (E) GABA-d6 was used for the data analysis. Data
presented as counts over acquisition time (A, D, E) and counts over mass (B, C).
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Figure 14: Mass spectrometry analysis of glutamate
Representative spectra of one cerebrospinal fluid sample following derivatization and
gas chromatography/mass spectrometry detection in negative chemical ionization.
Multiple-reaction monitoring (MRM) segments were defined for the amino acids of
interest. Segment six spans the acquisition time for glutamate at 6min (A), monitoring the reactions for glutamate (B) and glutamate-d5 (C). The area under the curve
for the product ion of (D) glutamate and (E) glutamate-d5 was used for the data analysis. Data presented as counts over acquisition time (A, D, E) and counts over mass
(B, C).
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Figure 15: Mass spectrometry analysis of glycine
Representative spectra of one cerebrospinal fluid sample following derivatization and
gas chromatography/mass spectrometry detection in negative chemical ionization.
Multiple-reaction monitoring (MRM) segments were defined for the amino acids of
interest. Segment one spans the acquisition time for glycine at 3.9min (A), monitoring the reactions for glycine (B) and glycine-d3 (C). The area under the curve for the
product ion of (D) glycine and (E) glycine-d3 was used for the data analysis. Data
presented as counts over acquisition time (A, D, E) and counts over mass (B, C).
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3.3

Results

After confirming the microdialysis probe location and K+ response for each animal, I
excluded the samples of two animals from the PFC group and one animal of the
dCA1 group.

3.3.1 Extracellular levels of GABA, glutamate and glycine in the prefrontal cortex
3.3.1.1 Treatment effect on extracellular GABA levels in the PFC
A one-way repeated measure ANOVA confirmed that the baseline GABA values
were not different before each treatment (F(1.4, 9.8)=1.16; P=0.33). The LMM analysis revealed that time (F(5, 121.8)=2.74; P<0.05), but not treatment (F(3,
123.9)=0.56; P=0.64) significantly effected extracellular GABA levels in the PFC,
with no interaction between both (F(15, 122.3)=1.21; P=0.27) (Figure 16). Further
analysis of individual time point differences by one-way ANOVA revealed that PCP
administration resulted in a significant reduction of GABA levels 20min after treatment (37.6±8.4% of baseline, P<0.05) (Figure 16A). Interestingly, this reduction was
not observed following combined NRG1 and PCP treatment (Figure 16A). NRG1
treatment caused an increase in extracellular GABA levels 10min after treatment
(194.2±47.8% of baseline, P<0.05) (Figure 16A). Furthermore, I assessed GABA
level differences across the treatment via LMM analysis of the area under the curve
(AUC). None of the three treatment options altered extracellular GABA levels compared to baseline-equivalent levels (F(3, 18.7)=0.89; P<0.46) (Figure 16B).
Of note, in a biased approach, I observed an increase in extracellular GABA levels
during PCP infusion in three animals (250±34.6% of baseline, P<0.05), which was
prevented by combined NRG1 and PCP treatment (84.3±23.7% of baseline, P=0.66).
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Figure 16: Treatment effect of neuregulin 1 (NRG1) and phencyclidine (PCP)
infusion on extracellular GABA levels in the prefrontal cortex of freely moving
mice.
Mice received a local infusion of NRG1 (10nM), PCP (10µM) or NRG1+PCP for
10min into the prefrontal cortex by retrodialysis. GABA levels are expressed as a
percentage of the respective baseline level (see Figure 12) and represented as the
means ± SEM: (A) for each sampling time point or (B) for total area under the curve
analysis. Dotted lines indicate baseline levels. #P<0.05 PCP vs baseline; &P<0.05
NRG1 vs baseline.
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3.3.1.2 NRG1 treatment reduced extracellular glutamate levels in the PFC
A one-way repeated measure ANOVA confirmed that the baseline glutamate values
were not different before each treatment (F(1.4, 9.8)=2.69; P=0.13). The LMM analysis revealed that treatment (F(3, 145.8)=11.4; P<0.001) and time (F5, 144.4)=3.7;
P<0.001) significantly effected extracellular glutamate levels, with no interaction between both factors (F(15, 144.4)=1; P=0.46) (Figure 17A). Detailed analysis showed
that NRG1 treatment caused a persistent reduction in extracellular glutamate levels in
the PFC throughout the recording period (50.8±12% of baseline, P<0.001) (Figure
17A). Neither PCP (118.3±9.8%) nor combined NRG1 with PCP (101.1±10.5%)
treatment had a significant effect on glutamate levels throughout the recording period
(Figure 17A). This observation was confirmed by a LMM analysis of the AUC,
showing that NRG1 significantly reduced glutamate levels (52.2±9.8% of baseline
equivalent, P<0.01), with no difference observed after PCP (114.7±12.2%) or NRG1
and PCP (109.35±14%) treatment (Figure 17B).
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Figure 17: Treatment effect of neuregulin 1 (NRG1) and phencyclidine (PCP)
infusion on extracellular glutamate levels in the prefrontal cortex in vivo.
Mice received a local infusion of NRG1 (10nM), PCP (10µM) or NRG1+PCP for
10min into the prefrontal cortex by retrodialysis. Glutamate levels are expressed as a
percentage of the respective baseline level (see Figure 12) and represented as the
means ± SEM: (A) for each sampling time point or (B) for total area under the curve
analysis. Dotted lines indicate baseline levels. &&P<0.01 NRG1 vs baseline equivalent.
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3.3.1.3 NRG1 treatment alters extracellular glycine levels in the PFC
Baseline extracellular glycine values were not different before each treatment (F(1.2,
8.6)=1.1; P=0.35). Glycine levels in the PFC were significantly affected by treatment
(F(3, 145.1)=6.85; P<0.001), but not sampling time (F(5, 144.5)=1.26; P=0.29), as
revealed by a LMM analysis (Figure 18A). Post-hoc analysis revealed a significant
increase in glycine levels after the onset of the combined NRG1 and PCP treatment
(190±29% of baseline, P<0.05) (Figure 18A). Neither PCP (90.6±24.4%, P=1) nor
NRG1 (57.1±24.9%, P=0.84) showed a significant effect on glycine levels throughout the recording (Figure 18A). An AUC analysis (F(1.577, 11.04)=3.97; P=0.05),
however, identified a significant reduction in overall glycine levels triggered by
NRG1 treatment (57.5±9.7% of baseline equivalent, P<0.01) (Figure 18B). The AUC
for glycine following PCP (94.24±23.5%) or combined PCP and NRG1
(125.1±10.4%) treatment was similar to the baseline equivalent levels (Figure 18B).
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Figure 18: Treatment effect of neuregulin 1 (NRG1) and phencyclidine (PCP)
infusion on extracellular glycine levels in the prefrontal cortex in vivo.
Mice received a local infusion of NRG1 (10nM), PCP (10µM) or NRG1+PCP for
10min into the prefrontal cortex by retrodialysis. Glycine levels are expressed as a
percentage of the respective baseline level (see Figure 12) and represented as the
means ± SEM: (A) for each sampling time point or (B) for total area under the curve
analysis. Dotted lines indicate baseline levels. *P<0.05 NRG1+PCP vs baseline;
&&
P<0.01 NRG1 vs baseline equivalent.
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3.3.2 Extracellular levels of GABA, Glutamate and Glycine in the dorsal hippocampus
3.3.2.1 NRG1 treatment prevents PCP-induced increase in extracellular GABA levels in the dCA1
A one-way repeated measure ANOVA confirmed that the baseline GABA values
were not different before each treatment (F(1.8, 19.9)=2.22; P=0.14). GABA levels
in the dorsal CA1 region of the hippocampus were not affected by the treatments
(F(3, 147.4)=1.39; P=0.25), but varied significantly over the sampling time (F(5,
144.8)=10.6; P<0.001) according to a LMM analysis. Furthermore, I identified a significant interaction between treatment and sample time on GABA levels (F(15,
144.4)=3.34; P<0.001) (Figure 19A). However, detailed analysis by one way ANOVA showed that GABA levels during the retrodialysis period were significantly affected by the treatment regimens (F(3, 25)=3.35; P<0.05) (Figure 19A). PCP treatment resulted in a significant increase in extracellular GABA levels during the treatment period (313.3±82.8% of baseline, P<0.01) (Figure 19A). Combined treatment
with NRG1 prevented the PCP-induced GABA increase (103.0±15.7% of baseline,
P=0.9) (Figure 19A). A trend towards increased GABA levels was observed during
NRG1 treatment (212.3±67.2%, P=0.09) (Figure 19A).
The LMM analysis of the AUC showed a trend towards a treatment effect on the
dCA1 GABA levels across the recording period (F(3, 19.9)=2.8; P=0.06) (Figure
19B). Neither PCP (83.24±8.6%) nor NRG1 (76.1±8.1%) by themselves showed any
effect on GABA levels. A trend towards reduced GABA levels was identified following combined NRG1 and PCP treatment (67±8% of baseline equivalent, P=0.07).
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Figure 19: Treatment effect of neuregulin 1 (NRG1) and phencyclidine (PCP)
infusion on extracellular GABA levels in the dorsal hippocampus CA1 in vivo.
Mice received a local infusion of NRG1 (10nM), PCP (10µM) or NRG1+PCP for
10min into the dorsal hippocampus CA1 by retrodialysis. GABA levels are expressed as a percentage of the respective baseline level (see Figure 12) and represented as the means ± SEM: (A) for each sampling time point or (B) for total area
under the curve analysis. Dotted lines indicate baseline levels. ##P<0.01, PCP vs
baseline; TP=0.07, NRG1+PCP vs baseline equivalent.
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3.3.2.2 NRG1 treatment reduces extracellular glutamate levels in the dCA1
A one-way repeated measure ANOVA indicated that baseline glutamate values did
not differ before each treatment (F(1.8, 19.6)=2.6; P=0.112). Extracellular glutamate
levels were significantly affected by the treatments (F(3, 158.9)=16.8; P<0.001) and
varied over the sampling time (F(5, 157.1)=2.4; P<0.05), with no interactions between both factors as identified by LMM analysis (F(15, 156.7)=1.3; P=0.21) (Figure
20A).
Post-hoc analysis showed that NRG1 (61.5±7% of baseline, P<0.001) and combined
NRG1 and PCP (52.1±8% of baseline, P<0.001) significantly reduced glutamate levels across the sampling period (Figure 20A). PCP, however, had no overall effect on
glutamate levels (92.4±8% of baseline, P=1). Detailed single-time point analysis
showed that combined treatment with NRG1 and PCP significantly reduced glutamate levels during the treatment period (28.3±18% of baseline, P<0.001), with extracellular levels only returning to baseline levels at the end of the sampling period
(Figure 20A). PCP treatment triggered an increase in glutamate levels 20min after
the treatment (135±12.8% of baseline, P<0.05). This peak was not present following
the combined treatment of NRG1 and PCP (56.8±12.6% of baseline, P<0.01) (Figure
20A).
The AUC analysis found a significant treatment effect (F(3, 23.1)=5.9; P<0.01).
Post-hoc comparison confirmed the observation that NRG1 and combined NRG1 and
PCP treatment resulted in glutamate levels below baseline values (36.3±5% of baseline equivalent, P=0.07 and 28.5±6.7% of baseline equivalent P<0.05 respectively)
(Figure 20B). PCP treatment had no effect on overall glutamate levels (96.7±9.4%).
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Figure 20: Treatment effect of neuregulin 1 (NRG1) and phencyclidine (PCP)
infusion on extracellular glutamate levels in the dorsal hippocampus CA1 in vivo.
Mice received a local infusion of NRG1 (10nM), PCP (10µM) or NRG1+PCP for
10min into the dorsal hippocampus CA1 by retrodialysis. Glutamate levels are expressed as a percentage of the respective baseline level (see Figure 12) and represented as the means ± SEM: (A) for each sampling time point or (B) for total area
under the curve analysis. Dotted lines indicate baseline levels. ***P<0.001, *P<0.05
NRG1+PCP vs baseline; T#P<0.05, PCP vs baseline; &P<0.05, T&P=0.07 NRG1 vs
baseline.
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3.3.2.3 NRG1 treatment reduces extracellular glycine levels in the dCA1
A one-way repeated measure ANOVA confirmed that the baseline glycine values
were not different before each treatment (F(1.4, 11.2)=2.3; P=0.15). Extracellular
glycine levels in the dCA1 were significantly affected by the treatment regimens
(F(3, 159)=6.7; P<0.001) and varied across the sampling time (F(5, 157.1)=3.1;
P<0.01). Furthermore, the LMM analysis revealed a trend for an interaction between
both factors (F(15, 158.8)=1.6; P=0.08). Post-hoc analysis showed that none of the
three treatment options altered glycine levels compared to baseline values (PCP:
127.5±12%; NRG1+PCP: 114±12%; NRG1: 74.1±12% of baseline) (Figure 21A).
Detailed single-time point one-way ANOVA revealed that PCP treatment caused an
increase in glycine levels 50min after the treatment (186.5±47.1% of baseline,
P<0.05), an effect not observed following either NRG1 and PCP or NRG1 treatment
(Figure 21A). Furthermore, glycine levels were increased in the presence of the
combined treatment of NRG1 and PCP (195.6±54% of baseline, P<0.05) (Figure
21A).
The AUC LMM analysis revealed a significant treatment effect on overall glycine
levels (F(3, 15.3)=7.3; P<0.01) (Figure 21B). Post-hoc comparison identified a significant reduction in glycine levels following NRG1 treatment (68.4±3.8%,
P<0.001), but not following the other treatments into the dCA1 (PCP:
121.7±112.5%, P=0.36; NRG1+PCP: 94.6±9.8%, P=1; of baseline equivalent)
(Figure 21B).
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Figure 21: Treatment effect of neuregulin 1 (NRG1) and phencyclidine (PCP)
infusion on extracellular glycine levels in the dorsal hippocampus CA1 in vivo.
Mice received a local infusion of NRG1 (10nM), PCP (10µM) or NRG1+PCP for
10min into the dorsal hippocampus CA1 by retrodialysis. Glycine levels are expressed as a percentage of the respective baseline level (see Figure 12) and represented as the means ± SEM: (A) for each sampling time point or (B) for total area
under the curve analysis. Dotted lines indicate baseline levels. *P<0.05 NRG1+PCP
vs baseline; #P<0.05, PCP vs baseline; &&&P<0.001 NRG1 vs baseline.
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3.4

Discussion

My microdialysis experiments showed that PCP-induced alterations to extracellular
GABA levels were prevented by combined treatment with NRG1 in the dCA1 and in
a subgroup of animals in the PFC (Figure 22). Furthermore, NRG1 treatment in the
presence of PCP altered extracellular glutamate and glycine levels in both brain regions (Figure 22).

Figure 22: Summary diagram of treatment-induced neurotransmitter level differences
Summary diagram of the neurotransmitter level differences following neuregulin 1
(10nM, blue), phencyclidine (10µM, black) or combined (red) infusion into either the
prefrontal cortex (PFC) or dorsal CA1 of the hippocampus. Treatment effects on extracellular GABA, glutamate or glycine levels during infusion period: ↑ above baseline, ↓ below baseline. Neurotransmitter area under the curve differences across sampling period: ≈ equal to baseline, ˅ below baseline, ˄ above baseline levels.

3.4.1

NRG1 treatment affects extracellular neurotransmitter levels in the PFC in
the presence of PCP

3.4.1.1 Extracellular GABA levels remained unchanged following NRG1 and PCP
treatment
Local infusion of PCP into the PFC had little effect on extracellular GABA levels in
the majority of animals (Figure 16A). I observed a PCP-induced increase in extracellular GABA levels in the PFC of a subgroup of animals (Figure 16C), which will
need to be explored in subsequent experiments.
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Published data on the effect of local PCP infusion on extracellular GABA levels by
Yonezawa et al. as well as Zhu and colleagues have shown a reduction in GABA
levels following local PCP administration in the rat PFC (Yonezawa et al. 1998; Zhu
et al. 2004). Both studies have significant methodological differences to my experiment. Firstly, significant reduction in GABA levels was observed after 40min of
consistent PCP retrodialysis (Yonezawa et al. 1998; Zhu et al. 2004), with no significant difference after 10min, which is similar to my experiment. Secondly, PCP was
infused at 50µM (Zhu et al. 2004) and 100-400µM (Yonezawa et al. 1998), compared to 10µM in my study. Finally, microdialysis treatment and sampling was performed 18-20h post-surgery (Yonezawa et al. 1998; Zhu et al. 2004), allowing very
little recovery time compared to the seven day period in my experiments. These
methodological differences are the likely cause for the observed treatment effect difference. Additionally, peripheral PCP treatment has shown to have no effect on PFC
GABA levels in rats (Martin et al. 1998), further supporting that GABA response to
PCP varies with method differences.
The lack of an overall effect of PCP on extracellular GABA levels hampered the efforts of assessing the NRG1 treatment effect on PCP-induced GABA differences.
However, since PCP interferes with several neurotransmitter receptors to cause
schizophrenia-relevant neurotransmission changes, I still assessed the effect of
NRG1 on neurotransmitter levels in the presence of PCP. Extracellular GABA in the
PFC remained at baseline levels following combined NRG1 and PCP treatment
(Figure 16A-B). In the subgroup of animals where PCP treatment induced a GABA
level increase, combining NRG1 with PCP prevented this increase, keeping GABA
at baseline levels. While these effects were not observed in the majority of animals,
the finding indicates a potential interaction which will need to be explored in future
work. NRG1 receptors are primarily located on GABA and glutamate releasing cells
in the PFC (Neddens et al. 2011; Sharif et al. 2009), which also express the dominant
PCP target NMDAR. The reported functional link between ERBB4 and NMDAR
might be the cause for the observed finding in this subgroup (Geddes et al. 2011), but
further investigations are required to assess this interaction.
Understanding the effect of NRG1-ERBB signalling on neurotransmission in the
PFC during physiological normal conditions is of critical importance for recent investigations into the use of NRG1 for neurological and cardiological treatments (Gao
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et al. 2010; Jabbour et al. 2011; Gauthier et al. 2013). Furthermore, such data would
allow the comparison with existing antipsychotics, which have shown to alter PFC
neurotransmitter levels in healthy rodents (Table 3). Since no published data exists
on the effect of NRG1 signalling on acute neurotransmission in vivo for the PFC, I
treated freely moving mice via retrodialysis with NRG1-only.
In vitro experiments have shown that NRG1 administration can lead to an increase in
depolarization-evoked GABA release via ERBB4 activation on PFC interneurons
(Wen et al. 2010; Woo et al. 2007). In my study, this effect was only observable in
the first post-treatment samples, showing elevated GABA levels in the PFC 10min
after the NRG1 only treatment (Figure 16A). This result indicates that a sudden increase in extracellular NRG1 does not directly influence GABA levels in vivo. The
delayed treatment effect, however, suggests that NRG1 indirectly affects GABA levels, possibly through interaction of ERBB4 with intracellular phosphatases and neurotransmitter receptors. Further experiments are required to explore the detailed signalling cascade underlying this finding in relation to the published in vitro results.
The antipsychotic zotepine has been shown to increase GABA levels in healthy animals (Table 3), an effect which has been attributed to an increased risk of inducing
seizures (Yamamura, Ohoyama, Hamaguchi, Nakagawa, et al. 2009). While the
zotepine-induced increase in GABA levels occurred in the presence of the drug,
NRG1 treatment only led to an increase in GABA levels after the treatment cessation
for one sampling time point (Figure 16A). It is therefore less likely that NRG1 treatment would cause a similar adverse reaction as has been associated with the GABAlevel increase following Zotepine treatment.
.
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Table 3: Effect of common antipsychotics and NRG1 on neurotransmitter levels in the PFC of rodents
Name

GABA

Glutamate

Glycine

↔ oralf

Aripiprazole

Dopamine

Serotonin

Noradrenaline

Acetylcholine

↔ oral o
↑ s.c. p, r

↑ oralf

↔ s.c. p, r
↑ s.c. q, s

Clozapine

↓ rd i

↔ oral k
↑ j; ↔ g; ↓e s.c.
↑ i.p. h
↑ rd g

↔ s.c.e

↑ s.c.e, q
↑ i.v. m
↑ rd m

↔g; ↓ s.c. g, l

Haloperidol

↑ s.c.e
↔ i.p. a
↓ rd i

↔ oralf
↔ s.c. e, g, j
↔ i.p. a, h
↔ rd g

↔ s.c.e

↔ s.c.e, q
↔ i.p. a
↔ i.v. m

↓ oralf
↔ g; ↓ l
↔ i.p. a
↔ rd g

↔ i.p. a

↔ s.c. s
↓ s.c. q

Olanzapine

↓ s.c.e

↔ oralf
↔ s.c.e

↔ s.c.e

↑ oral o
↑ s.c. e, r, t
↑ i.v. m
↑ rd m

↔ oralf
↔ s.c. l, t

↑ s.c. t

↔ s.c. r, t
↑ s.c. s

Quetiapine

↔ i.p.d

↑ i.p.d

↑ i.p.d

↔ i.p.d

↑ i.p.d

Risperidone

↑ s.c. r
↑ i.p.c
↑ rd m

↑ i.p.c

↑ i.p. c

Ritanserin

↔ i.p.b

↑ s.c. l

↑ i.p. a

↔ i.p. a

Zotepine

↑ i.p. a

↑ i.p.a

Neuregulin 1

↔ rd x

↓ rd x

↓ rd x
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↑ i.p. a

↑ s.c. r, s

Effect on extracellular neurotransmitter levels: ↔ no effect, ↑ increase, ↓ reduction; drug administration: s.c. subcutaneous; i.p. intraperitoneal;
i.v. intravenous; oral; rd: retrodialysis (local infusion via microdialysis probe).
References: a(Yamamura, Ohoyama, Hamaguchi, Nakagawa, et al. 2009), b(Kuroki et al. 1999), c(Ohoyama et al. 2011), d(Yamamura, Ohoyama,
Hamaguchi, Kashimoto, et al. 2009), e(Heidbreder et al. 2001), f(Carli, Calcagno, Mainolfi, et al. 2011), g(López-Gil et al. 2007), h(Abekawa et
al. 2006), i(Bourdelais & Deutch 1994), j(Daly & Moghaddam 1993), k(Carli, Calcagno, Mainini, et al. 2011), l(Amargos-Bosch et al. 2006),
m
(Bortolozzi et al. 2010), n(Gessa et al. 2000), o(Jordan et al. 2004), p(Li et al. 2004), q(Chung et al. 2004), r(Huang et al. 2006), s(Ichikawa et al.
2002), t(Koch et al. 2004) x(my study)
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3.4.1.2 NRG1 treatment reduces extracellular glutamate levels in the PFC
PCP retrodialysis did not affect local glutamate levels in the PFC (Figure 17). This
observation is in line with existing studies reporting unchanged extracellular glutamate levels following PCP and local NMDA receptor agonist administration in the
PFC of rats (López-Gil et al. 2007; Zhu et al. 2004). However, an increase in PFC
glutamate levels has been observed following peripheral PCP treatment (Abekawa et
al. 2007; Adams & Moghaddam 2001; Amitai et al. 2012; Baker et al. 2008; Li et al.
2010), which was preventable by clozapine and haloperidol treatment (Abekawa et
al. 2007; Amitai et al. 2012) (Table 2). The present and published data indicate that
peripheral and central PCP treatments differently affect glutamate and GABA levels
in the PFC. This strongly suggests that excitatory afferent connections contribute
largely to the systemic PCP effect on neurotransmission in the PFC (Suzuki et al.
2002). Changes to other neurotransmitters following local PCP infusions are therefore also likely to differ compared to systemic injections. PCP retrodialysis allows
precise control over treatment onset and intensity when interfering with local neurotransmission, avoiding the treatment duration and intensity ambiguity of systemic
injections. However, the clear difference between published neurotransmitter differences following systemic PCP and the present findings following local PCP infusion
show that the broad nervous system-wide effect of PCP is of importance when modelling schizophrenia-relevant neurotransmission impairments. Future experiments
will therefore need to include this route of PCP administration.
While PCP alone had no effect on extracellular glutamate levels, the combined infusion of NRG1 and PCP also did not affect extracellular glutamate levels in the PFC
(Figure 17). NRG1 by itself however, reduced glutamate levels in the PFC (Figure
17). The reduction in extracellular glutamate levels lasted longer than the infusion
period. This suggests that activation of NRG1 receptors triggers intracellular mechanisms which possibly outlast the direct receptor stimulation duration. However, since
glutamate levels in the samples collected 2.5h after the NRG1 infusion (i.e. baseline
samples before PCP treatment) did not differ compared to pre-NRG1 treatment samples, the intracellular reactions appear to return to their pre-treatment state within 2h.
The possible mechanisms behind the observed reduction in glutamate have been
studied by a small number of in vitro experiments. Bath application of NRG1 has
shown to reduce NMDA receptor currents on pyramidal cells (Gu et al. 2005), while
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not affecting glutamate release in electrophysiological slice preparations (Gu et al.
2005; Pitcher et al. 2011). It has therefore been proposed that the current reduction is
caused by internalization of the essential NMDA receptor NR1 subunit (Gu et al.
2005). Since the reduction in glutamate was not visible in the presence of PCP, it appears likely that NMDAR signalling and dopamine signalling are involved in the
NRG1 effect on glutamate. However, recent work has shown that activation of the
pre-synaptic protein LIMK1 following NRG1 application reduces the release of glutamate, which might be the contributing element in the present results (Yin et al.
2013). Additional neurotransmitter actions present in vivo and interactions between
ERBB4 and several intracellular kinases (Bjarnadottir et al. 2007; Liu & Kern 2002;
Pitcher et al. 2011; Ting et al. 2011) are also likely involvement in the observed reduction. Identifying the precise mechanism will require further in vivo experiments,
combining NRG1 retrodialysis with inhibitors for glutamate-signalling relevant enzymes such as FYN, SRC and others.

3.4.1.3 Combined treatment of NRG1 and PCP increases extracellular glycine levels in the PFC
Glutamatergic neurotransmission can be influenced by the extracellular levels of glycine, an allosteric modulator of NMDAR (Labrie & Roder 2010; Lee et al. 2009).
Retrodialysis of PCP had little effect on extracellular glycine levels in the PFC
(Figure 18). While no published data exists about the effect of local PCP on glycine
levels, PFC glycine levels are also unaffected by peripheral PCP administration (Li et
al. 2010).
Glycine levels were significantly increased during combined infusion of NRG1 and
PCP (Figure 18A). Several clinical trials have been performed aiming to increase activation of the glycine binding site on NMDAR by using direct agonists or glycine
uptake transport inhibitors (Labrie & Roder 2010). The ability of NRG1 to increase
glycine in the presence of PCP therefore indicates a potential for this line of clinical
investigations.
To address the lack of knowledge about the effect of NRG1 on glycine levels, I also
quantified glycine level differences following NRG1-only infusion into the PFC.
NRG1 treatment lead to a reduction in extracellular glycine levels (Figure 18A). Interestingly, while the combined NRG1 and PCP treatment led to a significant in78

crease during the infusion period, NRG1 treatment significantly reduced glycine
throughout the sampling period (Figure 18B). When comparing the glycine with the
glutamate results, it becomes apparent that both neurotransmitters are simultaneously
reduced following NRG1 treatment (Figure 17 and Figure 18). Interestingly, this pattern is not maintained following the combined NRG1 and PCP treatment, which triggers an increase in glycine levels, without affecting glutamate levels (Figure 17 and
Figure 18). The cause for this treatment difference will need to be assessed in separate experiments incorporating receptor antagonists for the different PCP targets.
In relation to the behavioural experiments in chapter 2, increasing glycine levels has
been shown to prevent the behavioural impairments as well as dopamine level increases following PCP treatment in rodents (Boulay et al. 2008; Javitt et al. 1999).
The observed increase in glycine following the combined NRG1 and PCP treatment
might have therefore potentially contributed to the prevention of PCP-induced behavioural impairments by NRG1.
The observed treatment effects on neurotransmitter levels in the PFC occurred during
different sampling time points as described above. The differences observed during
the perfusion period suggest that local PFC cell populations are involved in the
treatment responses, while the post-infusion differences indicate that afferent and
efferent connections to other cortical and subcortical structures are additionally involved in the present results (Hoover & Vertes 2007). The effect of PCP on PFC
neurotransmission has been reported to depend on PFC-hippocampal connections
(Jodo et al. 2005). My results suggest that the NRG1 infusion also triggers differing
feedback responses from other structures, which might have contributed to the observed differences in neurotransmitter levels.
Unlike hypothesised, PCP retrodialysis had no significant effect on the extracellular
levels of the three studied neurotransmitters. While I chose to use local PCP infusion
to have precise control over the treatment timing, the treatment effect in the PFC differed to published systemic PCP treatment studies. This prevented the analysis of a
NRG1 treatment effect on PCP-induced neurotransmitter level changes in the PFC.
The antipsychotic treatment potential of NRG1 against impaired PFC neurotransmission will therefore need to be assessed in a future experiment with peripheral PCP
treatment.
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3.4.2 NRG1 treatment effects extracellular neurotransmitter levels in the dCA1 in
the presence of PCP
Direct interactions between the PFC and the hippocampus have been implicated in
several schizophrenia-relevant cognitive functions, including spatial working
memory and decision making (Churchwell & Kesner 2011; Driesen et al. 2008; Godsil et al. 2013). Additionally, neurotransmission differences in the hippocampus have
been observed in patients with schizophrenia (Tamminga et al. 2010). I therefore assessed the ability of NRG1 to alter GABAergic, glutamatergic and glycinergic neurotransmission in vivo in the hippocampus in the presence of PCP.

3.4.2.1 NRG1 treatment prevents PCP-induced GABA level increase in the dCA1
Retrodialysis of PCP triggered a three-fold increase in extracellular GABA levels in
the dCA1 during the treatment period (Figure 19), without affecting GABA levels
post-treatment. This increase suggests that the GABAergic interneurons of the CA1
respond differently to local PCP stimulation than PFC interneuron populations,
where I only observed a similar effect in a subgroup of samples. Indeed, GABAergic
interneurons of the CA1 have been shown to be more sensitive to NMDAR antagonists than pyramidal neurons in the same region (Grunze et al. 1996), while GABAergic interneurons in the PFC do not share this characteristic (Rotaru et al. 2011).
This difference could explain why the increase in GABA levels following PCP infusion in the hippocampus was not observed in the majority of PFC samples.
No published study has so far described the effect of local PCP treatment on GABA
levels in the hippocampus in vivo. The effect of peripheral PCP treatment has been
reported by one study, observing a 25% reduction in hippocampal GABA levels for
3h (Martin et al. 1998). In my study, PCP increased GABA levels exclusively during
the treatment period, which suggests a direct treatment effect on local neurotransmitter release or uptake mechanisms in the dCA1. Peripheral injections of PCP, as in the
study by Martin et al. (1998), leads to prolonged alterations of neurotransmitter levels (Hagino et al. 2010; Martin et al. 1998), likely affecting intracellular signalling
cascades which have not been triggered in my study. Furthermore, it is possible that
peripheral PCP could have caused a brief increase in GABA as seen in my study and
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then returned to baseline levels. Such an effect would likely be hidden by the 30min
sampling interval in the study by Martin and colleagues (Martin et al. 1998).
Extracellular levels of GABA have been shown to be influenced by dopamine D2
receptor activation, with D2 agonists increasing and D2 antagonist decreasing extracellular levels (Grobin & Deutch 1998). The agonistic action of PCP on D2 receptors
might therefore be a possible mechanism of increased GABA levels observed in my
experiment.
No data has been published on the effect of local or peripheral administered antipsychotics on local or peripheral PCP-induced changes to hippocampal neurotransmitter
levels (Table 2). However, in patients with schizophrenia, activity levels of the CA1
region correlate with their symptom severity (Schobel et al. 2009). It was therefore of
importance to locally infuse NRG1 into the hippocampus under the modelled condition caused by PCP in an attempt to identify possible treatment-relevant characteristics of NRG1.
Combining NRG1 with PCP completely prevented PCP from inducing an increase in
GABA levels in the dCA1 (Figure 19). While the agonistic action of PCP on dopamine receptors together with the antagonistic action on NMDAR receptors might be
the cause for the GABA increase, it remains unclear how NRG1 signalling via ERBB
receptors can counteract the PCP effect. Interestingly, a recent study with GABA
transporter knockout animals has shown that the reversal of increased GABA signalling prevents several behavioural impairments otherwise present in these mice (Yu et
al. 2013). Preventing the PCP-induced GABA increase might therefore be one of the
mechanisms contributing to the observed behavioural effects of combined NRG1 and
PCP treatment in Chapter 2.
To further explore the effect of NRG1 signalling on extracellular neurotransmitter
levels, I analysed GABA levels following NRG1 infusion during physiological normal conditions.
NRG1 treatment had no overall effect on extracellular GABA levels in the dCA1
(Figure 19), which is similar to what I observed in the PFC samples (Figure 16).
Several in vitro experiments have indicated that increasing NRG1 signalling would
alter, possibly even increase GABA signalling (Woo et al. 2007; Wen et al. 2010;
Okada & Corfas 2004). The difference between published in vitro results and the
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present in vivo findings highlights the importance of a complete neuronal network
when studying the effects of NRG1 on neurotransmission.
Limited knowledge is available about the effect of current antipsychotics on neurotransmitter levels in the hippocampus of healthy animals, following either local infusion or peripheral administration (Table 4). However, the reported effect of these antipsychotics on acetylcholine levels in the hippocampus suggests that the levels of
other neurotransmitters might also be altered by these drugs (Lawrence 2008).
For NRG1, one study has shown that retrodialysis with the same NRG1 isoform as in
my study resulted in an increase in extracellular dopamine levels in the dCA1 of rats
(Kwon et al. 2008). Since no data on other neurotransmitters are available, it remains
unclear if this increase in dopamine caused to the treatment effect against PCPinduced GABA increase or if effects on other neurotransmitters contributed.
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Table 4: Effect of common antipsychotics and NRG1 on neurotransmitter levels in the hippocampus of rodents
Name

GABA

Glutamate

Glycine

Dopamine

Serotonin Noradrenaline

↑ s.c. b, e

Aripiprazole

Acetylcholine
↔ s.c. b, e
↑ s.c. a

Chlorpromazine
Clozapine

↑ s.c. c

↓ i.p. f

↑ s.c. a, c, d
↑ rd d

Haloperidol

↔ s.c. c

↔ s.c. a, ↑c

Olanzapine

↑ s.c. e

↑ s.c.a, d, e
↑ rd d
↔ i.p. f

Raclopride

↔ s.c. a

Risperidone

↑ s.c. a
↔ rd d

Thioridazine

↑ s.c. a, d
↑ rd d

Ziprasidone

↔ s.c. a, d
↑ i.p. a

Neuregulin 1

↔ rd x

↓ rd x

↔ rd x

↑ rd g

Effect on extracellular neurotransmitter levels: ↔ no effect, ↑ increase, ↓ reduction; drug administration: s.c. subcutaneous; i.p. intraperitoneal;
rd: retrodialysis (local infusion via microdialysis probe).
References: a(Shirazi-Southall et al. 2002), b(Li et al. 2004), c(Chung et al. 2004), d(Johnson et al. 2005), e(Huang et al. 2006), f(Assié et al.
1997), g(Kwon et al. 2008), x(this study)
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3.4.2.2 NRG1 treatment reduces extracellular glutamate levels in the dCA1
A small number of clinical studies indicate that glutamate levels differ in the hippocampus regions of patients with schizophrenia following antipsychotic treatment
(Poels, Kegeles, Kantrowitz, Javitt, et al. 2014). It is therefore of relevance to assess
the effect of NRG1 on glutamate levels both in the PCP-modelled and physiological
healthy conditions.
PCP retrodialysis had no effect on extracellular glutamate levels in the dCA1 (Figure
20), a result similar to what I observed in the PFC (Figure 17). Interestingly, while
PCP did not effect glutamate levels in either of the two brain regions, the effect on
GABA is markedly different, increasing levels in the dCA1 without affecting levels
in the PFC. This difference supports the previously made observation that GABAergic interneuron populations in both regions respond differently to PCP while glutamate-releasing pyramidal neurons do not appear to share this characteristics, as discussed above. No published study has so far described the effect of local or peripheral PCP treatment on glutamate levels in the hippocampus in vivo. It is therefore not
possible to say whether a treatment difference between local and peripheral PCP on
glutamate levels, as observed in the PFC, exists in the dCA1. While it might be interesting to explore the lack of an effect of PCP on local glutamate levels in future experiments, it is of limited relevance for the purpose of the present study on NRG1.
The combined treatment of NRG1 and PCP prevented the PCP-induced increase in
GABA as discussed above, while at the same time reducing extracellular glutamate
levels (Figure 20). Such a reduction in glutamate levels was not observed in the PFC
samples following the combined treatment, which supports the discussed response
difference of neuronal populations in both regions. Glutamatergic synapses from
CA3 pyramidal neurons are the primary source of glutamate in the CA1 region
(Takács et al. 2012). While NRG1 overexpression has shown to reduce glutamate
release in the CA1 via pre-synaptic intracellular mechanism in one study (Yin et al.
2013), how exogenous NRG1 might cause this effect remains unclear since ERBB34 are not expressed on glutamatergic pre-synaptic terminals (Fazzari et al. 2010). The
range of pharmacological actions of PCP combined with the activation of ERBB3-4
receptors on different cell types in the CA1 does not allow me to conclude on the
mechanism behind the glutamate reduction following the combined treatment.
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To explore the involvement of NRG1 in the observed glutamate level reduction, I
separately treated animals with NRG1 under physiologically healthy conditions.
NRG1 retrodialysis resulted in a trend towards reduced extracellular glutamate levels
(Figure 20), but to a lesser extent than observed in the PFC (Figure 17). The reduction in glutamate was also less pronounced than following the combined NRG1 and
PCP treatment in the dCA1. This result indicates that exogenous NRG1 was partially
responsible for the reduction following the combined NRG1 and PCP retrodialysis,
but that its effect was amplified by the pharmacological actions of PCP. It remains to
be assessed whether exogenous NRG1 reduced glutamate levels by altering the control of local GABAergic interneurons over connected glutamatergic synapses from
the CA3 region or via feedback mechanisms to the CA3, entorhinal cortex or thalamus (Chamberland & Topolnik 2012; Klausberger & Somogyi 2008).

3.4.2.3 Combined NRG1 and PCP treatment increased extracellular glycine levels
in the dCA1
Variations in hippocampal glycine levels have been reported to alter glutamate release via pre-synaptic mechanisms (Lee et al. 2009), without being affected by
GABA (Tanaka et al. 2003). The glycine signalling pathway offers an additional
possibility for NRG1 to influence glutamate levels and I therefore quantified extracellular glycine levels following the three different treatment options.
PCP retrodialysis had no overall effect on the extracellular levels of glycine aside
from a brief increase at the end of the sampling period (Figure 21).
The combined infusion of NRG1 and PCP however, caused an increase in extracellular glycine levels during infusion period (Figure 21). This increase in glycine following the combined infusion was of similar intensity and duration as observed in the
PFC samples (Figure 18). While glycine has been reported to trigger glutamate release in the hippocampus (Lee et al. 2009), the actions of PCP and NRG1 appear to
alter this response as glutamate levels dropped following the combined treatment
(Figure 20).
Interestingly, glycine levels remained unchanged following NRG1 retrodialysis in
the dCA1 (Figure 20). This treatment response again differs between both regions,
with significantly reduced glycine levels in the PFC (Figure 18). Neither the strong
reduction in glutamate nor the increase in glycine levels triggered by the combined
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NRG1 and PCP treatment was observed following the NRG1-only treatment. This
suggests that the effect of NRG1 on neurotransmitter levels depends significantly on
the current state of the neuronal network.
Existing in vitro experiments have indicated that NRG1 administration is more likely
to affect neurotransmitter receptor availability than neurotransmitter release in hippocampus slice preparations (Chang & Fischbach 2006; Liu et al. 2001; Okada &
Corfas 2004; Pitcher et al. 2011; Shamir et al. 2012). The observed differences in
rapid neurotransmitter level changes between PCP and NRG1-PCP treatment is
therefore remarkably. However, the temporal resolution of our samples limits our
ability to draw conclusions on the exact order of neurochemical events, such as
GABA or glycine control over glutamate levels (Lee et al. 2009; Tanaka et al. 2003).
The timing between treatments as well as the order of treatments could also have potentially influenced the neurotransmitter responses to the separate treatments. While
there was no difference between the pre-treatment baseline samples for each analysed neurotransmitter, I cannot exclude the possibility that other transmitters and
intracellular mechanisms were still influenced by the previous treatment after the
2.5h recovery period. Furthermore, continuous microdialysis has been reported to
drain the extracellular space around the probe (Chefer et al. 2009). While this limitation primarily occurs with larger probe pore sizes and faster fluid transport than used
in my study (Chefer et al. 2009), the possibility of this effect to alter neurotransmitter
production cannot be excluded.
Critically, a separate class of CNS cells has to be considered as contributing factor to
the observed treatment effects. Cortical astrocytes have been reported to express receptors for NRG1 (Sharif et al. 2009), GABA receptors and synthesizing enzymes
(Lee, McGeer, et al. 2011), NMDA receptors (Lalo 2006) and dopamine D2 receptors (Mladinov et al. 2010; Shao et al. 2012) among others. Furthermore, cortical astrocytes are able to release GABA (Le Meur et al. 2012; Lee, McGeer, et al. 2011),
glutamate and glycine (reviewed in (Hamilton & Attwell 2010)). Although I did
maintain natural osmotic levels to avoid stimulating GABA release from astrocytes
by lower osmotic pressure (Wang et al. 2013), it is likely that neurochemical responses of astrocytes have either directly or indirectly been triggered by NRG1 and
PCP treatment. However, as astrocyte function has also been implicated in the pathophysiology of schizophrenia (Halassa et al. 2007; Katsel et al. 2011), their contribu86

tion to the observed effects does not deter from the clinical potential of NRG1 treatment.
With the present microdialysis experiment I was able to study the treatment effects
on local neurotransmission in vivo. Retrodialysis administration of NRG1 and PCP
enabled me to control the localised treatment onset and duration to assess the acute
treatment effect in two distinct regions. The effect of PCP on local neurotransmitter
levels, was, however, not as hypothesised, likely due to the restricted treatment location. Future studies are therefore needed to assess the ability of NRG1 signalling to
reduce impairments in glutamatergic neurotransmission. However, the present study
shows that glutamatergic and glycinergic neurotransmissions are affected by NRG1
in vivo and that this effect on neurotransmitter levels differs when PCP is present.
The precise underlying mechanism needs to be explored in future experiments using
selective inhibitors for NRG1-ERBB signalling pathway elements. The microdialysis
findings support the observations from the behaviour studies in that NRG1 treatment
effects depend on the current state of the neuronal network.
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4 NRG1 PREVENTS PCP-INDUCED MRNA EXPRESSION CHANGES IN
GABAERGIC INTERNEURONS IN VITRO

4.1

Introduction

My behaviour experiments show that central and peripheral administration of human
recombinant NRG1 can prevent hyperlocomotion and PPI impairments induced by
acute PCP treatment in mice. Several CNS structures which have been implicated in
the regulation of locomotor activity and sensorimotor gating have also been associated with the pathophysiology of schizophrenia (Bast & Feldon 2003; Goulding 2009;
Swerdlow et al. 2008; Swerdlow et al. 2001). Exemplary are the frontal cortex and
hippocampus structures for their involvement in several symptom domains of schizophrenia and the assessed behavioural paradigms (Gonzalez-Burgos et al. 2011; Hall
et al. 2010; Keshavan et al. 2008). I therefore performed in vivo microdialysis of the
PFC and dCA1 described in the previous chapter, assessing the effect of NRG1 and
PCP on extracellular neurotransmitter levels in freely moving mice. NRG1 retrodialysis affected glutamate and glycine levels and prevented PCP-induced changes to
extracellular GABA levels. The behaviour and microdialysis experiments indicate
that NRG1 signalling can influence schizophrenia-relevant behaviour and neurotransmission and prevent modelled impairments triggered by acute PCP. This addresses elements of acute psychotic episodes as experienced by patients with schizophrenia.
Differences in protein and mRNA expression levels relevant to GABAergic and glutamatergic neurotransmission have been identified in frontal cortex regions of patients with schizophrenia (see 1.1.2 for details). GABAergic interneurons have received particular attention after differences in GAD, PV and GAT1 expression levels
where identified in frontal cortex regions of patients (Akbarian et al. 1995; Beasley
& Reynolds 1997; Dracheva et al. 2004; Duncan et al. 2010; Guidotti et al. 2000;
Hashimoto, Arion, et al. 2008; Hashimoto, Bazmi, et al. 2008; Hashimoto et al.
2003; Mellios et al. 2009; Sakai et al. 2008; Straub et al. 2007; Volk et al. 2012;
Volk et al. 2000; Woo et al. 2008). In combination with reported expression differences of GABAA receptors (Benes, Vincent, et al. 1996; Hashimoto, Bazmi, et al.
2008; Lewis et al. 2004), NMDAR (Geddes et al. 2011; Weickert et al. 2013) and the
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postsynaptic scaffold protein disrupted in schizophrenia 1 (DISC1) (Lipska et al.
2006; Nakata et al. 2009; Sawamura et al. 2005), these post-mortem findings suggest
altered neurotransmission between GABAergic interneurons and pyramidal neurons
in schizophrenia. Furthermore, structural differences in the frontal cortex interneuron-pyramidal neuron network in transgenic and lesion animal models suggest a vital
role for GABAergic interneurons in the symptom spectrum of schizophrenia (reviewed by (Bissonette & Powell 2012; Marín 2012)).
The GABAergic system is insufficiently addressed by the majority of available antipsychotics (Vinkers et al. 2010), which primarily target dopamine and serotonin receptors (see 1.1.3 for details). Closing this gap in the current treatment spectrum is of
critical importance since the limited effect on GABA-relevant targets might contribute to low treatment efficacy against the cognitive symptoms domain of schizophrenia (Lewis & Moghaddam 2006).
The post-synaptic density of GABAergic interneurons is the predominant site of neuronal ERBB4 expression in the frontal cortex (Fazzari et al. 2010; Neddens &
Buonanno 2010; Neddens et al. 2011; Vullhorst et al. 2009). With NRG1 being released from pyramidal neurons in the PFC (X. Liu et al. 2011), this suggests a possible role for NRG1-ERBB4 signalling in the interneuron-pyramidal neuron network.
The aim of this chapter was therefore to assess the ability of NRG1 to alter the expression levels of GABAergic system components and related elements in frontal
cortex neurons.
To study the effect of NRG1 treatment on local cell populations, I used primary
frontal cortex cultures. This excludes confounding effects of afferent synapses from
other cortical and subcortical regions. Furthermore, to assess the treatment effect of
NRG1 during schizophrenia-relevant neurotransmission interruption, I administered
NRG1 together with PCP.
Prolonged PCP treatment has shown to reduce NMDAR activity and alter PV and
GAD expression levels in rodent frontal cortex regions (Cochran et al. 2003; Karasawa et al. 2002; Thomsen et al. 2009), modelling differences similar to those
found in patients with schizophrenia (see 1.1.2.3 for details on the GABAergic system in schizophrenia). I investigated possible treatment effects of NRG1 on key elements of GABAergic interneurons, namely GAD67, GAD65 and PV, which indicate
differences in intracellular mechanisms of these neurons. PCP has also been found to
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impair synapse development in frontal cortex regions in several animal experiments
(Wang et al. 2004), while NRG1 has been reported to positively affect synapse structures (Ozaki et al. 1997; Yang et al. 1998; Ting et al. 2011). I therefore included the
presynaptic vesicle protein synaptophysin (SYP), DISC1 and the essential NMDA
receptor subunit 1 (NR1) in my analysis to identify potential interactions in the
treatment effects of NRG1 and PCP on synapses. Furthermore, as expression levels
of SYP (Chambers et al. 2005; Glantz & Lewis 1997; Honer et al. 1999; Landén et
al. 2002; Rao et al. 2013; Vawter et al. 1999; Webster et al. 2001), DISC1 (Lipska et
al. 2006; Nakata et al. 2009; Sawamura et al. 2005) and NR1 (recently reviewed by
Geddes et al. (2011)) have found to be altered in some patients with schizophrenia, a
possible effect of NRG1 treatment on these proteins would have potential relevance
for a clinical translation (Figure 1).
I hypothesised that PCP treatment will cause schizophrenia-relevant differences in
mRNA expression levels in frontal cortex cells due to its effect on several neurotransmitter receptors (see 1.4.2.2 for details). Since NRG1 treatment prevented behavioural and neurochemical changes induced by PCP in the previous experiments, I
further hypothesised that NRG1 treatment will alter the PCP effect in frontal cortex
cultures. I hypothesized that this effect would be particularly observable in GABAergic interneuron-relevant targets due to the location of the NRG1 receptor
ERBB4 on these neurons.
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4.2

Methods

4.2.1 Subjects
Pregnant female C57BL/6J mice were purchased from Australian BioResources
(Moss Vale, NSW, Australia). Animals were single housed in open-top cages with
minimum enrichment (M1 polypropylene cages with sawdust bedding; Able Scientific) and maintained on a 12h light/dark cycle (light on at 0600 hours) with food and
water available ad libitum in the animal facility of the University of Wollongong
(Wollongong, Australia). All research and animal care procedures were approved by
the Animal Ethics Committee of the University of Wollongong (AE 10/19) and were
in agreement with the ‘Australian Code of Practice for the Care and Use of Animals
for Scientific Purposes’. All steps were taken to ameliorate any suffering in all work
involving animals in my studies.

4.2.2 Drugs
All compounds were obtained from Sigma (Castle Hill, NSW, Australia) except
where specified otherwise. Drugs were freshly prepared on each treatment day. Recombinant human NRG1 (#396 NRG1-β1/HRG1-β1 EGF domain CF; R&D Systems, USA) and PCP were dissolved in ACSF (119mM NaCl; 2.5mM CaCl2; 2.5mM
KCl; 1.3mM MgSO4; 1mM NaH2PO4; 26.2mM NaHCO3; 11mM glucose, 7.4pH,
290mOsm/kg) for cell culture treatments.

4.2.3 Frontal cortex culture
On post natal day 1 or 2 mouse pups were decapitated and their brain removed aseptically. The brain was placed in ice cold dissection solution (Hilgenberg & Smith
2007) and the frontal cortex area of both hemispheres dissected in to 1-2mm blocks
following the careful removal of meninges and other superficial blood vessels. The
tissue pieces were incubated for 30min at 37°C in papain-containing enzyme solution
for tissue digestion, followed by enzyme inhibitor washing steps. Tissue pieces were
then dissociated in growth medium by trituration using glass pipettes. Dissociated
cells were collected in warm growth medium consisting of Neurobasal™ (21103,
91

gibco, Life Technologies Australia Pty Ltd, Mulgrave, Australia) supplemented with
1% B-27 supplement (Life Technologies Australia Pty Ltd, Mulgrave, Australia).
Cells were plated in complete medium on poly-d-lysine coated 96-well culture plates
(F-bottom, Cellstar, greiner bio-one, Germany) at 5 × 104 cells/well for mRNA analysis and maintained at 37°C in a humidified atmosphere of 5% CO2 and 95% air.
One day after the plating, the medium was replaced with new conditioned Neurobasal medium with B-27 supplement (cNBM/B27, (Hilgenberg & Smith 2007)) and
again in 48h intervals. For mRNA expression experiments, neurons were cultured
and maintained for 6 days before the drug treatment started. I used one week old high
density cultures to allow sufficient time for the development of excitatory and inhibitory responses to GABA signaling (Ben-Ari et al. 2007; Ting et al. 2011).

4.2.4 Cell culture treatment and mRNA expression analysis
All drugs were freshly prepared on each treatment day. NRG1 and PCP were dissolved and diluted in ACSF to prevent interference with growth factors in NBM/B27.
The suitability of ACSF for mixed neuronal culture treatment over 24h has recently
been confirmed by Pamenter and colleagues (Pamenter et al. 2013). Drug treatments
were added to the cultures by replacing the existing medium with fresh ACSF containing NRG1 (0.01, 0.1 or 1nM), PCP (10µM), NRG1 (0.01, 0.1, 1 or 10nM) +PCP
or no drug.
For the analysis of the neurotransmission signalling marker mRNA expression levels,
the mRNA isolations were carried out with a Cell-to-Ct kit (Ambion, Life Technology Pty Ltd, Mulgrave, Australia) according to the manufacturer’s instructions. Van
Peer and colleagues reported that cDNA synthesis from cell lysis matches the accuracy and sensitivity of classic RNA purification and cDNA synthesis from < 1x105
cells when using this kit (Van Peer et al. 2012). Reverse transcription reactions contained 15µl of lysis solution, with 3µl of the resulting cDNA-containing solution being used for each qPCR reaction. Hydrolysis probes (Cat# 4331182, Ambion, Life
Technology Pty Ltd, Mulgrave, Australia) were used in duplex reactions for targetspecific amplification. TaqMan Probe details can be found in Table 5.
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Table 5: Hydrolysis probes for real time mRNA quantification
Target
UniGene ID Assay ID
Reference Sequence
gene
PAK1IP1

Mm.24789

Mm0050941

NM_026550.3

UBC

Mm.331

Mm01198158_m1 NM_019639.4

DISC1

Mm.233504

Mm00533313_m1 NM_174853.2

GAD1/

Mm.272120

Mm00725661_s1

Mm.4784

Mm00484623_m1 NM_008078.2

GRIN1

Mm.278672

Mm00433790_m1 NM_001177656.1

PVALB

Mm.2766

Mm00443100_m1 NM_013645.3

SYP

Mm.223674

Mm00436850_m1 NM_009305.2

NM_008077.4

GAD67
GAD2/
GAD65

4.2.5 Selection of reference genes
The reference genes UBC and PAK1IP1 were selected after testing UBC, Pak1IP1,
AP3D1 and CsnK2a2 (GeNorm mouse kit ge-SY-6, Integrated Sciences Pty. Ltd.,
Australia) across a range of representative samples. The stability was assessed using
the GeNorm software. Validated reference genes exhibited average expression stability values (M) under 1.5 (Vandesompele et al. 2002).

4.2.6 Real Time Quantitative PCR method and data analysis
The amount of double stranded PCR product synthesised in each cycle was measured
using TaqMan Universal Mastermix (4440038, Ambion, Life Technology Pty Ltd,
Mulgrave, Australia) on a Lightcycler 480 real time PCR machine (Roche, Australia)
in 20µl reaction volume per technical replicate (n=3) according to the Cell-to-Ct kit
instructions. Samples with quantification cycles (Cq) of 35 and above were excluded
from the analysis (average Cq for DISC1=30.3, GAD1=30.4, GAD2=27.8,
NR1=28.2, PAK1IP1=28.4, PVALB=26.6, SYP=25.6 and UBC=22.6). Cq values for
each gene of interest were normalised to the Cq values of both reference genes from
the same cDNA preparations, considering the individual reaction efficiencies and
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inter-run calibrator values according to the 2-ΔCq method (Schmittgen & Livak
2008).

4.2.7 Statistical Analysis
Normalised quantification cycle values for each target gene were further normalised
to the relevant vehicle treatment values of either the 3h or 24h treatment group to assess fold change differences following each treatment intervention. Differences in
mRNA expression were separately analysed for the 3h and 24h treatment groups by
using one-ay ANOVA for each gene of interest. Bonferroni’s multiple comparison
was employed to identify individual differences when applicable. Analyses were performed using SPSS 19.0. Statistical significance was accepted at P<0.05, data are
presented as means±SEM. Outliers were screened as mean ±2 standard deviations
and removed.
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4.3

Results

4.3.1 NRG1 treatment prevents PCP-induced increase in GAD67 mRNA expression levels
Drug treatment for 3h had no significant effect on GAD67 mRNA expression levels
(F(10, 51)=1.28; P=0.26) (Figure 23).
Drug treatment for 24h had a significant effect on GAD67 mRNA expression levels
(F(8, 36)=20.28; P<0.001) (Figure 23). PCP treatment over 24h significantly increased GAD67 mRNA levels compared to vehicle treated cultures (203.6±14.9% of
vehicle, P<0.001) (Figure 23).
NRG1 prevented the PCP-induced increase in mRNA expression in a dosedependent manner: GAD67 mRNA expression levels following treatment with
0.01nM and 0.1nM NRG1 combined with PCP were similar to levels in vehicle
treated cells (73.79±15.63% of vehicle, P>0.99; 108.4±14.9% of vehicle, P>0.99 respectively) (Figure 23). Combined treatment of PCP with 1 or 10nM NRG1 resulted
in a significant increase in GAD67 mRNA expression levels compared to vehicle,
similar to PCP-only treated cells (191.5±15.6% of vehicle, P<0.001; 219.1±21.5% of
vehicle, P<0.001 respectively) (Figure 23).
NRG1 treatment for 24h did not change GAD67 mRNA levels at 0.1, and 1nM, but
significantly reduced expression levels at 0.01 nM (122.5±15.2% of vehicle, P>0.9;
110.5±15.2% of vehicle, P>0.9; 51.4±7.6% of vehicle, P<0.001 respectively) (Figure
23).
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Figure 23: GAD67 mRNA expression after 3h and 24h of neuregulin 1 (NRG1)
and PCP treatment in primary frontal cortex culture.
Primary cell cultures of frontal cortex cells from mice (post natal day 1-2, n=57/group) were treated with vehicle (artificial cerebrospinal fluid), phencyclidine
(PCP), NRG1+PCP or NRG1 (treatment concentration) for (A) 3h or (B) 24h after
six days in vitro. mRNA expression levels of glutamic acid decarboxylase 67
(GAD67) were analysed via quantitative real time polymerase chain reaction
(qPCR). Values are presented as the mean percentage expression difference compared to vehicle treatment + SEM. ##P<0.01, ###P<0.001 vs Vehicle; ***P<0.001
vs PCP.
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4.3.2 NRG1 treatment prevents PCP-induced decrease in GAD65 mRNA expression levels
Drug treatment for 3h had a significant effected on GAD65 mRNA expression (F(10,
50)=5.57; P<0.001) (Figure 24). A post-hoc analysis revealed a trend for reduced
GAD65 mRNA expression following 0.01nM NRG1 (82.5±1%, P=0.06 vs vehicle)
and 0.01nM NRG1 combined with PCP (78.3±3.2%, P=0.06 vs vehicle).
Treatment for 24h had a significant effect on GAD65 mRNA expression levels (F(8,
38)=4.68; P<0.001) (Figure 24).
PCP treatment over 24h significantly reduced GAD65 mRNA levels compared to
vehicle treatment (69.7±8.6% of vehicle, P<0.05) (Figure 24).
NRG1 prevented the PCP-induced reduction in mRNA expression in a dosedependent manner: combining PCP with 0.1nM NRG1 resulted in GAD65 mRNA
levels similar to vehicle treatment (92.1±7.9% of vehicle, P>0.9) (Figure 24). However, GAD65 mRNA levels following combined treatment of PCP with 0.01, 1 or
10nM NRG1 were similar to PCP-only treated cells (83.9±8.6% of vehicle, P>0.9;
86.4±9% of vehicle, P>0.9; 79.3±10.5% of vehicle, P>0.9 respectively) (Figure 24).
NRG1 treatment for 24h dose-dependently affected GAD65 mRNA levels. NRG1 at
0.1nM and 1nM had no effect on GAD65 mRNA expression (93.9±6.2% of vehicle,
P=0.7; 114.5±6.2% of vehicle, P=0.07 respectively) while 0.01nM NRG1 significantly reduced expression levels of GAD65 mRNA (72.6±7.6% of vehicle, P<0.01)
(Figure 24).
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Figure 24: GAD65 mRNA expression after 3h and 24h of neuregulin 1 (NRG1)
and PCP treatment in primary frontal cortex culture.
Primary cell cultures of frontal cortex cells from mice (post natal day 1-2, n=57/group) were treated with vehicle (artificial cerebrospinal fluid), phencyclidine
(PCP), NRG1+PCP or NRG1 (treatment concentration) for (A) 3h or (B) 24h after
six days in vitro. mRNA expression levels of glutamic acid decarboxylase 65
(GAD65) were analysed via quantitative real time polymerase chain reaction
(qPCR). Values are presented as the mean percentage expression difference compared to vehicle treatment + SEM. #P<0.05, vs Vehicle; TP=0.057 vs PCP.
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4.3.3 NRG1 treatment prevents PCP-induced increase in PV mRNA expression
levels
Drug treatment for 3h significantly affected PV mRNA expression levels (F(10,
50)=5.4; P<0.001) (Figure 25). Post-hoc analysis showed that 0.1nM NRG1 treatment significantly increased PV mRNA levels (131.4±7.7% of vehicle, P<0.001)
(Figure 25), while none of the other treatments affected PV mRNA levels.
Drug treatment for 24h had a significant effect on PV mRNA expression levels (F(8,
37)=4.8; P<0.001) (Figure 25). PCP treatment over 24h significantly reduced PV
mRNA levels compared to vehicle treated cells (133.4±11.8% of vehicle, P<0.01)
(Figure 25).
NRG1 prevented the PCP-induced reduction in PV mRNA expression in a dosedependent manner: combining PCP with 0.1nM NRG1 led to PV mRNA levels significantly lower than PCP-only treated cells (105.6±10.1% of vehicle, P<0.05)
(Figure 25). However, PV mRNA levels following combined treatment of PCP with
0.01, 1 and 10nM NRG1 were similar to PCP-only treatment (107.9±10.6% of vehicle, P=0.07; 134.8±10.6% of vehicle, P>0.9; 154±12.4% of vehicle, P=0.2 respectively) (Figure 25).
NRG1 treatment for 24h had no effect on PV mRNA levels at any of the tested concentrations (Figure 25).
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Figure 25: Parvalbumin (PV) mRNA expression after 3h and 24h of neuregulin
1 (NRG1) and PCP treatment in primary frontal cortex culture.
Primary cell cultures of frontal cortex cells from mice (post natal day 1-2, n=57/group) were treated with vehicle (artificial cerebrospinal fluid), PCP, NRG1+PCP
or NRG1 (treatment concentration) for (A) 3h or (B) 24h after six days in vitro.
mRNA expression levels of PV were analysed via quantitative real time polymerase
chain reaction (qPCR). Values are presented as the mean percentage expression difference compared to vehicle treatment + SEM. ###P<0.001, ##P<0.01, #P<0.05 vs
Vehicle; *P<0.05, vs PCP.
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4.3.4 DISC1 mRNA expression levels were not affected by NRG1 or PCP treatments
Drug treatment for 3h had a significant effect on DISC1 mRNA expression levels in
mice frontal cortex cells (F(10, 47)=2.03; P=0.05) (Table 6). Post-hoc analysis, however, failed to identify a significant treatment effect following any of the applied
treatments (Table 6). Furthermore, DISC1 mRNA expression levels were not affected after 24h exposure to any of the tested treatment combinations (F (8, 37)=0.97;
P=0.5) (Table 6).

Table 6: Unchanged DISC1 mRNA expression levels after 3h and 24h NRG1
and PCP treatment compared to vehicle in primary frontal cortex cultures
Treatment
3h
24h
ACSF

100%

100%

PCP (10µM)

99.8±4.4%

90.6±5.6%

NRG1 (0.01nM) + PCP 109.3±1.6%

101.1±19.8%

NRG1 (0.1nM) + PCP

106.5±5.7%

84.1±2.8%

NRG1 (1nM) + PCP

121.1±7.5%

105.2±3.8%

NRG1 (10nM) + PCP

98.9±8.6%

109.4±24.8%

NRG1 (0.01nM)

89.8±3.7%

108.5±7.8%

NRG1 (0.1nM)

86.4±13.1%

103.7±2.9%

NRG1 (1nM)

124±6.5%

103.6±3.6%

Primary cell cultures of frontal cortex cells from mice (post natal day 1-2, n=57/group) were treated with vehicle (artificial cerebrospinal fluid), PCP, NRG1+PCP
or NRG1 (treatment concentration) for 3h or 24h after six days in vitro. mRNA expression levels of DISC1 were analysed via quantitative real time polymerase chain
reaction (qPCR). Values are presented as the mean percentage expression difference
compared to vehicle treatment ± SEM.
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4.3.5 Synaptophysin mRNA expression levels were not affected by NRG1 or PCP
treatments
Drug treatment for 3h had no significant effect on SYP mRNA expression levels in
mice frontal cortex cells (F(10, 50)=1.4; P=0.2) (Table 7). Furthermore, SYP mRNA
expression levels were not affected by any of the tested treatment combinations after
24h (F (8, 40)=1.48; P=0.2) (Table 7).

Table 7: Unchanged synaptophysin mRNA expression levels after 3h and 24h
NRG1 and PCP treatment compared to vehicle in primary frontal cortex cultures
Treatment
3h
24h
ACSF

100%

100%

PCP (10µM)

105.7±7.5% 100.8±15.6%

NRG1 (0.01nM) + PCP

93.6±2.1%

NRG1 (0.1nM) + PCP

106.3±4.5% 96.6±11.4%

NRG1 (1nM) + PCP

99.5±3.5%

88.6±5.3%

NRG1 (10nM) + PCP

101.2±11%

133.6±29.3

NRG1 (0.01nM)

80.1±2.2%

92.1±11.9%

NRG1 (0.1nM)

132.7±5.9% 98.1±3.2%

NRG1 (1nM)

120.3±3.8% 112.6±3.7%

83.9±6.8%

Primary cell cultures of frontal cortex cells from mice (post natal day 1-2, n=57/group) were treated with vehicle (artificial cerebrospinal fluid), PCP, NRG1+PCP
or NRG1 (treatment concentration) for 3h or 24h after six days in vitro. mRNA expression levels of SYP were analysed via quantitative real time polymerase chain
reaction (qPCR). Values are presented as the mean percentage expression difference
compared to vehicle treatment ± SEM.
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4.3.6 NMDA-NR1 mRNA expression levels were not affected by NRG1 or PCP
treatments
Drug treatment for 3h had no significant effect on NR1 mRNA expression levels in
mice frontal cortex cells (F(10, 50)=0.63; P=0.78) (Table 8). Treatment for 24h had a
significant effect on NR1 mRNA expression levels (F (8, 38)=3.43; P<0.05). However, no significant NR1 mRNA expression level differences were observed between
vehicle and drug treated cells (Table 8).

Table 8: Unchanged NMDA receptor subunit 1 (NR1) mRNA expression levels
after 3h and 24h NRG1 and PCP treatment compared to vehicle in primary
frontal cortex cultures
Treatment
3h
24h
ACSF

100%

100%

PCP (10µM)

101.8±3.8%

82.2±4.4%

NRG1 (0.01nM) + PCP

104.7±2.1%

80.2±7.5%

NRG1 (0.1nM) + PCP

101.9±3.9%

97.5±6.4%

NRG1 (1nM) + PCP

94.1±2.5%

90.6±5.9%

NRG1 (10nM) + PCP

94.9±6.6%

104.7±3.2%

NRG1 (0.01nM)

79.9±3.4%

108.7±5.6%

NRG1 (0.1nM)

117.3±4.8%

109.8±7.3%

NRG1 (1nM)

105.5±6.7%

113.4±9.6%

Primary cell cultures of frontal cortex cells from mice (post natal day 1-2, n=57/group) were treated with vehicle (artificial cerebrospinal fluid), PCP, NRG1+PCP
or NRG1 (treatment concentration) for 3h or 24h after six days in vitro. mRNA expression levels of NR1 were analysed via quantitative real time polymerase chain
reaction (qPCR). Values are presented as the mean percentage expression difference
compared to vehicle treatment ± SEM.
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4.4

Discussion

My frontal cortex cell culture experiments showed that PCP changed gene expression
that is relevant for GABAergic signalling. Combined treatment with NRG1 prevented the PCP effect in a dose-dependent manner. Elements of interneuron and pyramidal neuron synapses were, however, unaffected by the applied treatments.

4.4.1 NRG1 treatment prevents PCP-induced mRNA expression changes relevant
for GABAergic signalling
PCP treatment caused an increase in GAD67 and PV mRNA expression while reducing GAD65 mRNA expression in the frontal cortex cultures after 24h (Figure 23,
Figure 24 and Figure 25). The altered expression of these genes indicates that PCP
treatment influenced the activity level of the GABAergic interneurons in the primary
cell culture.
To ensure that the observed differences in gene expression are the direct consequence of the applied treatments, I took several precautions to minimise the impact
of confounding factors: all cultures were treated in medium-free ACSF to avoid that
factors of the enriched medium could mask the actual treatment effect. Additionally,
the molarity of the treatment solution was adjusted to be equivalent to naturally produced CSF (290 mOsm/kg, (Rosen & Andrew 1990)), ensuring normal electrochemical cell responses. Finally, as PCP has been reported to have neurotoxic properties,
frontal cortex cultures were treated with a PCP concentration below its cytotoxic levels (Väisänen et al. 1999).
The effect of local PCP administration on GABAergic interneuron mRNA or protein
expression levels in vitro has not previously been reported, limiting the ability to
evaluate the observed PCP effect against existing data. Systemic sub-chronic administration of PCP in vivo has been reported to reduce GAD67 and PV mRNA and protein expression in the frontal cortex of adult rodents (Abdul-Monim et al. 2007;
Amitai et al. 2012; Cochran et al. 2003; McKibben et al. 2010; Reynolds et al. 2004;
Thomsen et al. 2010; Thomsen et al. 2009). While these treatment effects were not
observed in all PCP rodent studies (Benneyworth et al. 2011; Peat & Gibb 1983),
they show a clear difference to the present cell culture experiment. The differing PCP
104

treatment effects between my in vitro results and published systemic in vivo studies
on GAD67 and PV are likely due to interactions between cortical and subcortical regions following systemic PCP treatment which are excluded in our experiment
(Amitai et al. 2012; Benneyworth et al. 2011; Cochran et al. 2003; Del Arco et al.
2007; Martin et al. 1998; McKibben et al. 2010; Thomsen et al. 2010; Thomsen et al.
2009). Neurochemical changes following peripheral PCP treatment are the consequence of local receptor actions and several excitatory afferent connections to the
PFC, as discussed in relation to my microdialysis findings (see 3.4.1.2 for details),
differing in vitro findings are therefore to be expected. Furthermore, the significantly
longer treatment duration in the animal experiments (24h vs 7 to 21 days) is also
likely to contribute to the treatment effect difference.
4.4.1.1 NRG1 signalling has the potential to address GABAergic signalling impairments
Altered mRNA and protein expression levels relevant to GABAergic signalling have
been identified in frontal cortex regions of patients with schizophrenia (see 1.1.2.3
for details) (Fung et al. 2010; Hashimoto, Arion, et al. 2008; Konradi et al. 2011;
Woo et al. 2004). Existing antipsychotics have consequentially been assessed on
their ability to reduce or prevent some of the reported GABAergic system alterations
in pre-clinical studies. So far, only clozapine has been reported to be able to reverse
PV and GAD67 expression alterations in the sub-chronic PCP rat model, while neither haloperidol nor risperdine reduced the PCP treatment effect (Cochran et al.
2003; Amitai et al. 2012; McKibben et al. 2010).
Remarkably, combined treatment with NRG1 prevented the PCP-induced mRNA
expression alteration of GAD67, GAD65 and PV (Figure 23, Figure 24 and Figure
25). This might be an indication that the treatment effect of NRG1 is comparable to
the described clozapine treatment effect (Cochran et al. 2003) My results further
suggest that the NRG1 signalling system might have the potential of addressing
pathophysiological alterations of the GABAergic interneuron system.
4.4.1.2 The NRG1 treatment effect against PCP is dose-dependent
The ability of NRG1 treatment to prevent the PCP-induced mRNA expression differences was dose-dependent. I identified a u-shaped-like concentration effect of NRG1
in preventing the GAD67 mRNA increase (Figure 23), GAD65 mRNA decrease
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(Figure 24) and PV mRNA increase (Figure 25) in the presence of PCP. NRG1 at
0.1nM was most effective in preventing the induced changes for each target. The
gene expression level differences between vehicle treatment and low (0.01nM) or
high (1nM) NRG1 with PCP was larger than compared to 0.1nM NRG1 with PCP
treatment. The resulting concentration effect is similar to the observed u-shaped
dose-response curve from the behaviour experiments (Figure 10). A possible molecular explanation for this dose-response effect has been suggested in earlier publications, which proposed a u-shaped activation pattern for ERBB4 receptor phosphorylation (Role & Talmage 2007). ERBB4 stimulation by NRG1 leads to phosphorylation of intracellular signalling kinases such as phosphoinositide 3-kinase (PI3K)
(Krivosheya et al. 2008), protein kinase B (AKT) regulating intracellular Ca2+ levels
(Schapansky et al. 2009) and gene expression (Allison et al. 2011) (Figure 3). Furthermore, ERBB4 activation leads to (likely indirect) phosphorylation of neurotransmitter receptor kinases including proto-oncogene tyrosine-protein kinases SRC
and FYN which influence functional properties of NMDA receptors (Bjarnadottir et
al. 2007; Pitcher et al. 2011; Yu et al. 1997) (Figure 3). The reported dose-dependent
ERBB4 activation by NRG1 might consequentially lead to differing kinase phosphorylation patterns resulting in the observed dose-response effect seen for GAD67,
GAD65 and PV mRNA levels.
4.4.1.3 Treatment effect on GABAergic system is duration dependent
NRG1 retrodialysis had an immediate effect on extracellular neurotransmitter levels
in the PFC in my microdialsyis study. I therefore assess the effects different NRG1
and PCP treatment durations might have on GABAergic system relevant mRNA expression after 3h and 24h. Interestingly, the observed treatment effect on GAD67,
GAD65 and PV mRNA expression appeared to be strongly influenced by the treatment duration. None of the differences observed after 24h treatment were present
after 3h treatment, with GAD65 and GAD67 mRNA expression levels being indistinguishable between treated and untreated cultures. NRG1 at 0.1nM significantly
increased PV mRNA expression levels after the 3h, but not 24h treatment period
(Figure 25). The increase in PV might be a compensatory consequence of short-term
PI3K stimulation and resulting release of intracellular Ca2+ at this concentration (Gu
et al. 2005).
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PCP treatment has been reported to have a treatment duration-dependent effect on
mRNA expression after treatment onset. Adachi and colleagues observed increases in
brain derived neurotrophic factor expression 6h, but not 3h, after PCP injection
(Adachi et al. 2013). While Gao and colleagues showed that increased expression of
the early response gene cfos peaks between 2 and 3h after PCP treatment (Gao et al.
1998). This work, together with my results indicate that structural responses to PCP
treatment can be expected within 24h and are more likely to occur several hours into
the presence of PCP. This observation also suggests that a longer treatment duration
in the microdialysis study could potentially have triggered a change in GABA levels
in the PFC.
The relevance of treatment duration has also been reported for local NRG1 administration relevant to neurotransmitter responses. In a hippocampal neuronal cell culture study, Schapansky and colleagues assessed the ability of NRG1 to modulate intracellular calcium regulation in response to acute glutamatergic neurotransmission
(Schapansky et al. 2009). Cells treated with AMPA receptor agonists showed a
marked reduction in intracellular Ca2+ response after NRG1 treatment for 24h, but
not 1h (Schapansky et al. 2009). Furthermore, responses to NMDA receptor agonists
remained unaltered (Schapansky et al. 2009). These observations suggest an interaction of NRG1 signalling with neurotransmitter receptors beyond acute neurotransmitter release modulation. It is possible that such a modulatory action of NRG1 caused
the observed mRNA expression difference in my frontal cortex cultures, especially
as the three targets are critical to the electrochemical responsiveness of GABAergic
interneuron.
Interestingly, the experiment by Schapansky and colleagues shows that intracellular
Ca2+ regulation responds differently to extracellular glutamate after exposure to
NRG1 for 24h, but not 1h (Schapansky et al. 2009). As PCP treatment has been reported to influence intracellular Ca2+ levels by blocking Ca2+ ATPase in cerebellar
interneurons (Pande et al. 1999), the ability of NRG1 to influence intracellular Ca2+
regulation might contribute to the observed treatment effect in my experiment. Future studies into the effect of NRG1 on neurotransmission could therefore include in
vitro Ca2+ imaging to investigate this possible interaction.
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Existing antipsychotics such as clozapine, haloperidol and aripiprazole have shown
to increase the expression of GAD67 mRNA (Peselmann et al. 2013; Zink et al.
2004), but not PV (Cahir et al. 2005), when administered to healthy animals. Future
experiments will need to assess how this effect contributes to the antipsychotic potential of these drugs. NRG1 treatment did not show such an effect in my study at the
treatment-relevant concentration. However, the long-term effect of NRG1 treatment
on these targets in unimpaired interneurons remains to be determined, as well as possible treatment response differences following in vivo administration.

4.4.2 Pre- and post-synaptic markers under the influence of PCP and NRG1
The mRNA expression of pre-synaptic (SYP) and post-synaptic (DISC1, NR1)
markers assessed in my experiment was unaffected by PCP treatment (Table 6, Table
7 and Table 8). Several studies have reported differences to SYP (Fattorini et al.
2009; Thomsen et al. 2010; Thomsen et al. 2009; Wang et al. 2004) and NR1 (Hanania et al. 1999; Lindahl & Keifer 2004; Wang et al. 2005; Wang et al. 1999; Yu et al.
2002) mRNA and protein expression following peripheral PCP treatment in rodents,
with no data on DISC1. Treatment duration (3h or 24h compared to 5 and more
days), PCP concentration and in vivo vs in vitro administration differences are the
most-likely reasons for the varying outcomes.
The three pre- and post-synaptic targets are expressed in different cell types, including GABAergic interneurons (Steinecke et al. 2012; Geddes et al. 2011; Bragina et
al. 2010). Since the expression of the three targets was not affected by PCP, I can
assume that the observed differences in GAD67, GAD65 and PV expression are likely due to a change in demand for the respective proteins and not due to a change in
cell or synapse numbers in the primary cultures.
NRG1 treatment had no effect on the mRNA expression of SYP, NR1 or DISC1. A
previous study utilizing a cancer cell line had shown that NRG1 treatment for 2h induced a lasting DISC1 increase (Seshadri et al. 2010), but no data from neuronal cultures is available. Using frontal cortex cultures, a recent study has shown that treatment with NRG1 for 48h induces synaptogenesis (Ting et al. 2011). This finding
suggests that a longer treatment duration might be required to trigger such an effects.

108

Furthermore, it remains to be seen if NRG1 can induce synaptogenesis in neurons in
the presence of PCP or other modelling mechanisms.
Current antipsychotics have shown to alter the expression of SYP (Eastwood et al.
2000; Ozdemir et al. 2012; Park et al. 2013; Scarr & Dean 2012), NR1 (Fumagalli et
al. 2008; O’Connor et al. 2006; Schmitt et al. 2003) and DISC1 (Chiba et al. 2006)
both in vitro and in vivo. These studies have been performed in physiological healthy
environments and it therefore remains unclear if these effects contribute to the therapeutic or adverse treatment response.
In summary, the frontal cortex cell culture study shows that stimulating the NRG1
signalling pathway can prevent PCP-induced gene expression changes relevant to
GABAergic signalling. The molecular mechanisms behind the observed doseresponse curve will need to be studied in future experiments to understand if similar
mechanisms might have contributed to the dose-dependent treatment effect of NRG1
in the behaviour studies. No differences have been observed in the pre- and postsynaptic targets for any of the treatment combinations. A longer treatment duration
might be necessary to assess the potential of NRG1 treatment to address impairments
schizophrenia-relevant impairments in synapse structures.
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5 OVERALL DISCUSSION AND CONCLUSION

5.1

The Antipsychotic Potential of NRG1 Treatment

Current antipsychotics are of limited benefit against a wide range of schizophrenia
symptoms (Tandon et al. 2009). This restriction has been attributed to their predominantly anti-dopaminergic action, which does not address the GABAergic and glutamatergic neurotransmission differences observed in patients with schizophrenia
(reviewed in 1.1.3). Drug development efforts have therefore shifted towards altering
GABAergic and glutamatergic neurotransmission (reviewed in 1.1.4 and by Vinkers
et al. (2010).
Past research has shown that NRG1 administration can alter dopaminergic transmission in vivo as well as GABAergic and glutamatergic transmission in vitro (reviewed
in 1.2.3 and by (Buonanno 2010; Rico & Marín 2011)). I hypothesised that NRG1
treatment has antipsychotic-like potential in a rodent schizophrenia model. Limited
knowledge is available on the effects of NRG1 on neurotransmission in the PFC,
hippocampus and striatum. However, neither the behavioural consequences of NRG1
administration nor the effect of NRG1 treatment on schizophrenia-relevant paradigms have been explored.
I therefore studied the effects of NRG1 treatment against PCP-induced schizophrenia-like behaviour impairments in mice. Animals receiving central or peripheral injection of NRG1 together with a peripheral PCP injection, displayed normal locomotor activity, unlike animals only receiving PCP. Furthermore, peripheral NRG1 prevented sensorimotor gating impairment otherwise observed following PCP alone.
Preventing schizophrenia-relevant behaviour impairments otherwise caused by PCP
indicates antipsychotic-like characteristics of NRG1 treatment, since several available antipsychotics show similar treatment effects against PCP in rodents (Table 1).
Critically, while several of these antipsychotics negatively affect healthy behaviours
(Adage et al. 2008; Nordquist et al. 2008; Okuyama et al. 1999), NRG1 treatment
caused no change in locomotor activity nor sensorimotor gating. Finally, the rapid
treatment response following peripheral injections of NRG1 suggests a potential
suitability as a peripherally administrable substance against CNS impairments.
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The outcome of the behaviour experiments formed the foundation for biochemical
investigations into the antipsychotic potential of NRG1 treatment with a focus on the
GABAergic and glutamatergic systems.
Altered neurotransmitter levels and neurotransmission-related protein expression
have been observed in the PFC and hippocampus of patients with schizophrenia. The
GABAergic and glutamatergic neurotransmitter systems appear particularly affected
in both of these regions (reviewed in 1.1.2.2 and 1.1.2.3). I therefore studied the effect of NRG1 treatment on acute GABAergic and glutamatergic neurotransmission in
the presence of PCP in the PFC and dCA1 of mice.
In the PFC, NRG1 reduced glutamate and glycine levels, while combined NRG1 and
PCP treatment triggered an increase in extracellular glycine. Despite a range of
pharmacological actions of PCP treatment, extracellular GABA, glutamate and glycine levels were unaffected. As there was no PCP-induced neurotransmission deficit
in the PFC, it is not possible to say whether NRG1 treatment would have attenuated
altered levels of these neurotransmitters. The NRG1 treatment effect on glutamate
and glycine, however, provides direct in vivo evidence for the proposed involvement
of NRG1 signalling in adult neurotransmission and might have contributed to the
prevention of PCP-induced behavioural impairments (see 5.1.1 below for details).
In the hippocampus, PCP treatment triggered a significant increase in GABA levels
without affecting glutamate or glycine. The GABA increase was not observed following combined NRG1 and PCP treatment, suggesting that NRG1 prevented the
original PCP effect. An increase in glycine was again observed following combined
treatment, this time accompanied by a reduction in glutamate levels. The differences
in neuronal network structure and cellular make up between the PFC and hippocampus likely accounts for the variation in neurotransmitter level differences between
these regions.
Several pharmacological treatment options are currently under development aiming
to increase glycine and adjust GABA-glutamate signalling in patients with schizophrenia (reviewed in (Javitt 2009; Miyamoto et al. 2012; Rudolph & Knoflach
2011)). The ability of NRG1 treatment to alter GABA, glutamate and glycine levels
in the presence of PCP also suggests that NRG1 treatment has the potential to alter
disrupted neurotransmission in patients with schizophrenia. In the present study, the
behavioural and microdialysis experiments focused on the treatment effects of NRG1
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in the acute PCP rodent model with relevance to acute psychotic episodes experienced by patients with schizophrenia (Adell et al. 2012; Javitt et al. 2012; Pratt et al.
2012). However, neurotransmission impairments are present throughout the course of
the disease, as suggested by differences in neurotransmission-relevant protein expression discovered in post-mortem tissue of patients (see 1.1.2 for details).
The purpose of the final experiment of my PhD was thus to form an initial investigation into the effects of prolonged NRG1 treatment on altered neurotransmission. I
treated frontal cortex networks with NRG1 in the presence of PCP, measuring components of the GABAergic system relevant to the pathophysiology of schizophrenia.
PCP changed the mRNA expression of GABA producing enzymes and the calcium
binding protein PV. Combined treatment with NRG1 dose-dependently prevented
these PCP-induced expression differences in the dissociated frontal cortex cultures.
While results from primary cell culture experiments can only be considered as an initial step in the treatment development process, the outcome of this study shows that
extended stimulation of the NRG1 signalling pathway has the potential to change
GABAergic interneuron activity during modelled neurotransmission impairments.
Altered neurotransmission and aberrant inhibitory synaptic function in the PFC and
the hippocampus are highly implicated in the symptoms of schizophrenia (Hall et al.
2010; Keshavan et al. 2008; Gonzalez-Burgos et al. 2011). The ability of NRG1 to
improve aspects of the GABAergic inhibitory system in frontal cortex neurons in
vitro is therefore of strong relevance for its potential as an antipsychotic treatment
option against altered GABA signalling observed in patients (Kegeles et al. 2012).
The identified effect of NRG1 on GABAergic signalling also opens the possibility of
a combined NRG1-antipsychotic therapy, since current antipsychotics have little effect on impaired GABAergic signalling in individuals with schizophrenia.
The present work is an initial exploration into the treatment potential of NRG1
against PCP-induced impairments in mice with relevance to schizophrenia. Using
three separate experimental approaches enabled me to study the treatment potential
of NRG1 on different CNS complexity levels. This strategy, however, limited the
possibility of drawing conclusions about the mechanisms underlying the behaviour
and molecular findings. In future experiments, including inhibitors for neurotransmitter transporters (e.g. GAT) and receptors (e.g. NMDAR and D2) as well as intracel112

lular kinases (e.g. FYN/SRC and AKT), will aid the identification of the mechanisms
underlying the observed treatment effect following combined NRG1 and PCP administration.
5.1.1 Possible mechanisms underlying the effect of NRG1 on PCP impairments
While the experiments of my PhD focused on the antipsychotic potential of NRG1,
the observed results allow me to hypothesise regarding the underlying molecular
mechanism of the NRG1-PCP interaction.
PCP is a commonly used substance to induce psychotic-like deficits against which
antipsychotics can be tested for their therapeutic potential. PCP has been reported to
inhibit membrane bound Ca2+ ATPase on GABAergic interneurons (Pande et al.
1999), additionally to its pharmacological action on neurotransmitter receptors (see
1.4.2.2 for details). Consequently, PCP-induced increase in intracellular Ca2+ could
have triggered the observed demand for Ca2+ binding proteins (Figure 25) as well as
the elevation in GABA levels (Figure 19) (Bardo et al. 2002). Increased GABA signalling has been previously related to hyperlocomotion and disrupted PPI (Yeomans
et al. 2010; Yu et al. 2013). The effect of NRG1 against the PCP-induced changes
could have been mediated by reducing intracellular Ca2+ through activation of PI3K
via ERBB4 (Z. Liu et al. 2011), subsequently preventing an increase in GABA release and behavioural impairments.
Additionally, the NRG1-induced increase in glycine in the presence of PCP (Figure
18 and Figure 21) is likely to have contributed to the reduction of PCP-induced behavioural impairments. Increase in glycine has been shown to attenuate PPI impairments following treatment with the NMDAR antagonist MK-801, prevent PCPinduced hyperlocomotion and prevent PCP-induced increases in extracellular dopamine (Javitt et al. 1999; Kanahara et al. 2008; Toth & Lajtha 1986).
However, since PCP exerts its effect through a range of targets on both neurons and
glia, additional molecular mechanisms are likely contributing to the observed NRG1PCP treatment effects. While conclusions on the exact mechanisms underlying the
observed results can surely not be drawn from my studies, they present a basis and
allow the formation of a hypothesis for promising further investigation.
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5.1.2 NRG1 treatment potential beyond schizophrenia
With my PhD I have focused on antipsychotic-relevant consequences of NRG1 signalling by using the PCP-induced schizophrenia rodent model. In recent years, however, several other research groups have studied the treatment potential of the NRG1ERBB4 signalling pathway for a number of brain disorders. For example, Carlsson
and colleagues have shown that NRG1 treatment can be neuroprotective in a Parkinson’s disease mouse model by using the same NRG1 isoform as in my experiments
(Carlsson et al. 2011). In regards to Alzheimer’s disease pathology, NRG1 treatment
has also shown to be neuroprotective in pre-clinical in vitro and in vivo rodent models against amyloid protein neurotoxicity (Woo et al. 2012; Chen et al. 2011; Min et
al. 2011; Ryu et al. 2012; Cui et al. 2013). The neuroprotective properties of NRG1
have also been explored in relation to neurological disorders such as stroke and nerve
injury, showing promising early pre-clinical treatment effects (Li et al. 2012; Ronchi
et al. 2013; Gauthier et al. 2013; Shyu et al. 2004; Xu et al. 2004; Guo et al. 2006;
Syed et al. 2010).
The most promising finding for the treatment relevance of NRG1, however, has been
made in relation to cardiovascular disease (Wadugu & Kühn 2012). Patients with
chronic heart failure have been treated with NRG1 for ten days leading to lasting improvements in cardiac function (Gao et al. 2010; Jabbour et al. 2011). No indication
of nervous system impairments have been reported during and following the treatment period. While its efficacy for central nervous system pathologies remains to be
evaluated, this suggests that treatment with NRG1 is tolerated by humans, which
overcomes a critical hurdle in the drug development process.

5.2

Recommendation for Future Research

5.2.1 The role of dopamine in the treatment effect of NRG1
Differences in the dopaminergic neurotransmitter system in patients with schizophrenia are well documented, as descripted in section 1.1.2.1. The present experiments, however, assess the effect of NRG1 on the GABAergic and glutamatergic
neurotransmitter system in the schizophrenia-relevant PCP model. The results from
the microdialysis study suggest that additional transmitters are involved in the NRG1
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treatment effect. Dopamine is a likely candidate, particularly as NRG1 retrodialysis
has been shown to trigger an increase in extracellular dopamine levels in the hippocampus of mice (Kwon et al. 2008). A logical next step would therefore be to repeat
the microdialysis experiment with NRG1 and PCP retrodialysis and quantify extracellular dopamine levels. Further, recent experiments indicate an involvement of the
dopamine receptor D4 in the effect of NRG1 on hippocampal extracellular DA levels
(Andersson et al. 2012). Including antagonists selective for different dopamine receptors in the retrodialysis solution would assist with the identification of the treatment-relevant NRG1 signalling pathway.

5.2.2 NRG1 treatment effect on cognitive performance
The outcome of the behaviour study indicates that NRG1 treatment has the potential
to be beneficial against symptoms experienced during an acute psychotic episode, as
modelled by PCP treatment in mice. The period between psychotic episodes is dominated by impairments to cognitive abilities (Tandon et al. 2009). It is therefore of
strong clinical relevance to study the effect of NRG1 treatment on cognitive functions. Memory deficits and attention deficits have been modelled in rodents through
different strategies, such as chronic amphetamine and PCP treatment, neonatal hippocampal lesion and perinatal immune activation (Mouri et al. 2013). Assessing the
effect of NRG1 treatment on the performance in latent inhibition, 5-choice serial reaction time task and radial arm maze experiments with these animal models will shed
light on the treatment potential against schizophrenia-relevant cognitive impairments.

5.2.3 Long-term effects of NRG1 treatment
The existing pre-clinical and clinical studies, as well as the experiments from my
PhD, focus predominantly on acute or short-term NRG1 treatment effects. The neurotrophic role of NRG1 suggests the possibility that long-term changes in NRG1 signalling could result in lasting structural differences in several peripheral and central
nervous system structures.
Current transgenic and knockout animal models with mutations in the NRG1 or
ERBB4 genes alter this signalling pathway from early development onwards and are
therefore not suited to shed light on the consequences of NRG1 treatment on the ful115

ly developed organisms. Furthermore, the effect of NRG1 appears dose-dependent,
which cannot easily be studied in transgenic animals.
Recent animal work indicates that even a short duration of NRG1 treatment can induce lasting structural differences, with four days NRG1 treatment resulting in increased dentate gyrus neurogenesis 28 days later (Mahar et al. 2011). While this
structural change has been suggested to be of potential benefit in relation to depression, structural changes in other regions could be of potential disadvantage.
Furthermore, the observed reduction in glutamate by NRG1 observed in my microdialysis study and in vitro experiments might lead to compensatory mechanisms on
both pre- and postsynaptic neurons (with unknown consequences ), if maintained for
extended periods.
The next step in evaluating the suitability of NRG1 as a treatment option for the
mentioned disorders and especially schizophrenia, will therefore require detailed behavioural and molecular analysis following long-term peripheral NRG1 administration.

5.2.4 Potential treatment effect of NRG1 on existing impairments
My experiments show that NRG1 treatment can prevent PCP-induced behavioural
and molecular changes in mice. To advance on the clinical relevance of the observed
NRG1 treatment effect, future research will require the administration of NRG1 after
the formation of clinical relevant impairments. By treating non-acute schizophrenia
animal models, it will be possible to assess the ability of NRG1 treatment to restore
pre-existing impairments. For example, the pre-natal immune challenge and pre-natal
vitamin D deficiency models trigger lasting neurochemical differences such as altered dopamine metabolism and GABAergic interneuron function (McGrath et al.
2010; Meyer & Feldon 2010). The involvement of the NRG1 signalling in cell
mechanisms beyond acute neurotransmission (e.g. synapse formation and nerve migration (Mei & Xiong 2008; Cahill et al. 2013)), might attenuate impairments caused
by schizophrenia modelling strategies and would therefore have stronger relevance to
a clinical setting.
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5.2.5 NRG1 treatment effect on human nervous system
Different acute and chronic modelling strategies can provide environments where
potential treatment characteristics of the NRG1 signalling pathway can be explored.
While the ERBB4 expression pattern appears consistent across species (Neddens et
al. 2011), differences have been observed in the NRG1 isoforms expressed, with
NRG1 type IV only found in humans, not rodents (Tan et al. 2007; Shamir & Buonanno 2010). This highlights the need for comparing the effect of NRG1 treatment
between the rodent and primate brain. Additionally, the broad distribution of
ERBB3-4 receptors throughout peripheral tissue types will require careful analysis of
potential species-specific adverse effects, such as those indicated by breast cancer
studies in humans (Montero et al. 2008).

5.3

Conclusion

With the present series of experiments I have demonstrated that NRG1 treatment can
prevent PCP-induced behavioural impairments, PCP-induced neurotransmission
changes and PCP-induced disruptions to the frontal cortex neuronal network.
Prevention of PCP-induced hyperlocomotion and PPI impairments demonstrates a
clear involvement of the NRG1 signalling pathway in neuronal circuits relevant for
spontaneous behaviour. The region-specific influence of NRG1 on glutamate and
glycine levels confirms the involvement of NRG1-ERBB signalling in adult excitatory neurotransmission. Furthermore, preventing the PCP-induced GABA level increase in the hippocampus provides support for a functional role in inhibitory neurotransmitter hippocampal signalling. An involvement in the regulation of inhibitory
neurotransmission of NRG1 was further supported by in vitro frontal cortex experiments where NRG1 treatment prevented changes to the expression of GABA producing enzymes.
The treatment effects of NRG1 against PCP were dose-dependent in most experiments, suggesting that NRG1-ERBB signalling is tightly regulated in the adult nervous system.
The combined outcomes of my experiments provide initial support for potential antipsychotic-like characteristics of NRG1 treatment in a mouse model with induced
schizophrenia-relevant behavioural and molecular impairments. The observed effica117

cy of peripherally administered NRG1 to prevent PCP-induced behavioural deficits
indicates its potential as a new therapy for schizophrenia patients. Exploring the consequences of NRG1 treatment in the long-term, on a broader spectrum of behavioural
tasks and further schizophrenia-relevant molecular changes will be required to advance on the present findings and finally evaluate the suitability of NRG1 treatment
in the clinic.
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